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The negative impacts of the illicit drug trade touch every society
in the world. This year's World Drug Report estimates that 200
million people, or 5% of the global population age 15-64, have
consumed illicit drugs at least once in the last 12 months. The
drug trade is pernicious and large. UNODC estimates its retail
value at US$ 321bn. It impacts almost every level of human
security from individual health, to safety and social welfare. Its
consequences are especially devastating for countries with
limited resources available to fight against it.    
The World Drug Report 2005 provides one of the most
comprehensive overviews of illicit drug trends at the
international level. In addition, this year it presents the work of
UNODC in two new areas of research. Both aim to provide tools
to enrich our understanding of an immensely complex situation:
an estimate of the financial value of the world drug market, and
the preliminary steps towards the creation of an illicit drug
index. The analysis of trends, some going back 10 years or more,
is presented in Volume 1. Detailed statistics are presented in
Volume 2. Taken together these volumes provide the most up to
date view of today's illicit drug situation. 
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Drugs and Crime (UNODC) on 1 October 2002. The Office on Drugs and Crime
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Last year the United Nations Office on Drugs and Crime (UNODC) merged its former Global
Illict Drug Trends series with the World Drug Report, issued it in two volumes comprising Analy-
sis and Statistics, and decided to make it an annual publication.  Feedback on the new format and
frequency has been positive.  There is also continuing evidence that the world needs such annual
assessments from the United Nations.  They help the international community to judge where it
is, how it is performing, and whether it is reaching the targets it sets for itself.  Particularly in areas
as globally inter-connected as drugs and crime, such assessments also help individual countries -
the building blocks of the international community - to steer their own ways forward.
The World Drug Report 2005 includes an overview of our work in two new areas of research. Both
aim to provide tools to enrich our understanding of an immensely complex situation: an estimate
of the financial value of the world drug market, and the preliminary steps towards the creation of
an Illicit Drug Index. Now that we are able to systematically analyse trends which tell us where
we are and which could tell us where we are going - we work towards defining another equally
important piece of the puzzle: the baseline from which to measure progress.    
Production and trafficking of illicit drugs is driven substantially, if not exclusively, by economic
motives.  Understanding the scale of the finances involved can be of great use to those working
in the field. Who earns the most in the global illicit drug business? How does the size of this
market compare with legitimate enterprises? Which substances and markets are the most prof-
itable? How are the monetary incentives changing over time? Which sectors of the market are most
vulnerable to economic sanctions? This World Drug Report takes a further  step towards provid-
ing policy relevant answers to such questions. 
The Index is a single value used to summarise the drug situation in a particular location at a given
point in time. The creation of an index is an exercise fraught with controversy, because there is no
objective way of deciding on the weight assigned to each of the variables included. While it is
bound to generate debate which will inform its refinement and adaptation, the Index is introduced
this year because there is a need to provide a substantiated answers to the most basic questions in
our collective struggle with drugs: is the situation getting better or worse? Are we winning or are
we losing? Can we get beyond the problem, so well known in this field, of using the same data to
arrive at diametrically opposed conclusions? If production of a particular drug goes down in a cer-
tain area, but abuse of the same drug goes up in the same area, is this to interpreted as success,
failure or stagnation? A single index, provided we can agree on one, will go a long way towards
answering these kinds of questions.
It is precisely because the international community has resolved to be the winner of the struggle
against illicit drugs and for enhanced human security that we need to know more about where we
stand and explore all possible means of measurement and comparison. This will help our assess-
ment in 2008, when we will have to judge how we, as an international community, have done
over the decade in meeting the goals and commitments made at the 1998 Special Sesion of the
General Assembly (UNGASS).  
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2On a very practical level, we need information of the sort provided by these two new tools in order
to steer our efforts and interventions. For far too long the illicit drug market as been able to oper-
ate and hide in obscurity. It has taken much work and dedication, across the world, to shed light
on this pernicious market. The goal of the information presented in the World Drug Report has
always been to make that light shine brighter. 
The global retail market for illicit drugs is estimated at US$320bn. For all the caveats that one may
put on such a figure, and the text notes them, it is still larger than the individual GDPs of nearly
90% of the countries of the world.  This is not a small enemy against which we struggle. It is a
monster.  With such an enormous amount of capital at its disposal, it is bound to be an extremely
tenacious one. We know that there are few dimensions of human security that are not affected in
some way by the illicit drug market.  Let us continue then, armed with new knowledge and light,
to fight, in both word and deed, for those whose very existence is threatened by this trade.
Antonio Maria Costa
Executive Director
United Nations Office on Drugs and Crime
3This report  has been reproduced without formal editing.
The designations employed and the presentation of the material in this publication do not imply the expression
of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of
any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or
boundaries.  The names of territories and administrative areas are in italics.
In various sections, this report refers to a number of regional designations. These are not official designations.
They are defined as follows: West and Central Europe: EU 25 plus EFTA plus San Marino and Andorra; East
Europe: European CIS countries; Southeast Europe: Turkey and the non-EU Balkan countries; North America:
Canada, Mexico and USA.
The following abbreviations have been used in this report:
ARQ Annual reports questionnaire
ATS         Amphetamine-type stimulants. Amphetamines (amphetamine, methamphetamine 
and related substances) and substances of the ecstasy group (ecstasy, MDMA,
MDEA, MDA etc.)
CICAD       Inter-American Drug Abuse Control Commission
CIS        Commonwealth of Independent States
DEA         Drug Enforcement Administration (United States of America)
DELTA UNODC Database for Estimates and Long-term Trends Analysis
DUMA Drug Use Monitoring in Australia
EMCDDA     European Monitoring Centre for Drugs and Drug Addiction
ESPAD European School Survey Project on Alcohol and other Drugs (Council of Europe)
F.O. UNODC Field Office
ICMP UNODC Global Illicit Crop Monitoring Programme
IDU Injecting drug use
INCB        International Narcotics Control Board
INCSR International Narcotics Control Strategy Report (United States of America)
Interpol/ICPO    International Criminal Police Organization
LSD         lysergic acid diethylamide
NAPOL National Police
PCP         phencyclidine
UNAIDS      Joint and Co-sponsored United Nations Programme on Human
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
WADAT Weighted Analysis on Drug Abuse Trends, referred to as Drug Abuse Trend Index
in this report.
WCO World Customs Organization
WHO         World Health Organization
Govt. Government
bn Billion
ha Hectare
kg Kilogram
lt. Litre
mn Million
mt Metric ton
u. Unit
Explanatory notes

51.1. The Dynamics of the World Drug Market
1.1.1 How is the drug problem evolving?
What is the level of drug use in the world, and how is it changing? 
Some 200 million people, or 5% of the world’s population age 15-64, have used drugs at least once in the last 12
months. This is 15 million people higher than last year’s estimate but remains significantly lower than the number
of persons using licit psychoactive substances (about 30% of the general adult population use tobacco and about
half use alcohol).  The number of cannabis users worldwide is now close to 160 million people or 4% of the pop-
ulation age 15-64. Estimates of the number of ATS users - 26 million people using amphetamines and 8 million
using ecstasy -  are slightly lower than those of last year’s World Drug Report (WDR), reflecting declines of metham-
phetamine use in South-East Asia (notably Thailand) and of ecstasy use in North America (notably in the USA).
The number of opiate users is estimated to have risen slightly to around 16 million people (11 million of which
abuse heroin), mainly reflecting increasing levels of opiate abuse in Asia.  No significant changes were observed in
most other parts of the world. The number of cocaine users – close to 14 million people – rose slightly.   
Unsurprisingly, the main problem drugs at the global level continue to be the opiates (notably heroin) followed by
cocaine. For most of Europe and Asia, opiates continued to be the main problem drug, accounting for 62% of all
treatment demand in 2003. In South-America, drug related treatment demand continued to be mainly linked to
the abuse of cocaine (59% of all treatment demand). In Africa, the bulk of all treatment demand – as in the past –
is linked to cannabis (64%).   
Executive Summary
Chapter 1: Trends in World Drug Markets
Annual prevalence is a measure of the number/percentage of people who have consumed an illicit drug at least once in the 12 month-
period preceding the assessment.
Sources: UNODC, Annual Reports Questionnaire data, National Reports, UNODC estimates. 
Extent of drug use (annual prevalence*) estimates 2003/04 (or latest year available)
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analysis of these responses suggests that overall drug consumption continues to spread at the global level. Although
countries indicating rising levels of drug consumption continue to outnumber those with falling levels of drug use,
the proportions have shifted in recent years in a slightly more positive direction. While in 2000 53% of all report-
ing countries saw rising levels of drug use, the corresponding proportion fell to 44% in 2003. In parallel, the pro-
portion of countries seeing declines rose from 21% in 2000 to 25% in 2003.
For the main drug categories, specific drug use trend indices were established.  The indicies are based on the trends
reported by the competent authorities and partially weighted by the size of the countries' drug using population.
This procedure gives a greater weight to countries with a larger drug using population, thus more accurately reflect-
ing the overall trend at the global level. The methodological details are described in the methodology section. In
2003, these indices show (1) an ongoing increase in the use of cannabis, (2) some signs of stabilization for opiates
and cocaine and (3) a stabilization/decline for ATS. Over the last decade, ATS, followed by cannabis, experienced
the strongest increases.   
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Drug Use Trend Index (based on expert opinion: weighted by estimated number of users)
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A total of 95 countries reported the number of drug seizures made to UNODC in 2003. Between 1985 and 2003,
the number of seizures increased four fold. In the last few years, with the exception of a dip in 2002, the number
of seizures seems to have plateaued at about 1.3 million cases. More than half of these were cannabis seizures, about
a quarter involved opiates; amphetamines were seized in 10% of the cases, and cocaine in 7%.
In the last decade, the most significant trend has been the increase in the number of seizures of amphetamine-type
stimulants (ATS). In 2003, however, this trend reversed sharply, mainly as a result of the decline in ATS seizures
from Thailand following a major crackdown on the drugs in the previous year. It is also estimated that ATS con-
sumption dropped globally in the last year, so the reduction in seizures is probably more than just an artefact of
changing enforcement patterns.
In contrast, the proportion of opiates seizures rose significantly in 2003, mainly reflecting the revival of Afghan
opium production and more seizures in the countries surrounding Afghanistan. The number of cannabis cases has
been on the rise since the early 1990s, and its rate of growth exceeded that of other drugs in 2002-2003, in line with
a growth in global consumption. Cocaine has remained relatively stable.
The global production trend is rather stable for opium, declining  for coca but seems to be increasing for cannabis
as well as,  following some declines,  for ATS.  Currently about 196,000 ha are under opium poppy and 158,000
ha are under coca cultivation worldwide. 
Following strong increases in 1980s, opium production has been basically stable at around 4,000 – 5,000 metric
tons since the early 1990s. Production stood at 4,765 and 4,850 metric tons in 2003 and 2004 respectively.1 About
87% of opium for the illicit market is now produced in Afghanistan.  The long-term trend has been towards rising
levels of opium production in Afghanistan. This has largely offset the strong declines reported from Myanmar and
Lao PDR in recent years, bringing global potential heroin production in 2004 to 565 metric tons. 
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1 These figures represent potential rather than actual heroin or cocaine production. Potential production refers to the amount of heroin or cocaine
produced if all of the raw material (opium/coca leaf ) produced in a country were transformed into the end product.  Actual heroin/cocaine
production of a country may well differ. It would be lower if not all of the raw material were transformed into the end-products (e.g. as there is local
consumption of the raw material) or it could be higher if raw material was imported from a neighbouring country, or if the manufacturing processes
improved.  
Proportion of seizure cases according to drug category, 1990-2003
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Potential cocaine production peaked in the second half of the 1990s (950 mt in 1996 and 925 mt in 1999), but has
been declining significantly thereafter to 674 mt in 2003. In 2004, cocaine production increased marginally to 687
metric tons.  Despite this, overall production remains 26% lower than in 1999. The declines of potential cocaine
production in recent years were mainly the result of progress made in Colombia. The increase in 2004 was due to
stronger coca leaf production in both Peru and Bolivia. Both countries had already made significant progress in cut-
ting coca leaf production a few years earlier, however, and production is thus still lower than in 1998 or previous
years. 
More than 7,000 mt of cannabis resin and slightly more than 40,000 mt of cannabis herb were produced in 2003,
exceeding last year’s published estimate of an annual production of around 32,000 mt of cannabis herb. A global
total of 332 mt of amphetamines (methamphetamine and amphetamine) and 90 mt of ecstasy were produced in
2003.
1.1.2  The outlook for world drug markets 
Afghanistan will determine the size and development of the world’s main opiate markets. As compared to last year,
the situation looks slightly more positive for Afghanistan. Presidential elections were held in 2004 and the govern-
ment is gradually strengthening its control over the country and those involved in the opium business.  A Rapid
Assessment conducted by UNODC earlier in 2005 indicated that the area under poppy cultivation has declined in
2005 as compared to the record levels in 2004. It is, however, not yet certain whether the reduction of the land
under opium poppy cultivation would be sufficient to offset a possibly higher yield than observed in 2004.      
In the meantime, the country’s last opium harvest is still finding its way to the consumer markets of Europe and
other regions. Purity levels of heroin in some European countries have already started to rise – a clear indication that
there is sufficient and rising supply. Thus, while the mid-term prospects are rather positive, problems could still
emerge in some of the main consumer markets this year.
Opium production in South-East Asia  is now 78% lower than it was in 1996.  Production in this sub-region is fore-
cast to decline further in 2005. If the declines witnessed over the last few years are sustained, it would not be too
far outside the realm of possibility that South-East Asia could become virtually free of illicit cultivation over the next
few years.
The trend towards lower production of cocaine did not continue in 2004, as the area under coca cultivation rose in
both Bolivia and Peru. This is a worrying loss of momentum for both countries, which had already made signifi-
cant progress to curb coca production. The net results (+2%) were not a real problem in 2004. However, ongoing
increases in these two countries could eventually weaken the progress the region has made in controlling coca supply.
This is a vital juncture, and it will be important for the international community to continue to support alternative
livelihoods programmes. 
In parallel, the risk of a further dispersion of the cocaine markets continues. Europe is particularly vulnerable, having
already seen a steady growth of its cocaine markets over the last decade. Even though there are signs of stabilization
in some countries, consumption continues to increase in others. In 2003, 14 European countries reported an increase
and 10 a stabilization. Not a single country experienced a decline in cocaine use.  A particular challenge will be con-
trolling the spread of crack-cocaine: 7 European countries reported an increase,  9 saw stable levels while, again, not
a single European country identified a decline in 2003.
Cannabis continues to be the most widely produced, trafficked and consumed drug worldwide. All indicators – pro-
duction, seizures and consumption - suggest that the market at the global level is expanding further. For the time
being, there is no reason to believe that this expansion will stop. 
Signals from the ATS market are complex.  Although there are clear indications that the strong increases in ATS use
observed in the 1990s were not continued into the first years of the new millennium, future increases cannot be dis-
counted.
10
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1.2 Opium/Heroin Market
1.2.1 Production
There are two distinct factors to keep in mind with regard to global production of opiates: the land area dedicated
to growing opium poppy and the rate at which this crop is converted into drugs. While the total land area used for
poppy cultivation increased in 2003, yields were small due to adverse climatic factors, and thus total production
remained much the same as it has been since the early 1990s: about 4850 metric tons of opium in 2004, with the
potential to produce about 565 mt of heroin.
The increase in land dedicated to opium cultivation was located almost entirely in Afghanistan, where an unprece-
dented 131,000 ha were under the crop, grown in all 34 provinces of the country. Fortunately, in the world’s other
major heroin producing region - Southeast Asia - cultivation has been in decline since 1998. In 2004, the area ded-
icated to poppy in Myanmar declined 23%, and in Lao PDR cultivation was down 43%. But these dramatic reduc-
tions were not enough to offset the increase in Afghanistan, resulting in a net increase in global cultivation area of
16% over the previous year. Bad weather negatively impacted yields in both major production areas, however, so
total opium production only increased by about 2% over the previous year. 
Not surprisingly, prices were inversely proportional to supplies, and Afghan opium farmers saw the value of their
produce drop by 69% as compared to the previous year, to US$92/kg of fresh opium. However, this is still two to
three times higher than in the second half of the 1990s. In contrast, Southeast Asian poppy growers commanded
higher prices: in Myanmar, US$ 234/kg, an increase of 80%, and in Laos, US$ 218/kg, an increase of 27% over
2003.
1.2.2 Trafficking
Opiate seizures increased by a third in 2003 to achieve a record high of 110 metric tons. Comparing this figure to
production estimates, it now appears that law enforcement is intercepting nearly a quarter of all the opiates pro-
duced. The most pronounced increase was in the countries immediately bordering Afghanistan, particularly Pak-
istan (34.7 mt) and the Islamic Republic of Iran (26.1 mt).  This is reflected in the large share of seizures that were
semi-processed products (opium or morphine, rather than heroin). In Europe, seizures declined by 13% to 19.4 mt
in 2003.
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1.2.3 Abuse
A total of 16 million people worldwide use opiates, including some 10.6 million people who abuse heroin. More
people (1.3 million) are treated for opiates abuse than for any other substance. Over 60% of treatment demand in
Europe and in Asia is related to the abuse of opiates. In 2003, use levels remained stable globally, but some increases
could be related to Afghan production going up.
Changes in abuse of heroin and other opiates, 2003 (or latest year available)
Seizures of opiates (in heroin equivalents), 1980-2003
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1.3 Coca/Cocaine Market
1.3.1 Production
Most of the world’s cocaine is produced in the just three countries: Columbia (50%), Peru (32%), and Bolivia
(15%). In  2004, coca cultivation in Columbia decreased by 6000 ha, but this was more than offset by increases in
Peru (up 14%) and Bolivia (up 17%). This resulted in a year-on-year global increase of about 3%, but that is still
29% less than the peak production year of 2000. The sustained high price for coca leaf was the likely motivation
for farmers in Peru and Bolivia to increase coca cultivation in 2004. Prices for coca leaf have doubled since the mid-
1990s in Peru, commanding US$ 2/kg, and in Bolivia the price was even higher, at US$ 5/kg.
1.3.2 Trafficking 
Global cocaine seizures increased by a third in 2003, to a record high of 495 mt, more than half of which were made
in South America. Based on production estimates and taking purity into account, this represents an interception
rate of 44%, also a record high. Columbia alone seized 146 mt, or 29% of global seizures. Oddly, rather than forc-
ing prices up, prices dropped slightly in most of the major markets for the drug. It would appear that North Amer-
ican cocaine markets are in decline and that European ones are on the rise. Most of the cocaine smuggled into the
United States transits Mexico or the Caribbean. Europe’s supply is increasingly transiting Africa, in addition to tra-
ditional routes via Spain and the Netherlands.
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1.3.3 Abuse
There are an estimated 14 million cocaine users worldwide, with two-thirds residing in the Americas. Globally,
cocaine use seems to have stabilised, after years of strong increases, although school surveys suggest a rising trend in
Western Europe.
1.4 Cannabis Market
1.4.1 Production
Cannabis production has been rising and may have exceeded 40,000 mt in 2003. The production of herbal cannabis
is extremely dispersed, and most Member States report some cannabis cultivation in their countries. Production of
cannabis resin (hashish) on the other hand, seems to be concentrated in Morocco, which supplies 80% of the resin
consumed in Europe, the world’s largest resin market. The land dedicated to cannabis cultivation in Morocco
declined between 2003 and 2004 by 10%. Pakistan and Afghanistan also contribute resin to the international
market, for a total global production of about 7000 mt.
1.4.2 Trafficking 
Cannabis herb is the most widely trafficked drug, and seizures rose again in 2003, to 5,845 mt, 58% of which
occurred in North America, with Africa providing another 26%. Cannabis resin seizures also increased to a new all
time high in 2003 - 1,361 mt - 70% of which was seized in Western Europe.
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1.4.3 Abuse
Cannabis is far and away the most commonly consumed street drug in the world. An estimated 161 million people
used cannabis in 2003, equivalent to 4% of the global population between the ages 15 and 64. According to expert
opinions solicited from Member States, far more countries felt that cannabis use was increasing (46% of 101 coun-
tries responding) than declining (16%) in 2003. Use among students appears to be on the increase in Europe,
though not in the United States or Australia. 
Cannabis seizures, 1985-2003
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1.5 Amphetamine-type Stimulants Market
1.5.1 Production
Global ATS production is currently above 400 mt, three quarters of which is either methamphetamine or amphet-
amine and one quarter of which is ‘ecstasy’. Production of amphetamines is concentrated in Europe; methamphet-
amine in China, Myanmar, the Philippines, and North America; and ecstasy in the Netherlands and Belgium.
1.5.2 Trafficking 
After some years of decline, ATS seizures increased in 2003, with the largest volumes seized in Thailand (20% of
the total), followed by China (18%), the United States (14%), the Philippines (10%), and the UK, the Netherlands
and Australia (6% each). Methamphetamine seizures increased by 40% in 2003 though they are still 40% less than
the peak year of 2000. The largest seizures of methamphetamine in 2003 were reported by Thailand (6.5 mt), China
(5.8 mt), the United States (3.9 mt) and the Philippines (3.1 mt). Global amphetamine seizures (5.4 mt) are back
to the levels reported in 1997/98, having increased by 22% in 2003. Amphetamine seizures continue to be con-
centrated in Europe (>90%), notably in West and Central Europe (79%). Ecstasy seizures in kilogram equivalents
amounted to 4.3 mt, 37% less than in the peak year of 2002, and were made mainly in West and Central Europe
(54%) and Oceania (26%).
1.5.3 Abuse
An estimated 26 million people used methamphetamine, amphetamine, or related substances in 2003, while about
7.9 million people used ecstasy. After the opiates, ATS are the main problem drugs in Asia, and in some countries
they have overtaken heroin in terms of their contribution to treatment demand. Almost two thirds of the world’s
amphetamine and methamphetamine users reside in Asia, most of whom are methamphetamine users in East and
South-East Asia. Prevalence of ecstasy use is highest in the Oceania region (3.1%), followed by West and Central
Europe (0.9%) and North America (0.8%).
Seizures of amphetamine-type stimulants 1980-2003
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Chapter 2: Estimating the value of illicit drug markets
The illicit drug industry operates outside the law. Its ‘companies’ are not listed on the stock exchange, they are not
valued by any private accounting firm, and the dynamics of the drug industry are not regularly pored over by ana-
lysts, economists and forecasters. Yet the overall size of the illicit drug industry is known to be huge. 
The obscurity of the global illicit drug market makes the exercise of estimating its size extremely difficult.  This is
not because the drug market does not behave like most others in terms of supply and demand - there is a growing
acceptance that it does. It is rather because the most basic inputs which are needed for such an estimation – data on
production, prices, quantities exported, imported and consumed – are themselves often estimates and are frequently
based on less than complete data.
This year UNODC presents an estimate of the value of the illicit market. Three guiding principles were applied to
this exercise: first, only readily available data were used; second, the methodology and the model were kept straight-
forward and the assumptions transparent; and third, it was ensured that the model, by distilling the market down
to its most basic economic rules, would be easily updateable.  In addition, the methodology chosen tries to com-
bine, as far as possible, the top-down with the bottom-up approach. 
The value of the global illicit drug market for the year 2003 was estimated at US$13 bn at the production level, $94
bn at the wholesale level (taking seizures into account), and US$322 bn at the retail level (based on retail prices and
taking seizures and other losses into account). 
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The size of the global illicit drug market is substantial. The value, measured at retail prices, is higher than the GDP
of 88% of the countries in the world (163 out of 184 for which the World Bank has GDP data) and equivalent to
about three quarters of Sub-Saharan Africa’s total GDP (US$439 bn in 2003). The sale of drugs, measured at whole-
sale prices, was equivalent to 12% of global export of chemicals (US$794 bn), 14% of global agricultural exports
(US$674 bn) and exceeded global exports of ores and other minerals (US$79 bn) in 2003. Such sales of drugs were
also higher than the combined total licit agricultural exports from Latin America (US$75 bn) and the Middle East
(US$10 bn) in 20032.
The largest market, according to these estimates, is cannabis herb (with a retail market size of $113 bn), followed
by cocaine (US$71 bn), the opiates (US$65 bn) and cannabis resin (US$29 bn).  The ATS markets together
(methamphetamine, amphetamine and ecstasy) amount to US$44 bn. The valuation does not take into account the
value of other drugs. 
While UNODC is reasonably confident with its estimations on opiates, cocaine and the ATS, the degree of cer-
tainty is far lower for cannabis, notably for cannabis herb, as information for production and consumption of this
substance is highly contradictory. If better information becomes available, a major revision cannot be ruled out.  
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Chapter 3: HIV/AIDS and Drugs
Globally, sexual transmission of HIV continues to be the most common way the virus is spread, but drug use is con-
tributing to the pandemic in at least four ways. First, the most common and best-researched method of transmis-
sion is via the use of contaminated injection equipment between people who inject drugs. Second, there is sexual
transmission of the virus between those who inject drugs and their sexual partners. The dual transmission risk in
the case of sex workers who also inject drugs leads to epidemics that expand quickly and act as a bridge to the rest
of the population. Third, non-injecting use of drugs such as cocaine and amphetamine-type stimulants leads to high-
risk sexual behaviour. And finally, HIV can be transmitted from an infected mother to her child. 
In the early stages of the pandemic, HIV/AIDS among injecting drug users was largely viewed as self-limiting, affect-
ing injectors and their immediate sexual partners but not leading to a more generalised spread of the virus. Recent
work on the Asian and Eastern European HIV/AIDS epidemics has proven this perspective to be incorrect.3 Glob-
ally, it is estimated that 5% -10% of all HIV infections are attributable to injecting drug use, mostly via the use of
contaminated injection equipment.4 In many countries of Europe, Asia, the Middle East and the Southern Cone of
Latin America, the use of non-sterile injection equipment has remained the most important mode of HIV trans-
mission, accounting for 30%-80% of all reported infections. 
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Australia &
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HIV/AIDS prevalence (%) among injecting drug users (1998- 2003)
3 WHO/ UNAIDS/ UNODC Advocacy Guide: HIV/AIDS Prevention Among Injecting Drug Users, WHO, 2004.                                              
4 UNAIDS, Institute OS, Agency CID. The Warsaw declaration: A framework for effective action on HIV/AIDS and injection drug use. 2nd
International Policy Dialogue. Warsaw; WHO/ UNAIDS/ UNODC. Advocacy Guide: op.cit.                                                                            
19
Executive Summary
Epidemics driven by injecting drug use have different characteristics than epidemics where sexual transmission is the
main mode of infection.5 Most importantly, the efficiency of HIV transmission per injection is almost six times
higher than for heterosexual acts. Most studies also found that heroin injectors inject about 1-3 times per day, and
cocaine users even more frequently, so the number of possible exposures is also greater. Due to the greater efficiency
and higher frequency of risk-exposure associated with injecting drug use, these epidemics tend to spread more rap-
idly than those driven by sexual transmission. Soon after HIV is introduced into a community of injecting drug
users, infection levels in these populations can rise from zero to 50–60% within 1–2 years.6
Despite insufficiencies of data, particularly on non-injecting drug use, there is no doubt that the use of drugs,
whether injected or taken otherwise, increases the risk of becoming infected with HIV. If injected, the use of con-
taminated injection equipment can lead to the rapid spread of the virus in the injecting community and beyond.
Certain drugs that are not injected can also increase HIV transmission due to their impact on sexual risk-taking
behaviour. The sexual partners of drug users, whether drugs users themselves or not, can spread the virus to the larger
community, particularly if they are commercial sex workers. 
Chapter 4: Towards the creation of an Illicit Drug Index
The "drug problem" has so far not found a representation that goes beyond the existing mosaic of perceptions and
statistics, and encompasses them into a single standard measure. Entrusted by Member States to promote and sup-
port a coordinated and multilateral response to the world's drug problem, UNODC has been striving to improve
the analytical tools at the disposal of governments and the international community to develop increasingly effec-
tive control measures.  
In this context, UNODC has been working with governments and a variety of organizations to establish norms and
standard indicators; to improve data collection and reporting systems; and to facilitate the dissemination of data and
information on the nature, extent and evolution of the drug problem and its various dimensions. As part of the ongo-
ing effort to expand the knowledge base that informs policy making, UNODC is now working towards developing
a global Illicit Drug Index (IDI).
The Illicit Drug Index would provide a single, standard and comparable measure of a country's overall drug prob-
lem, weighted by the size of its population. The Illicit Drug Index combines all the main categories of illicit drugs
by converting them into a hypothetical reference drug. It also combines the extent of illicit drug production, traf-
ficking and abuse into a single measure of potential harm that moves along the market chain. Once refined the index
could reflect the extent of the drug problem affecting a particular country in comparison with others, weighted by
the size of its population. 
5 Pisani E, Garnett GP, Grassly NC, Brown T, Stover J, Hankins C, Walker N, Ghys PD. Back to basics in HIV prevention: focus on exposure. BMJ
2003;326:1384-7.  
6 WHO Training Guide for HIV Prevention Outreach to Injection drug users. Geneva. 2003
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What is the level of drug use in the world, and how is it
changing?
Some 200 million people, or 5% of the world’s popula-
tion age 15-64, have used drugs at least once in the last
12 months. This is 15 million higher than last year’s
estimate but remains significantly lower than the
number of persons using licit psychoactive substances
(tobacco: around 30%; alcohol: around half of the gen-
eral adult population).  The number of cannabis users
worldwide is now close to 160 million people or 4% of
the population age 15-64. Estimates of the number of
ATS users - 26 million people using amphetamines and
8 million using ecstasy -  are slightly lower than those of
last year’s World Drug Report (WDR), reflecting declines
of methamphetamine use in South-East Asia (notably
Thailand) and of ecstasy use in North America (notably
in the USA).   The number of opiate users is estimated
to have risen slightly to around 16 million people (11
million of which abuse heroin), mainly reflecting
increasing levels of opiate abuse in Asia.  No significant
changes were observed in most other parts of the world.
The number of cocaine users – close to 14 million
people – rose slightly.   
In addition to UNODC estimates on the total number
of drug users, derived from national survey results and
extrapolations from partial information of the drug sit-
uation in the various countries, the competent authori-
ties of Member States provide UNODC with their
perceptions of the development of the drug situation in
their country on a five-point scale (large increase, some
increase, no great change, some decrease, large
decrease).  The statistical analysis of these responses sug-
gests that overall drug consumption continues to spread
at the global level.1
Based on the drug use trends provided by Member
States, cannabis use has seen the largest increase over the
last few years, notably cannabis herb. This is followed by
ATS, cocaine and opiate (mainly heroin) consumption.
Amphetamines Ecstasy
All illicit 
drugs 
Cannabis
Amphetamine-type 
stimulants
Cocaine Opiates
of which 
heroin
(million people) 200 160.9 26.2 7.9 13.7 15.9 10.6
in % of global 
population age 15-64
5.0% 4.0% 0.6% 0.2% 0.3% 0.4% 0.23%
Table 1: Extent of drug use (annual prevalence*) estimates 2003/04 (or latest year available)
1. Trends in world drug markets
1.1 The Dynamics of the World Drug Market
1.1.1 How is the drug problem evolving?
1  Although countries indicating rising levels of drug consumption continue to outnumber those with falling levels of drug use, the proportions have
shifted in recent years in a slightly more positive direction. While in 2000 53% of all reporting countries saw rising levels of drug use, the
corresponding proportion fell to 44% in 2003. In parallel, the proportion of countries seeing declines rose from 21% in 2000 to 25% in 2003.
Sources: Annual Reports Questionnaire Data, National Reports, UNODC estimates.  
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There seems to be a net spread of these substances in
geographical terms with the number of authorities
reporting falling levels of consumption of these sub-
stances less than those reporting rising levels of use. This
does not necessarily mean, however, that the total
number of drug users is rising, because increases in
smaller countries could be offset by declines in a few
larger ones. The strongest ‘net increases’ (number of
countries reporting an increase less those reporting a
decline) in 2003 were reported for cannabis herb,
cocaine, ATS and the benzodiazepines. With the excep-
tion of the benzodiazepines, the ‘net increases’ in 2003
were lower than those reported in 2001, suggesting that
the upward trend in consumption lost momentum.  The
least frequently reported increases concern substances
such as morphine, methaqualone, GHB, khat, opium
and LSD.    
For the main drug categories of concern, specific drug
use trend indices were established.  The indicies are
based on the trends reported by the competent author-
ities and weighted by the size of the countries’ drug
using populations. This procedure gives a greater weight
to information from countries with a larger drug using
population, thus more accurately reflecting the overall
trend at the global level (the methodological details are
described in the methodology section). For 2003, these
indices show (1) an ongoing increase in the use of
cannabis, (2) some signs of stabilization for opiates and
cocaine and, (3) a stabilization/decline for ATS. Over
the last decade, ATS, followed by cannabis, experienced
the strongest increases.   
… and how are changes affecting the main problem
drugs?  
Another key indicator used identify the evolution of the
drug problem is treatment demand. This is also used by
UNODC as a proxy for the identification of the main
‘problem drugs’ in the various countries.2  Unsurpris-
ingly, the main problem drugs at the global level con-
tinue to be the opiates (notably heroin) followed by
cocaine. For most of Europe and Asia opiates continued
to be the main problem drug, accounting for 62% of all
treatment demand in 2003. In South-America, drug
related treatment demand continued to be mainly
linked to the abuse of cocaine (59% of all treatment
demand). In Africa, the bulk of all treatment demand –
as in the past – is linked to cannabis (64%).   
There have also been some important shifts to estab-
lished patterns in recent years, for example: 
• cannabis in treatment demand in North America,
Oceania, Europe, Africa and South-America has 
increased since the late 1990s;
• cocaine has declined in overall drug treatment in
North America and has risen in Europe; 
• opiates have declined in overall treatment in the 
Oceania region, a late consequence of Australia’s 
heroin shortage in 2001; and 
• ATS in treatment has increased in Asia, Europe, 
North America and Africa. 
2  Difficulties faced here are that some countries only have data available from a few clinics while others have country-wide monitoring systems in
place. Simply adding up the number of people treated for the various drugs would give a strong bias in favour of the countries which have a nation-
wide monitoring system in place while disregarding the information provided by others. In order to overcome this problem,  UNODC decided to
calculate the proportions at the country level and, based on these results, to calculate the (unweighted) averages for the respective region.  
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Fig. 1:  Estimates of annual prevalence of drug use
at the global level in the late 1990s and in
2001-2003
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1. Trends in world drug markets The dynamics of the world drug market
Fig. 2: Global drug use trends in 2000 (based on
information from 96 countries) 
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Fig. 4: Global drug use trends in 2002 (based on
information from 95 countries) 
9%
large increase
14%
no great 
change
29%
some increase
31%
some 
decrease
17%
Source: UNODC, Annual Reports Questionnaire Data.
Fig. 3: Global drug use trends in 2001 (based on
information from 96 countries) 
Fig. 5: Global drug use trends in 2003 (based on
information from 102 countries) 
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Fig. 7: Drug use trends 2001, 2002 and 2003 (Number of countries reporting increases less number of
countries reporting declines)
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Fig. 6: Global drug use trends of selected drugs in 2002 and 2003  (based on information from 95
countries in 2002 and 102 in 2003)
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Fig. 8: Drug Use Trend Index (based on expert opinion; weighted by estimated number of users) 
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Fig. 9: Proportion of people in drug treatment being treated for specific substances – 1997/98 and 2003
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Seizures – another indicator for the evolution of the
drug problem. 
Since the time of the League of Nations, data on inter-
national drug seizures have been gathered in developed
and developing nations alike. Seizures thus represent
our most comprehensive data set on drugs, although
they do suffer from one important shortcoming. Drugs
rarely drop into the laps of law enforcement authorities,
and large seizures are often the result of considerable
detective work. Law enforcement capacity, as well as the
share of that capacity dedicated to the drug issue, varies
considerably between nations. As a result, drug seizures
can confirm the presence of drugs in an area, but the
lack of seizures does not demonstrate their absence, and
it is never absolutely clear what share of drugs in circu-
lation are being intercepted. In combination with other
indicators, however, seizure data are a powerful tool for
investigating trafficking flows and their trends. To
understand seizure data, both the number of seizures
and the volumes seized need to be taken into account. 
A total of 95 countries reported the number of drug
seizures made to the UNODC in 2003. Between 1985
and 2003, the number of seizures increased four fold. In
the last few years, with the exception of a dip in 2002,
the number of seizures seems to have plateaued at about
1.3 million cases. More than half of these were cannabis
seizures, about a quarter involved opiates; ampheta-
mines were seized in 10% of the cases, and cocaine in
7%.
In the last decade, the most significant trend has been
the increase in the number of seizures of amphetamine-
type stimulants (ATS). In 2003, however, this trend
reversed sharply, mainly as a result of the decline in ATS
seizures from Thailand following a major crackdown on
the drugs in the same year. It is also estimated that ATS
consumption dropped globally since 2000, so that the
reduction in seizures is probably more than just an arte-
fact of changing enforcement patterns.
In contrast, the proportion of opiates seizures rose sig-
nificantly in 2003, mainly reflecting the revival of
Afghan opium production and more seizures in the
countries surrounding Afghanistan. The number of
cannabis cases has been on the rise since the early 1990s,
and its rate of growth exceeded that of other drugs in
2002-2003, in line with a growth in global consump-
tion. Cocaine has remained relatively stable.
Quantities of drugs seized increased substantially in
2003. 
Turning from the number of seizures to the quantities
seized, 115 countries reported total tonnages in 2003.
Expressed in terms of weight, quantities increased
between 2002 and 2003 in all of the major drug cate-
gories: depressants (up 51%), opium (up 38%),
heroin/morphine (up 32%), cocaine (up 33%),
cannabis (up 24%), and ATS (up 18%). While the
quantities of drugs seized has increased, year on year, for
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Fig. 10: Number of seizure cases, 1985-2003
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Fig. 11: Proportion of seizure cases according to
drug category, 1990-2003
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the last decade, last year’s increases were higher than
average in all categories, except ATS, which was about
the same. The reasons for this surge are still unclear.
By weight, cannabis tends to top the rankings of quan-
tities seized, and 2003 was no exception, with cocaine,
opium, heroin/morphine, and ATS following. This
ranking is different than that of the number of seizures
made, particularly for cocaine. This is because cocaine
tends to be transported in large quantities, the global
average per seizure being 3.1 kg, almost 35 times the
size of the average ecstasy seizure (0.09 kg).
A more meaningful comparison can be made by reduc-
ing total volumes to dose-units. In 2003, global drug
seizures increased by 10% and more than doubled
between 1985 and 2003, from 14.3 billion to 31.3 bil-
lion doses. Cannabis still remains the top drug seized,
with 70% of all drug doses seized being cannabis, fol-
lowed by cocaine (16%), opiates (9%) and ATS (3%). 
Thus, in terms of the quantities involved, trends for
most substances tend to be upward in recent years, and
this increase is not confined to any geographic region.
Europe shows the strongest growth rate of seizures (13%
per annum), followed by Oceania (9% per annum). The
largest seizures, however, continue to be made in the
Americas (40% of the world’s seizures by weight in
2003, down from 58% in 1985), followed by Europe
(30% in 2003, up from 7% in 1985)), Asia (16%),
Africa (13%), and Oceania (0.4%).
31
1. Trends in world drug markets The dynamics of the world drug market
Fig. 12: Global cannabis seizures (in weight
equivalents), 2001-2003
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Fig: 13: Global drug seizures, excluding cannabis (in
weight equivalents), 2001-2003
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Fig. 14: Average annual change in seizures, 1993-
2003
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Fig. 15: Trends in world seizures, 1993 -2003 (in metric mt)
The global production trend is rather stable for opium,
and declining  for coca but seems to be increasing for
cannabis and,  following some declines,  for ATS .
UNODC, in collaboration with selected governments,
uses a sophisticated monitoring system based on the use
of modern satellite technology with on the ground ver-
ification (‘ground truthing’) and yield surveys. This
method produces some of the most rigorous data on the
drug problem, because the measurement is direct and
quantifiable. Production data for opium and coca leaf
are thus probably the most reliable indicators of how the
drug problem is evolving at the global level. Information
on the final output – heroin or cocaine – is more diffi-
cult to obtain and subject to a higher degree of uncer-
tainty as direct access to the operators of clandestine
laboratories is difficult. Existing transformation ratios
are usually based on rather small samples of case studies
in which operators demonstrated the cocaine/heroin
transformation processes to law enforcement bodies.
How representative the results of these case studies are
for the clandestine manufacturing process as a whole is
unknown but they are the best estimates currently avail-
able.
While production is clearly linked to trafficking and
consumption, sometimes the links are less direct than
they appear. There can be, for example, important time
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Fig.16:  Global drug seizures in unit equivalents,
1985-2003
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Fig. 17: Proportion of drug categories in seizures, in
unit equivalents, 1985-2003
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Fig. 18: Regional breakdown of drug seizures in unit
equivalents, 1985-2003
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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lags (of 1 or 2 years) as a result of the manufacturing
processes (opium J morphine J heroin; coca leaf J
coca paste J coca base J cocaine-HCL), the length of
the trafficking routes, and the existence of stocks which
are known to have the potential to reduce the impact of
supply side changes.
Currently about 196,000 ha are under opium poppy
and 158,000 ha are under coca cultivation worldwide.
To put this in perspective, the area under opium and
coca cultivation is a similar size as the land area covered
by a small country such as Liechtenstein (160,000 ha)
or an extended urban area such as London (168,000
ha), or about twice the size of cities such New York
(78,000 ha) or Berlin (89,000 ha).  
Following strong increases in 1980s, opium production
has been basically stable at around 4,000 – 5,000 metric
mt since the early 1990s. Production stood at 4,765 mt
in 2003 and 4,850 mt in 20043. 87% of opium for the
illicit market is now produced in Afghanistan. Probably
because of the large stocks built up in the late 1990s, the
2001 opium production ban in Afghanistan4 had only
limited consequences for the global supply of opiates.
The long-term trend has been towards rising levels of
opium production in Afghanistan. This has largely
offset the strong declines reported from Myanmar and
Laos in recent years, bringing global potential heroin
production in 2004 to 565 metric mt. 
Potential cocaine production peaked in the second half
of the 1990s (950 mt in 1996 and 925 mt in 1999), but
has been declining significantly thereafter to 674 mt in
2003.5 In 2004, cocaine production increased margin-
ally to 687 mt.  Despite this, overall production remains
26% lower than in 1999. The declines of potential
cocaine production in recent years were mainly the
result of progress made in Colombia. The increase in
2004 was due to stronger coca leaf production in both
Peru and Bolivia. Both countries had already made sig-
nificant progress in cutting coca leaf production a few
years earlier, however, and production is thus still lower
than in 1998 or previous years. 
34
World Drug Report 2005 Volume I. Analysis
3 UNODC usually speaks of potential rather than actual heroin or cocaine production. Potential production refers to the amount of heroin or cocaine
produced if all of the raw material (opium/coca leaf ) produced in a country, were transformed into the end product.  Actual heroin/cocaine
production of a country may well differ. It would be lower if not all of the raw material was transformed into the end-products (e.g. as there is local
consumption of the raw material) or it could be higher if raw material was imported from a neighbouring country, or if the manufacturing processes
improved.  
4 Which caused production in Afghanistan to fall to 185 metric mt.
5 Given revised production estimates from Bolivia, total cocaine estimates for the year 2003 differ slightly from production estimates published in last
year’s World Drug Report.
Fig. 19: Global potential opium production,
1980-2004
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Fig. 20: Global potential cocaine production, 
1980-2004
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Cannabis production has been rising in recent years and
the THC content of cannabis produced in a number of
developed countries has been increasing. Available
information on the extent and the trends of cannabis
production is far less reliable than that for coca and
opium. With the exception of the survey UNODC con-
ducts with the Moroccan Government on cannabis resin
production, estimates for cannabis resin production are
usually made on the basis of indirect indicators.  Based
on such information, UNODC estimates that more
than 7,000 mt of cannabis resin. Production of cannabis
herb is estimated at slightly more than 40,000 mt in
2003, exceeding last year’s published estimate of an
annual production of around 32,000 mt of cannabis
herb. A significant part of this increase can be linked to
methodological changes. Nonetheless, actual produc-
tion is likely to have increased as well.      
Following years of massive increases, UNODC esti-
mates of global ATS production for the year 2003 were
slightly lower than those published in last year’s World
Drug Report: 332 mt of amphetamines (methampheta-
mine and amphetamine) and 90 mt of ecstasy for 2003
versus 410 mt of amphetamines and 113 mt of ecstasy
published in last year’s WDR for 2000/2001. The
methodological approach to arrive at these estimates did
not change. Nonetheless, it is difficult to judge to what
extent this ‘decline’ in production was real (as opposed
to a statistical artefact). Estimates of the extent of global
ATS production can be only established by indirect
means. These estimates were derived from estimates of
the number of ATS drug users,  ATS seizures and ATS
precursors seizures. Early indications for 2004 indicate
that ATS production and consumption have begin to
increase again.
1.1.2  The outlook for world drug 
markets 
Afghanistan will  determine the size and development of
the world’s main opiate markets…
The global heroin market was basically stable in 2003
with increases in production limited to Afghanistan and
increases in consumption limited to countries in the
neighbourhood of Afghanistan. In 2004,  although the
area under cultivation increased by 64%, the yield per
hectare declined strongly as a consequence of drought
and various plant diseases. Opium production thus rose
by ‘just’ 17% in the country.  At the global level, this
increase was largely offset by a  54%, and 64%, decline
in opium production in Myanmar and Laos respectively.
The net result was a marginal 2% increase in opium
production at the global level.  Early indications are that
overall production will remain stable through 2005. 
Opium production in South-East Asia  is now 78%
lower than it was in 1996.  Production in this sub-
region is forecast to decline further in 2005. If the
declines witnessed over the last few years are sustained,
it would not be too far outside the realm of possibility
that South-East Asia could become virtually free of
illicit poppy cultivation over the next few years.  Of
course, encouraging trends are no reason for compla-
cency. There is evidence, for example, that in the East-
ern Shan States of Myanmar – as already highlighted in
last year’s World Drug Report - some  communities are
facing a serious humanitarian crisis. As Myanmar and
Laos attempt to reach the goals agreed upon by the
international community at the 1998 United Nations
General Assembly Special Session (UNGASS), it is of
paramount importance that the donor community take
its share of the burden and provide relief and develop-
ment assistance to the most affected populations in
these areas. The risk being that a humanitarian crisis
could cause farmers to revert to opium production.
Strong opium price rises are already increasing the
attractiveness of the latter option.   
As compared to last year, the situation looks slightly
more positive for Afghanistan. Presidential elections
were held in 2004 and the Government is gradually
strengthening its control over the country and those
involved in the opium business.  A Rapid Assessment
conducted by UNODC earlier in 2005 indicated that
the area under poppy cultivation has declined in 2005
as compared to the record levels in 2004. It is, however,
not yet certain whether the reduction of the land under
opium poppy cultivation would be sufficient to offset a
possibly higher yield than observed in 2004.        
In the meantime the country’s last opium harvest is still
finding its way to the consumer markets of Europe and
other regions. Purity levels of heroin in some European
countries have already started to rise – a clear indication
that there is sufficient and rising supply. Thus, while the
mid-term prospects are rather positive, problems could
still emerge in some of the main consumer markets this
year. Opium produced in Afghanistan usually ends up
in these markets in the form of heroin with a one year
delay. Some of the transit countries have already started
to report higher levels of heroin abuse.
Slow downs have been observed over the last few years
in the Oceania region. Following the dismantling of sev-
eral major networks importing heroin into Australia in
late 2000, heroin abuse rates declined substantially and
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remained at low levels in subsequent years, including
2004. This is encouraging given that the acute heroin
shortage of 2001 has largely disappeared.  It is now pos-
sible that these lower prevalence rates will be maintained
in the foreseeable future.   
…while lower levels of coca leaf production have not
prevented the ongoing geographical spread of cocaine
consumption.   
While overall levels of cocaine use remained largely
stable and production estimates show a decline as com-
pared to the late 1990s, there are still far more countries
reporting rising rather than falling levels of cocaine use.
Moreover, the increase in cocaine seizures and the high
interception rate in 2003 did not lead to price rises or
any significant declines in cocaine purity in the main
consumer markets. This puzzles analysts and law
enforcement. Possible hypotheses to explain such dis-
crepancies could be (i) the existence of unknown areas
in the three Andean countries or in other countries
where coca cultivation takes place;  (ii) a rise in yields
which is not, as yet, reflected in production estimates;
(iii) the existence of cocaine stocks, built up in the late
1990s,  which still fuel the markets; and/or (iv)
improvements in the cocaine manufacturing process
(following some deterioration in the late 1990s), result-
ing in more cocaine being produced out of less coca leaf.
How likely are these hypotheses? (i) UNODC has, so-
far, no indications of any large-scale coca production
outside the three traditional coca producing countries,
but this does not mean that there could be some
improvements in the ability of ‘cocaleros’ to hide their
production, thus reducing the likelihood of such fields
to be detected by satellite photos or by aerial photogra-
phy. (ii) There are ongoing studies in the three Andean
countries to verify the yields that are currently being
applied. While the results of these studies are not yet
available, so far there is some suggestion that in some
regions the yields could be slightly higher.  (iii) The exis-
tence of important cocaine stocks in the Andean region
is a potentially plausible explanation. However,  there is
not much evidence for this. If such stocks had been built
up in the late 1990s, they should be soon exhausted and
a contraction of the market should then become visible.
(iv) There is some evidence for the last  hypothesis,
though not sufficient to fully explain the above men-
tioned market paradox.  Given successful operations in
the late 1990s to stop the diversion of potassium per-
manganate, a key precursor chemical in the manufac-
ture of cocaine, the quality and the yield of coca leaf
appears to have deteriorated. This could have meant
that actual cocaine production was less than the poten-
tial cocaine production estimates calculated for the late
1990s. In subsequent years, however, cocaine manufac-
turers seem to have adapted by using alternative chem-
icals (e.g. sodium hypochlorite, know as leja in the
region)  which led again to better quality cocaine and
better extraction rates. There has also been speculation
that clandestine laboratories have diverted various oxi-
dizers from the cement industry to cocaine processing in
order to improve the output of cocaine manufacture. All
of this could have meant that the actual decline in the
cocaine output - despite a 30% reduction in the area
under coca cultivation between 1999 and 2003 - may
have been  less significant over this period.   
Further investigation and the conclusion of these ongo-
ing studies will help us to better understand this para-
dox, and thus the market. In any case, the trend towards
lower production of cocaine did not continue in 2004,
as the area under coca cultivation rose in both Bolivia
and Peru. This is a worrying loss of momentum for both
countries which had already made significant progress
to curb coca production. The net results (+2%) were not
a real problem in 2004. However, ongoing increases in
these two countries may eventually weaken the progress
the region has made in controling coca supply.  This is
a vital juncture, and it will be important for the inter-
national community to continue to support alternative
livelihoods programmes.
In parallel, the risk of a further dispersion of the cocaine
markets continues. Europe is particularly vulnerable,
having already seen a steady growth of its cocaine mar-
kets over the last decade. Even though there are signs of
stabilization in some countries, consumption continues
to increase in others. In 2003, 14  European countries
reported an increase and 10 a stabilization. Not a single
country experienced a decline in cocaine use.  
A particular challenge will be the spread of crack-
cocaine: 7 European countries reported an increase,  9
saw stable levels, while, again, not a single European
country identified a decline in 2003. 
As trafficking routes evolve, paying local assistants in
kind along new routes,  the ongoing dispersion to coun-
tries in the Americas and in Africa will continue. Recent
trends saw the increased use of various West African
countries as transit routes to Europe. Data from South
Africa on treatment demand, provided by the South
African Community Epidemiology Network on Drug
Use (SACENDU), clearly show that treatment for
cocaine abuse was on the rise over the 2002-2004
period, notably in locations where previous prevalence
rates had not been high.   
In contrast, cocaine use has stabilized in the United
States, the world’s largest cocaine market. Fortunately,
there are no indications that this will change over the
foreseeable future. Given increased treatment possibili-
ties for hard-core cocaine addicts, there is even a likeli-
hood that the overall amounts of cocaine consumed in
the USA might decline.   
The cannabis market continues to thrive…
Cannabis continues to be the most widely produced,
trafficked and consumed drug worldwide. All indicators
– production, seizures and consumption - suggest that
the market at the global level is expanding further. For
the time being, there is no reason to believe that this
expansion will stop.  
Between 1993 and 2003, 163 countries and territories
were identified as cannabis producing countries. This
clearly highlights its pervasiveness, as opposed to opium
or coca leaf production, which are limited to just a few
countries and locations.  Nonetheless, there are some
concentrations. The bulk of cannabis herb production
takes place in North America and in Africa.  The largest
seizures of cannabis herb took place in 2003 in Mexico
(37% of total) and in the USA (21%), followed by a
number of African (Tanzania, Nigeria) and South
American (Colombia, Brazil) countries.  
Cannabis resin production is far more concentrated,
with Morocco, Afghanistan and Pakistan being the
main producers. Survey results from Morocco showed
that cannabis resin production fell 10% to 2,760 mt in
2004. 
Overall cannabis consumption has been rising in South-
America (including the Caribbean and Central Amer-
ica), in Africa, in Europe and in several Asian countries.
By contrast, it has remained largely stable in North
America. Declines were reported for some countries in
South-East Asia as well as the Oceania region.  No sig-
nificant changes of these patterns is expected in the
short run. 
… as signals from the ATS markets are mixed –
although a future increase is likely.
Signals from the ATS market are complex. Overall the
strong increases in ATS use observed in the 1990s were
not continued into the first years of the new millen-
nium. This year’s signals include: an ongoing strong
increase in the number of ATS laboratories being dis-
mantled, lower levels of ‘amphetamines’ (methamphet-
amine and amphetamine together) seizures as compared
to the year 2000, falling ecstasy seizures in 2003, falling
ATS precursor seizures over the 2000-2003 period, and
a stable/declining ATS use trend index in 2003.
However, a number of (still very partial) indicators sug-
gest that a decrease in use will not be repeated in the
near future. One reason for this forecast is that ATS
seizures started rising in 2003. Amphetamine seizure
reports received from some European countries indicate
a further increase in 2004. Also, the fact that ampheta-
mine prices have fallen in a number of European coun-
tries over the 2000-2004 period suggests that
production may have been rising.  Finally, early reports
of abuse trends received from countries in East and
South-East Asia suggest that the stabilization/ decline
seen in 2003 did not continue in 2004. While ecstasy
use declined strongly in the USA among high school
students over the 2001-2004 period, methamphetamine
use among 12th graders started increasing again slightly
in 2004. After several years of decline, availability of
methamphetamine was reported by US students to have
increased slightly in 2004.  
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While global cultivation of opium poppy is increasing…
In 2004, global illicit opium poppy cultivation
increased by 16%, due entirely to increased cultivation
in Afghanistan.  In Southeast Asia, in contrast, opium
poppy cultivation has decreased continuously since
1998. In 2004, only 50,900 ha of opium were cultivated
in Lao PDR and Myanmar, as compared to 158,000 ha
in Lao PDR, Myanmar, Thailand and Viet Nam in
1998.  Despite this year’s increase, global opium poppy
cultivation is still far less than it was in the nineties, and
since 1998 - the year of the UNGASS - global cultiva-
tion has declined by 18%. 
In 2004, 67% of the global opium poppy cultivation
took place in Afghanistan. The area under cultivation
increased from about 80,000 ha in 2003 to an unprece-
dented 131,000 ha in 2004. Of greatest concern is the
fact that  opium poppy cultivation has been introduced
into previously unaffected areas and is now found in all
34 provinces of the country. 
Over the last six years, the Governments of Lao PDR
and Myanmar have achieved a reduction of illicit culti-
vation in their countries. In Myanmar, rapid reduction
is being promoted in line with a national action plan to
eradicate the crop by the year 2014. The total area
under opium poppy cultivation in Myanmar was
reduced 23% to 44,200 ha in 2004. The Government
of the Lao PDR has a similar goal of eliminating opium
poppy cultivation by the year 2005. The total area
under opium poppy cultivation in 2004 was down 43%
to 6,600 ha in 2004. Both countries promote alternative
livelihood programmes to increase the likelihood that
these reductions will be sustainable and the overall goals
will be met on target.  But many farmers still lack access
to these programmes, and assistance from the interna-
tional community is limited. 
After a short boom in 1994, opium poppy cultivation
in Colombia has remained relatively stable and was
about 4,000 ha during 2002-2004. The Government
reported that 3,000 ha of opium poppy were sprayed
and 800 ha manually eradicated in 2004. This is an
increase of 71% compared to 2003. The Government of
Peru estimated opium poppy cultivation in that coun-
try at around 1,500 ha in 2004, about the same as the
estimate of 1,400 ha in 2001. 
Following declines in the early 1990’s, opium cultiva-
tion in Pakistan remained below 1,000 ha over the 1996
- 2002 period before increasing strongly in 2003 and
2004. The government has been proactive in imple-
menting eradication, thus keeping cultivation under
control.  Low levels of opium poppy cultivation exist in
many regions and countries such as Viet Nam, Russia,
Ukraine, Central Asia, the Caucasus region, Egypt, Peru
and Thailand.
…global opium production is almost stable.
Global opium production increased by only 2% to
4,850 metric tons in 2004.  The increase was minimal
due to a relatively low opium yield per hectare in
Afghanistan, Lao PDR and Myanmar. Unfavourable
weather conditions (insufficient rain and cold tempera-
tures) and disease kept potential opium production in
Afghanistan at around 4,200 metric tons (mt), repre-
senting an increase of about 17% compared to 2003. In
Myanmar, the North Shan experienced a severe drought
and the maximum potential yield fell to 8 kg/ha. In Lao
PDR the average national opium yield potential for
2004 was even lower, at 6.5 kg/ha. The potential opium
production in Lao PDR and Myanmar is around 43 and
370 metric tons respectively. Opium production in Pak-
istan, Thailand and Viet Nam remained relatively low in
2004. 40 metric tons of opium were produced in Pak-
istan in 2004.  For Latin America opium production is
estimated at around 160 metric tons.
The potential farm gate value of opium production in
2004 at the global level is estimated at US$ 747 million,
1.2 Opium / Heroin market
1.2.1 Production
40
World Drug Report 2005 Volume I. Analysis
less than in 2003 ( 1.2bn). About 80% of this was gen-
erated in Afghanistan. Given the strong fall of opium
prices in Afghanistan in 2004, the overall farm gate
value of opium production was some 41% lower than in
2003 (US$ 600 million in 2004 against US$ 1,020 mil-
lion in 2003).
Opium prices are inversely proportional to supply trends
in Afghanistan. 
Opium prices in Afghanistan were declining with
increasing supplies. The average price for fresh opium at
the time of harvest, weighted by regional opium pro-
duction, amounted to US$ 92 per kilogram in 2004, a
69% decline compared to the previous year. Prices for
fresh opium at the farm-gate are, however, still two to
three times higher than in the second half of the 1990s.
The opposite trend is observed in Southeast Asia, where
farm gate prices of opium have increased in Lao PDR
and Myanmar. The average farm gate sale price of
opium in 2004 in Myanmar was estimated at US$
234/kg,  an increase of 80%, in US$ terms. In Laos, the
average farm gate price of opium was estimated at US$
218/kg, an increase of  27% over 2003.
Despite increased farm gate prices, it is expected that
the decline of cultivation in Southeast Asia will continue
as the Government of Lao PDR and the Government of
Myanmar remain determined to achieve the goals set in
their respective national drug control programmes. The
sustainability of these reductions in cultivation will
depend on the availability of alternative livelihoods
opportunities for local communities. In Afghanistan,
the Government has indicated that it will renew its
efforts to curb opium poppy cultivation. The first indi-
cations of a possible reduction have been reported in the
rapid assessment survey conducted by UNODC in the
beginning of February 2005.
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(a) Harvestable after eradication.
(b) Due to small production, cultivation and production were included in the category " Other countries", for Viet Nam as of  2000 and for Thailand
as of 2003.
(c) According to the Government of Colombia, cultivation covered 7,350 ha and 6,500 ha and production amounted to 73 mt and 65 mt in 1998 and
1999 respectively. 
(d) Sources: As its survey system is under development, the Govt of Mexico indicates it can neither provide cultivation estimates nor endorse those
published by UNODC which are derived from US Government surveys. 
(e) Includes countries such as Russia, Ukraine, Central Asia, Caucasus region, Egypt, Peru, Viet Nam (as of 2000) and Thailand (as of 2003).
(f ) For calculation of regional sub-total for 2004 previous year's estimates were used.
(g) Based on the Afghanistan Opium Survey 2004, estimates of potential heroin production is 500 metric tons (mt) in Afghanistan. For other countries
a 10:1 ratio is used for conversion from opium to heroin.
OPIUM
Table 1. GLOBAL ILLICIT CULTIVATION OF OPIUM POPPY AND PRODUCTION 
OF OPIUM, 1990-2004
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
CULTIVATION(a) IN HECTARES
SOUTH-WEST ASIA
  Afghanistan 41,300 50,800 49,300 58,300 71,470 53,759 56,824 58,416 63,674 90,583   82,171 7,606 74,100 80,000 131,000
  Pakistan 7,488 7,962 9,493 7,329 5,759 5,091 873 874 950 284 260 213 622 2,500 1,500
  Subtotal 48,788 58,762 58,793 65,629 77,229 58,850 57,697 59,290 64,624 90,867 82,431 7,819 74,722 82,500 132,500
SOUTH-EAST ASIA
  Lao PDR 30,580 29,625 19,190 26,040 18,520 19,650 21,601 24,082 26,837 22,543 19,052 17,255 14,000 12,000 6,600
  Myanmar 150,100 160,000 153,700 165,800 146,600 154,070 163,000 155,150 130,300 89,500 108,700 105,000 81,400 62,200 44,200
  Thailand (b) 1,782 3,727 3,016 998 478 168 368 352 716 702 890 820 750
  Viet Nam (b) 18,000 17,000 12,199 4,268 3,066 1,880 1,743 340 442 442
  Subtotal 200,462 210,352 188,105 197,106 168,664 175,768 186,712 179,924 158,295 113,187 128,642 123,075 96,150 74,200 50,800
LATIN AMERICA
  Colombia (c) 1,160 6,578 5,008 15,091 5,226 4,916 6,584 7,350 6,500 6,500 4,300 4,100 4,100 3,950
  Mexico (d) 5,450 3,765 3,310 3,960 5,795 5,050 5,100 4,000 5,500 3,600 1,900 4,400 2,700 4,800 n.a.
  Subtotal 5,450 4,925 9,888 8,968 20,886 10,276 10,016 10,584 12,850 10,100 8,400 8,700 6,800 8,900 8,750 (f)
OTHER
  Combined (e) 8,054 7,521 2,900 5,704 5,700 5,025 3,190 2,050 2,050 2,050 2,479 2,500 2,500 3,000 3,890
GRAND TOTAL 262,754 281,560 259,686 277,407 272,479 249,919 257,615 251,848 237,819 216,204 221,952 142,094 180,172 168,600 195,940
POTENTIAL PRODUCTION IN METRIC TONS
SOUTH-WEST ASIA
  Afghanistan 1,570     1,980     1,970     2,330     3,416     2,335     2,248     2,804     2,693     4,565     3,276     185        3,400     3,600     4,200
  Pakistan 150        160        181        161        128        112        24          24          26          9            8            5            5            52          40           
  Subtotal 1,720 2,140 2,151 2,491 3,544 2,447 2,272 2,828 2,719 4,574 3,284 190 3,405 3,652 4,240
SOUTH-EAST ASIA
  Lao PDR 202        196        127        169        120        128        140        147        124        124        167        134        112        120        43
  Myanmar 1,621     1,728     1,660     1,791     1,583     1,664     1,760     1,676     1,303     895        1,087     1,097     828        810        370
  Thailand (b) 20          23          14          17          3            2            5            4            8            8            6            6            9            
  Viet Nam (b) 90          85          61          21          15          9            9            2            2            2            
  Subtotal 1,933     2,032     1,862     1,998     1,721     1,803     1,914     1,829     1,437     1,029     1,260     1,237     949        930 413
LATIN AMERICA
  Colombia (c) 16          90          68          205        71          67          90          100        88          88          80          76          76          73           
  Mexico 62          41          40          49          60          53          54          46          60          43          21          71          47          84          n.a.
  Subtotal 62          57          130        117        265        124        121        136        160        131        109        151        123        160 157 (f)
OTHER
  Combined (e) 45          45          -        4            90          78          48          30          30          30          38          18 14 24          40
GRAND TOTAL 3,760      4,274      4,143      4,610      5,620      4,452      4,355      4,823      4,346      5,764      4,691      1,596      4,491      4,765      4,850
Potential HEROIN 376         427         414         461         562         445         436         482         435         576         469         160         449         477         565 (g)
OPIUM
HEROIN
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Fig. 1: Global opium poppy cultivation 1990-2004 (ha)
Fig. 2: Global opium production 1990-2004 (metric tons)
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Fig. 3: 
Annual opium poppy cultivation and opium production in main producing countries, 1990 - 2004
AFGHANISTAN - OPIUM POPPY CULTIVATION, 1990-2004 (ha) AFGHANISTAN - OPIUM PRODUCTION, 1990-2004 (metric tons)
MYANMAR - OPIUM POPPY CULTIVATION, 1990-2004 (ha) MYANMAR - OPIUM PRODUCTION, 1990-2004 (metric tons)
  LAO PDR - OPIUM POPPY CULTIVATION, 1990-2004 (ha) LAO PDR - OPIUM PRODUCTION, 1990-2004 (metric tons)
REST OF THE WORLD - OPIUM POPPY CULT., 1990-2004 (ha) REST OF THE WORLD - OPIUM PRODUCTION, 1990-2004 (metric tons)
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Fig. 4: Opium poppy cultivation 
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Differences in opium yield between Afghanistan and Myanmar are due to differences in opium
poppy varieties and growing conditions. Variations of yields from year to year in the same country
are mostly caused by changes in weather conditions and/or, as in the case of Afghanistan in 2001,
by a shift in the relative distribution of cultivation from irrigated to rain-fed land.
*Data for the 'rest of the world' is still tentative.
*Data for the 'rest of the world' is still tentative.
Fig. 5: Opium Yields in Afghanistan and Myanmar (kg/ha)
Fig. 6: Opium production
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Table 2. Estimated farmgate prices for potential opium, 2004 
Farmgate price Production
US$ per kg metric tons
Myanmar 234                      370                            87
Afghanistan 142                      4,200                         600
Lao, PDR 218                      43                              9
Colombia (1) 194                      76                              15
Mexico (1) 194                      (2) 84                              16
Other (1) (4) 196                      (3) 103                            20
Total opium 4,876 747
(4) Includes countries such as Pakistan, Central Asia, Russia, Ukraine, Caucasus region, Viet Nam, Thailand, Egypt and Peru.
Potential value
(millions of US$)
(2) Farmgate price not available: value based on price in Colombia
(3) Average price based on the total value and production from the five countries listed above.
(1) Based on 2002 opium prices and calculated with 2003 production data.
61 87
600
Afghanistan
MyanmarOthers
Fig. 7: Potential farmgate value of opium, 2004 (millions of US$)
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Fig. 8: USA: heroin retail and wholesale prices, 
1990-2003 (US$/gram)
Fig. 9: Europe: heroin retail and wholesale
prices, 1990-2004 (US$/gram)
* premilinary data for 2003.
Note: Retail and wholesale prices are not directly comparable because purity levels differ.
Table 3. Reported opium poppy eradication, in ha, 1993 - 2004
Fig. 10: Wholesale heroin prices in Europe and the USA, 1990-2004 (US$/gm, at street purity)
* preliminary data for 2003
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Afghanistan 400      121      21,430 
Colombia 9,400   5,314   5,074   7,412   7,333   3,077   8,434   9,279   2,583   3,371   2,994   3865
Lao PDR 4,134   3,556
Mexico 13,015 10,959 15,389 14,671 17,732 17,449 15,461 15,717 15,350 19,157 20,034 
Myanmar 160      1,041   3,310   1,938   3,093   3,172   9,824   1,643   9,317   7,469   638      2,820
Pakistan 856      463      867      654      2,194   1,197   1,704   1,484   n.a. 4,185   5200
Thailand 1,706   1,313   580      886      1,053   716      808      757      832      507      767      
Vietnam 672      477      1,142   340      439      426      n.a. 32.47
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Opiates seizures reached a record high in 2003…
Global seizures of opiates7 in 2003  reached 110 mt, a
record high and an increase of 33% as compared to a
year earlier.  The large increase in seizures is thought to
reflect  higher rates of opiate production and trafficking
as well as improved law enforcement activities, notably
in the countries surrounding Afghanistan.  The  inter-
ception rate, i.e. seizures of opiates expressed as a per-
centage of global illicit production, increased to 23% in
2003, up from 18% in 2002 and 14% in 1993.  
Interestingly, the increase in seizures was more pro-
nounced for morphine and opium than for heroin,
reflecting improved enforcement activities in and
around the main producer countries. Broken down by
substance, opium seizures increased in 2003 by 38% to
134 mt (or 13.4 mt in heroin equivalents)8, morphine
seizures increased by 77% to 43.7 mt and heroin
seizures increased by 10% to 53.3 mt. 
…with seizures having risen particularly in and around
Afghanistan, the world’s largest opium producer…
The countries reporting the largest total opiates
seizures9 for 2003 were Pakistan (34.7 mt) and the
Islamic Republic of Iran (26.1 mt) — equivalent to
31% and 24% of global opiate seizures respectively.
Encouragingly, the growth of seizures in countries
1.2.2 Trafficking 
Fig. 11: Seizures of opiates (in heroin equivalents)7,
1980-2003
Source: UNODC, Annual Reports questionnaire Data/DELTA.
7 Opium, morphine and heroin, expressed in heroin equivalents using a 10 : 1 ratio for opium to heroin (i.e. 10 kg opium for the manufacture of 1 kg
of heroin) and a 1:1 conversion rate for morphine to heroin. 
8 Using a 10 : 1 ratio for opium to heroin. 
9 In heroin equivalents.
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Fig. 12: Seizures of opiates (in heroin equivalents)7,
1980-2003
Source: UNODC, Annual Reports questionnaire Data/DELTA.
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neighbouring Afghanistan was stronger than the growth
of Afghanistan’s opium production in 2003. Opiates
seizures  rose in the Near and Middle East/South-West
Asia region (which includes Iran, Pakistan and
Afghanistan) by 75% in 2003 to 62.9 mt (57% of
global opiates seizures). These were the highest opiates
seizures ever recorded in this sub-region. Seizures in
Central Asia rose by 33% in 2003 to 7.1 mt. Most of
the opiates trafficked via Central Asia are destined for
the Russian Federation and other CIS countries. 
UNODC’s 2004 Afghanistan Opium Survey revealed
that of Afghanistan’s total opiates exports (500 mt of
morphine and heroin and close to 1000 mt of opium),
about a quarter are being shipped abroad via Central
Asia (30% of heroin and morphine exports); the bulk,
however, are still exported via Pakistan and Iran to
Turkey (directly or via Iraq). The analysis of seizure data
in these regions suggests that processing of opium to
end products in Afghanistan increased over the last few
years, with the trend towards seizing semi-processed
(morphine) or end products (heroin) continuing in
countries surrounding Afghanistan. UNODC’s 2004
Afghanistan Opium Survey showed that 77% of all opi-
ates seizures in the sub-regions surrounding Afghanistan
(South-West and Central Asia) are already in the form
of either morphine or heroin, up from 40% in 1995. 
…and temporarily declined in Europe.
In Europe, in stark contrast to South-West and Central
Asia, seizures declined by 13% to 19.4 mt in 2003.
Seizures declined both in Western and Central Europe
(-11%) and along the Balkan route (-35% as compared
to 2002; though up by 12% as compared to 2001). The
largest opiate seizures in Western and Central Europe
over the last few years have been reported by the UK
and Italy, Europe’s largest opiate markets.  
Heroin prices in Western Europe have continued falling
slightly in euro-terms (from €69 per gram in 2001 to
€63 in 2002 and €60 in 2003), suggesting that there is
no shortage in the availability of heroin. In economic
terms, Western and Central Europe continues to be the
world’s most lucrative heroin market.  The continent’s
overall heroin market (see the market model presented
in Chapter 2) is estimated to amount to some 170 mt
of which about half is used in Western and Central
Europe. 
Preliminary data for 2004 suggest that seizures along the
Balkan route, through which the bulk of opiates des-
tined for Western Europe continue to be smuggled,
increased again.  This was primarily the result of suc-
cesses by the Turkish authorities. In 2003, Turkey’s over-
all opiate seizures10 amounted to 5.7 mt, representing
5% of global seizures or 30% of all European opiate
seizures. In 2004, opiate seizures in Turkey increased by
almost 160% to 14.7 mt. Since 1987, Turkey has
accounted for Europe’s largest opiate seizures.
Criminal groups of Turkish/Kurdish origins continue
playing a significant role in wholesale shipments of opi-
ates from Turkey to re-distribution centers across West-
ern Europe.11 In recent years criminal groups of
Albanian origins (based in Kosovo, FYR of Macedonia
and Albania) have gained in importance and various
other criminal groups from other Balkan countries also
participate in this business.  Much of the retail trade in
Western Europe, however, is now in the hands of crim-
inal groups of West African origin. 
10 In heroin equivalents.
11  HONLEA Meeting, Vienna, February 2005.
Fig. 13: Proportion of heroin and morphine in opiates
seizures in South-West and Central Asia*,
1995-2003  
* using a 6.5:1 conversion ratio of opium to heroin and a 1:1
conversion ratio for morphine to heroin. 
Source: UNODC, 2004 Afghanistan Opium Survey; UNODC,
Annual Reports Questionnaire Data / DELTA
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In East Europe (defined as the CIS countries),  opiates
seizures continued to rise strongly in 2003 (+78%).
According to the Russian authorities, 85% of opiates
seized are for domestic use and 15% are intended for
onward shipment to other European countries. For the
time being not much evidence exists among West Euro-
pean enforcement agencies that opiates trafficked to CIS
countries are actually reaching Western Europe; most of
these opiates seem to remain within the CIS region  for
domestic consumption. 
Seizures remained stable - at lower levels - in South-East
Asia…
With opium production in Myanmar and Laos PDR
continuing to decline, opiates seizures in South-East
Asia (12.4 mt or 11% of global seizures) remained basi-
cally stable in 2003 (+4%). In contrast to South-West
Asia, opiate seizures in South-East Asia, where heroin is
refined close to source, are almost exclusively in the
form of heroin. China reported the world’s third largest
total seizure of opiates (9.6 mt in 2003, or 9% of global
seizures) after Pakistan and Iran, ahead of Tajikistan,
Turkey and the Russian Federation, and accounted for
77% of all opiates seizures in East and South-East Asia.
As almost all of this was heroin (9.5 mt), authorities in
China made, for the third year in a row, the world’s
largest total heroin seizures (18% of the global total),
ahead of Pakistan, Tajikistan and Turkey.   
… but increased in the Americas.
The Americas account for 6% (6.4 mt), of global opiate
seizures. In 2003, opiate seizures increased by 20% in
the Americas, mainly reflecting increases in Central
America (+97%) and in North America (+33%).
Seizures in South America, in contrast, declined (-8%).
The main heroin trafficking flows within the Americas
are from Mexico and Colombia to the USA. The largest
opiate seizures in the Americas are made in the USA
(2% of global seizures), followed by Mexico and Colom-
bia. The US authorities also name Venezuela and
Panama as important transhipment locations. 
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OPIATES INTERCEPTED - AFRICA – 
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Year 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Metric tons 85        145      247      174     196     179     239     213     106      97        134       
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Fig. 16: Global seizures of heroin and morphine, 1993 - 2003
Year 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Metric tons 56        42       44        40         54         56        61         78         65         73        97        
 * data refer to 2002
** total seizures reported by national as well as State & Territory law enforcement agencies which may result in double counting.
 * metric ton equivalents. 1 kilogram of morphine is assumed to be 1 kilogram of heroin. 
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The extent of opiates abuse remains broadly stable…
A total of 16 million people worldwide abuse opiates.
This is 0.4% of the population age 15-64 and includes
some 10.6 million people who abuse heroin (0.3% of
the adult population). Opiates, notably heroin, con-
tinue to be the main problem drugs in the world. More
people (1.3 million) are treated for opiates abuse than
for any other substance. Over 60% of drug related treat-
ment demand in Europe and in Asia is related to the
abuse of opiates.  Out of 1000 opiate (opium, morphine
and heroin) users, 78 people worldwide are in treatment
for opiate abuse and 2.6 die per year, the highest such
ratios for any kind of substance.     
More than half of the world’s total opiates abusing pop-
ulation is in Asia (8.5 million people) and all indications
are that abuse is increasing in this region. In a number
of Asian countries, opiates are reported to be the most
or secondmost widely consumed drug. The countries
with the highest levels of opiate abuse are found in Asia,
notably along routes where the drugs are trafficked out
of Afghanistan (Iran and Kyrgyzstan).  
…with the highest prevalence rate found in Europe…
The highest regional prevalence rate, however, is found
in Europe (0.8%), and the highest levels of opiates
abuse can be found in East Europe (notably in the Russ-
ian Federation). The number of heroin users in West
and Central Europe is estimated at 1.5 million or 0.5%
of the population age 15-64. The UK and Italy continue
to report high levels of abuse.
Abuse of heroin in the Americas is concentrated in the
USA.  Heroin abuse continues to be minimal in South
America, where abuse of opiates is largely limited to
diverted pharmaceutical preparations.   
Heroin abuse in the Oceania region, which a few years
ago was among the highest in the world, is now near the
average. This reflects primarily the success of Australia
in substantially lowering heroin abuse following the
heroin shortage in 2001. 
…despite some worrying increases linked to the increase
in Afghan supply.
Overall, global trends in opiate abuse were broadly
stable in 2003.  According to regional experts abuse
decreased in several countries of  South-East Asia, Aus-
tralia, and East Europe and was stable in West and Cen-
tral Europe and in North America. Abuse rose in
Central Asia, the Near and Middle East/South-West
Asia, South-East Europe,  as well as in Eastern and
Southern Africa. Almost all of these increases can be
linked to the re-emergence of large-scale opium pro-
duction in Afghanistan.   
1.2.3 Abuse
Fig. 17: Drug Use Trend Index - Opiates based on
expert opinions (weighted by estimated
number of opiate users), 1993-2003 
Source: UNODC, Annual Reports questionnaire Data/DELTA.
-4.0
-3.0
-2.0
-1.0
0.0
1.0
2.0
3.0
4.0
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
(d
ec
lin
e 
- 
in
cr
ea
se
)
57
1. Trends Opium / Heroin market
Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
Table 4. Annual prevalence of opiate abuse, 2002-2004
Number of in % of  population Number of in % of  population
abusers  age 15-64 abusers  age 15-64
EUROPE 4,200,000 0.8 2,920,000 0.5
West & Central Europe 1,600,000 0.5 1,500,000 0.5
South-East Europe 180,000 0.2 200,000 0.2
Eastern Europe 2,420,000 1.7 1,200,000 0.8
AMERICAS 2,350,000 0.4 1,560,000 0.3
 North America 1,300,000 0.5 1,240,000 0.4
South America 1,050,000 0.4 320,000 0.1
ASIA 8,480,000 0.3 5,290,000 0.2
OCEANIA 90,000 0.4 30,000 0.2
AFRICA 820,000 0.2 810,000 0.2
GLOBAL 15,940,000 0.4 10,610,000 0.3
            Above global average
            Around global average
            Below global average
Abuse of opiates of which abuse of heroin
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1.3.1 Production
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
CULTIVATION(a) OF COCA BUSH IN HECTARES
Bolivia (b) 50,300 47,900 45,300 47,200 48,100 48,600 48,100 45,800 38,000 21,800 14,600 19,900 21,600 23,600 27,700
Colombia (c) 40,100 37,500 37,100 39,700 44,700 50,900 67,200 79,400 101,800 160,100 163,300 144,800 102,000 86,000 80,000
Peru (d) 121,300 120,800 129,100 108,800 108,600 115,300 94,400 68,800 51,000 38,700 43,400 46,200 46,700 44,200 50,300
Total 211,700 206,200 211,500 195,700 201,400 214,800 209,700 194,000 190,800 220,600 221,300 210,900 170,300 153,800 158,000
POTENTIAL PRODUCTION OF DRY COCA LEAF IN METRIC TONS
Bolivia 77,000 78,000 80,300 84,400 89,800 85,000 75,100 70,100 52,900 22,800 13,400 20,200 19,800 18,500 25,000
Colombia 45,300 45,000 44,900 45,300 67,500 80,900 108,900 129,500 165,900 261,000 266,200 236,000 222,100 168,000 148,900
Peru 196,900 222,700 223,900 155,500 165,300 183,600 174,700 130,600 95,600 69,200 46,200 49,300 52,500 50,790 70,300
Total 319,200 345,700 349,100 285,200 322,600 349,500 358,700 330,200 314,400 353,000 325,800 305,500 294,400 237,290 244,200
POTENTIAL MANUFACTURE(e) OF COCAINE IN METRIC TONS
Bolivia 189 220 225 240 255 240 215 200 150 70 43 60 60 79 107
Colombia 92 88 91 119 201 230 300 350 435 680 695 617 580 440 390
Peru 492 525 550 410 435 460 435 325 240 175 141 150 160 155 190
Total 774 833 866 769 891 930 950 875 825 925 879 827 800 674 687
Table 5. GLOBAL ILLICIT CULTIVATION OF COCA BUSH AND PRODUCTION 
OF COCA LEAF AND COCAINE, 1990-2004
(a) Harvestable after eradication
(b) Sources: 1990-2002: CICAD and US Department of State, International Narcotics Control Strategy Report; 2003-2004: National Illicit Crop
Monitoring System supported by UNODC. 
(c) Sources: 1990-1998: CICAD and US Department of State, International Narcotics Control Strategy Report; 1999-2004: National Illicit Crop
Monitoring System supported by UNODC.
(d) Sources: 1990-1999: CICAD and US Department of State, International Narcotics Control Strategy Report; 2000-2004: National Illicit Crop
Monitoring System supported by UNODC.
(e) Amounts of cocaine that could be manufactured from locally produced coca leaf (due to imports and exports actual amounts of cocaine
manufactured in a country can differ).
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Global cultivation of coca is on the increase…
After three consecutive years of decline, global coca cul-
tivation has increased slightly in 2004. The total area
under coca cultivation in Colombia, Peru and Bolivia
rose 3% to 158,000 ha. This is still 29% less than the
peak of cultivation in 2000, but is a worrying reversal of
the previous positive trend. The majority of all coca cul-
tivation (50%) continues to take place in Colombia, fol-
lowed by Peru (32%) and Bolivia (15%).  
About 80,000 ha of coca were cultivated in Colombia
in 2004, a year-on-year decline of 6,000 ha. The
decrease of coca cultivation is consistent with the sus-
tained level of aerial spraying and manual eradication
that peaked at 139,200 ha in 2004. The continued
implementation of alternative development projects also
contributed to the success of the government’s eradica-
tion efforts. 
Unfortunately, the decline in Colombia was offset by
increases in cultivation in both Bolivia and Peru. Culti-
vation in Bolivia increased 17% to 27,700 ha in 2004,
reinforcing the rising trend of the past five years. In Peru
cultivation rose 14% to 50,300 ha to its highest level
since 1998. 
…including in vital National Park regions and pro-
tected areas.
Coca cultivation continues to take place in areas that do
not meet the ecological conditions for agriculture and
should be protected or used exclusively for forestry
activities. In Colombia, coca cultivation was found in
13 out of 50 National Parks. Coca cultivation in
National Parks represented 7% of the total level of coca
cultivation in 2004. A comparison of the location of the
coca fields in 2003 and 2004 showed that about 60% of
the coca fields were new, indicating the important
mobility of this crop in Colombia. This trend is worri-
some. In Bolivia, a total of 40% of the coca cultivation
in the Chapare region (4,100 ha) was in two National
Parks. In 2004, coca cultivation in these National Parks
increased by 71%, to 4,100 ha. Similar developments
were observed in Peru. In 2004, 24% of coca was culti-
vated in protected areas, including national parks and
biosphere reserves. The most important increase in
2004 took place in the Alto Huallaga region, where
52% of cultivation was in protected and forest areas. 
Sustained eradication activities continued in all three
countries…  
The Colombian anti-drugs strategy includes a number
of measures ranging from aerial spraying to forced or
voluntary manual eradication, and includes both alter-
native development and crop substitution pro-
grammes.12 The Colombian Anti-Narcotics Police
(DIRAN) reported that spraying activities reached
record levels in 2004, for the fourth consecutive year.
The DIRAN sprayed a total of 136,551 hectares, up 3%
from 2003, and the Army manually eradicated 2,589 ha
of coca.13
In 2004, the Bolivian Government reported the eradi-
cation of 8,437 ha of coca fields14.  Most of this took
place in the Chapare region. In 2004, the level of
reported eradication was 16% less than in 2003. In
2004, the Peruvian government reported the eradication
of 10,257 ha of coca fields, 10% less than in 2003. It
was the third largest level of eradication since 1999. 
…but alternative livelihood options need further invest-
ment.  
The budget for alternative development projects imple-
mented at the municipality and department levels in
Colombia increased to US$78 million in 2004. Docu-
menting the impact of this investment is not straight-
forward, and whereas the reductive effects of aerial
spraying can be almost immediate, it takes longer to
understand and assess the impact of alternative devel-
opment. Aerial spraying and alternative development
efforts were intense in Putumayo and Caqueta between
2000 and 2004, producing a decrease of about 80,000
ha of coca cultivation. However, between 2000 and
2004, coca cultivation increased in Nariño by about
5,000 ha, despite of intense aerial spraying and an
12 UNODC does not participate in or supervise spraying activities.                                                                                                                      
13 Once coca fields are sprayed, it normally takes 6-8 months to recover productive crops when the bushes are pruned or replanted. However, if heavy
rains occur or if farmers wash the coca bushes immediately after spraying, the loss of coca leaf could be minimal.
14 In Bolivia, the eradication of coca cultivation is exclusively manual and no chemicals are used.
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US$11million investment in alternative development.
In Meta, coca cultivation increased by about 7,600 ha
during the same period, due to some extent to the
absence of alternative development projects and the low
level of aerial spraying of coca cultivation. 
Peru has had remarkable results with alternative liveli-
hood programmes. In the 1990s, a large proportion of
the total coca cultivation in the country was grown in
Aguatya and Lower Huallaga.  By 2004, following the
successful implementation of many such programmes
coca cultivation had virtually disappeared from both
regions. Only 11% of Peruvian farmers dependent on
coca have access to sustainable livelihood activities.
Bolivia can also point to numerous alternative liveli-
hoods schemes that have reduced the dependence of
rural economies on coca cultivation. However, these
programmes still do not reach enough coca growers and
far too many people remain dependent on coca. In Cha-
pare, the focus of alternative development projects was
the region defined by the Ministry as ‘multiple use
forest’. Between 2003 and 2004, coca cultivation
remained stable in this region. In contrast, areas with
little or no alternative development  intervention
showed an increase in coca cultivation between 2003
and 2004.
The high prices of coca leaf  continue in Bolivia and
Peru...
The sustained high price for coca leaf was the likely
motivation for the farmers in Peru and Bolivia to
increase coca cultivation in 2004. In Peru, the price has
remained above US$ 2/kg since 2000, compared to
prices below US$ 1/kg in 1996/1997. Prices in Bolivia
are even higher at about US$ 5/kg, creating an incen-
tive for smuggling Peruvian coca leaf into Bolivia. Boli-
vian authorities seized 27 metric tons of Peruvian coca
leaves, out of a total of 155 metric tons.
Contrary to Bolivia and Peru, the market for coca leaf is
not developed in Colombia because most farmers
process the coca leaves into coca base. However, for the
remainder who sold leaf, prices were much lower than
in Peru and Bolivia, ranging between US$ 0.4/kg and
US$ 1.8/kg.  In 2004, the average price for one kg of
coca base was about US$807. Although production
decreased in Colombia in 2004, coca leaf prices did not
increase.  Compared to 2003, the prices even decreased
in Colombian pesos.  One possible explanation of this,
still to be confirmed, is that the reduction of coca leaf
production in Colombia was offset by imports of coca
paste/base.
The total farm gate value of potential global coca base
production was US$ 565 million in 2004.15
15 Using the average price for coca paste of US$ 80/kg in 2004 and assuming a 1:1 conversion rate between coca base and cocaine, the total farm-gate
value of the 390 metric tons of coca base produced in Colombia in 2004 would amount to about US$315 million. In Peru, the potential production
of cocaine was estimated at 190 metric tons. Using the 1:1 conversion rate between coca base and cocaine, the farm gate value of the potential coca
base production was calculated at US$ 122 million. The potential cocaine production in Bolivia is estimated to have amounted to 107 metric tons
in 2004, which corresponded to an increase of 35% compared to last year potential cocaine production of 79 metric tons. The farm gate value of
potential coca base production in Bolivia would amount to US$ 128 million.      
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Fig. 18: Global coca bush cultivation, 1990-2004 (in ha)
Fig. 19: Potential cocaine production, 1990-2004 (metric tons)
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Estimates for Colombia for 1999 and subsequent years come from the national monitoring system established by the Colombian
government with the support of UNODC.   Due to the change of methodology, figures for 1999 and after cannot be  directly compared
with data from previous years.
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COLOMBIA - COCA BUSH CULTIVATION, 1990 - 2004 (ha) COLOMBIA - POTENTIAL COCAINE PRODUCTION, 1990 - 2004 (mt)
PERU - COCA BUSH CULTIVATION, 1990 - 2004 (ha) PERU - POTENTIAL COCAINE PRODUCTION, 1990 - 2004 (mt)
BOLIVIA - COCA BUSH CULTIVATION, 1990 - 2004 (ha) BOLIVIA - POTENTIAL COCAINE PRODUCTION, 1990 - 2004 (mt)
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Estimates for Colombia for 1999 and subsequent years come from the national monitoring system established by the Colombian government with 
the support of UNDCP.  Due to the change of methodology, figures for 1999 and after cannot be directly compared with data from previous years.
Fig. 20. 
Annual coca bush cultivation and cocaine production in main producing countries, 1990 - 2004
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Fig. 22: Potential cocaine production (in % of global total)
Fig. 21: Coca bush cultivation (in % of global total)
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Table 5. Estimated farmgate value of coca base, 2004 
Farmgate price Production
US$ per kg metric tons
Colombia 810                390 315
Peru 640                190 122
Bolivia 1,200             107 128
(UNODC estimates)
Potential value
millions of US$
315
128
122
ColombiaPeru
Bolivia
Fig. 23: Estimated farmgate value of coca base, 2004 (millions of US$)
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1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Bolivia 2,400 1,100 5,493   7,512   7,000   11,620 15,353 7,653   9,395   11,839    10,089    8,437        
Colombia 946    4,904 25,402 23,025 44,123 69,155 44,157 61,574 95,898 126,933  136,828 139,161    
Peru 240    7,512   7,512   3,462   17,800 13,800 6,200   3,900   7,000      11,312    10,257      
Table 7. Reported eradication of coca bush, in ha 
Fig. 24: USA: cocaine retail and whole sale prices,
1990-2003 (US$/gram)
Fig. 25: Europe: cocaine retail and wholesale prices,
1990-2004 (US$/gram)
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Fig. 26: Wholesale cocaine prices in Europe and the USA, 1990-2004 (US$/gram)
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Global cocaine seizures reached a record high in 2003...
Global cocaine seizures rose to 495 mt in 2003, a 33%
increase as compared to a year earlier, and a new all-time
high. Cocaine seizures increased by 20% in North
America, 29% in South America, 80% in Europe and
77% in the rest of the world.  Fifty five percent of total
global cocaine seizures took place in South America,
28% in North America and 17% in Europe.
Given declining levels of cocaine production in 2003,
such increases probably were due to improvements in
international cooperation among enforcement agencies.
Taking the purity of seized cocaine into account
(around 60%) , the cocaine interception rate rose to
record levels from 28% in 2002 to 44% in 2003 (32%
on average over the 2001-2003 period). 
Contrary to expectations, however, the rising intercep-
tion rate was not reflected in rising cocaine prices or
falling cocaine purity levels. In fact, the average inflation
adjusted wholesale cocaine price in the USA even
declined marginally, from $23,000 per kg in 2001 to
$22,000 per kg in 2003. In Western Europe, average
wholesale prices increased slightly from $38,000 per kg
in 2001 to $43,000 in 2003 and $46,000 in 2004; how-
ever, expressed in local currency, inflation adjusted
prices actually fell from €43,000 per kg in 2001 to
€38,000 in 2003 and €37,000 in 2004. This gives rise
to speculations that large stock-piles of cocaine in the
Andean region, built up over the last few years, may still
be entering the market. Other possible explanations
could be higher yields on recent production, improve-
ments in the cocaine manufacturing processes leading to
more cocaine production, and/or new sources of cocaine
manufacture which are currently unknown. Investiga-
tions into the possible causes of this disparity have
already started. 
... with the largest cocaine  seizures reported from
Colombia.
Seizures in the Andean region - notably Colombia -
have shown a clear upward trend over the last few years,
reflecting the increased determination of the authorities
to fight the cocaine trade; as a consequence, the overall
cocaine interception rate of the Andean region rose
from 9% in 1999 to 18% in 2002 and 25% in 2003.
For the second year in a row Colombia reported the
world’s largest cocaine seizures (145.6 mt, 29% of global
seizures and 87% of the three Andean countries com-
bined). The United States seized 117 mt or 24% of
global seizures, and Spain 49.3 mt or 10% of global
seizures.
1.3.2 Trafficking
Fig. 27: Seizures of cocaine (base and HCL),
1980-2003
Source: UNODC, Annual Reports Questionnaire Data /
DELTA.
Fig. 28: Cocaine interception rate, 1990-2003,
based on 60% purity of seized cocaine
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The long-term trend reveals a decline in North America
and an increase in Europe…
According to UNODC’s cocaine market model,16
North America, the largest cocaine market, was the des-
tination of some 350 mt of cocaine in 2003, of which
280 mt were actually consumed. In the same year,
Europe was the destination of some 140 mt of which
some 110 mt were consumed.
Overall, cocaine seizures in North America over the last
decade has been showing a declining trend, reflecting
lower levels of cocaine consumption as compared to the
second half of the 1980s. The share of global cocaine
seizures that were made in North America (‘NAFTA
region’) in global cocaine seizures declined from 47% in
1990 to 36% in 2000 and 28% in 2003. 
Cocaine seizures in Western and Central Europe, in
contrast,  have been on the increase, reflecting rising
levels of cocaine consumption. Western and Central
Europe accounted for 3% of global cocaine seizures in
1980, 6% in 1990, 8% in 2000 and 17% in 2003.
European data for 2003 include exceptionally high
seizure figures reported from Spain.
... with Africa playing a more significant role in traf-
ficking cocaine to Europe ...
Most of the cocaine destined for Europe enters through
Spain or the Netherlands, though the entry of cocaine
via other countries (notably countries with less well con-
trolled airports) has also increased in recent years. Large
amounts of cocaine are either shipped directly from the
Andean countries to Spain or they transit Venezuela  or
Brazil. Cocaine entering Spain and the Netherlands is
both for local consumption and for other destinations in
Europe, including France and Italy. Most of the cocaine
destined for the Netherlands transits the Caribbean
region, notably the Netherlands Antilles. Much of the
retail trade in Western Europe has been taken over by
criminal groups of West African origin. Cocaine des-
tined for the UK, one of the largest cocaine markets in
Europe, transits the Caribbean region, notably Jamaica,
but is also imported from Spain and the Netherlands.
New trends in cocaine trafficking include the rising
importance of cocaine shipments from the Andean
region through Western Africa to Europe.17 In this case
the route goes from the Andean region to Brazil18 and
then to countries of Southern Africa and increasingly to
countries of Western Africa (Nigeria and other countries
located around the Gulf of Guinea) from where cocaine
is trafficked by couriers to various European countries.
The trade is often organized by West-African crime
groups. This diversion of the traditional trafficking
route seems to be linked to better controls in the
Netherlands (notably the port of Rotterdam and the air-
port of Schiphol) and along the northern cost of Spain.
Another example of a diversion of trafficking routes is
organized by Colombian groups that are now traffick-
ing cocaine to Spain through the islands and countries
off the cost of Senegal and Mauritania. Once reaching
these islands the cocaine is taken over by cannabis resin
trafficking groups of Moroccan origin for onward
exports to southern Spain.  In addition, various Balkan
16 The model, which is discussed in Chapter 2, uses data from 2002.                                                                                                                   
17 HONLEA Meeting , Vienna, February 2005.    
18 Authorities in Brazil estimate that about 60% of the cocaine destined for or transiting Brazil originated in Colombia, 30% in Bolivia and 10%   in
Peru.  
Fig.29: Cocaine seizures: North America and
Western and Central Europe
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countries are being used for the onward shipment of
cocaine by local drug trafficking networks to Western
Europe.      
.. while Mexico and the Caribbean remain the main
transit points for cocaine to the USA.
According to estimates by US authorities, 77% of the
cocaine destined for the USA transited Central America
and Mexico while 22% transited the Caribbean in
2003. About 90% of the cocaine detected departing
South America and moving toward the United States in
2003 was transported in non-commercial maritime con-
veyances, particularly go-fast boats. 
Mexican, Colombian and Caribbean groups continue to
control much of the wholesale distribution in the USA.
Criminal groups of Mexican origin control most whole-
sale cocaine distribution in the Pacific, Southwest, and
West Regions as well as in most areas of the Midwest
and Southeast Regions of the United States.  Colombian
criminal groups control most of the wholesale cocaine
distribution in the Northeast Region as well as whole-
sale cocaine distribution in Miami, Puerto Rico and
some of the wholesale distribution in Houston, Dallas,
Los Angeles, and New Orleans. In addition, a number
of criminal groups from the Caribbean region are
involved in wholesale distribution in the USA. Domini-
can wholesale cocaine distributors are prominent in the
Northeast Region and control most wholesale cocaine
distribution in Philadelphia and Washington, but also
in Atlanta, Cleveland, Detroit, Houston and Milwau-
kee. Jamaican, Haitian, and Puerto Rican criminal
groups control some wholesale distribution in large
cities in the Southeast Region.  
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* Converted to 100% purity, assuming an actual average purity of 60%. 
 * excluding seizures in liquid form.
** data refer to 2002
145,601
117,025
49,279
32,329
21,106
12,881
9,631
9,487
9,194
7,941
7,728
6,848
3,521
3,021
2,411
2,038
1,993
1,586
1,138
1,110
1,009
3,576
4,173
4,361
4,292
5,649
17,560
- 20,000 40,000 60,000 80,000 100,000 120,000 140,000 160,000
Colombia
United States
Spain
Venezuela
Mexico
Netherlands
Bolivia
Brazil
Panama
Guatemala
Peru
Netherlands Antilles
Ecuador
Honduras
Bahamas
Costa Rica
France
United Kingdom
Italy
Portugal
Chile
El Salvador
Argentina
Jamaica
Martinique
Nicaragua
Germany, Federal Republic of
3%
44%1
1
29%
24%
10%
4%
7%
4%
3%
2%
2
%
**
221,053
138,603
84,003
31,827
17,652
816
382
2
6
15
53
97
154
163
295
- 50,000 100,000 150,000 200,000 250,000
South America
North America
West & Central Europe
Central America
Caribbean
Southern Africa
Southeast Europe
Oceania
Near and Middle East /South-West Asia
West and Central Africa
East and South-East Asia
East Europe
North Africa
East Africa
South Asia
(45%)
(28%)
(17%)
(6%)
(4%)
SEIZURES OF COCAINE* in % of world total and Kg- HIGHEST RANKING COUNTRIES – 2003
SEIZURES of COCAINE (Kg and %) – BY REGION - 2003
605
684
745 746
667
588
705 674
608 577
377
769
891
930 950
875
825
925
879
827
800
674
0
200
400
600
800
1,000
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Cocaine
intercepted*
- in % of production
Total Cocaine 
Production
- in metric tons
Cocaine
available for 
consumption
(potential)
- in metric tons
23%
20%
29%
24% 23%
24%
27%
28%
21%
21%
44%
2%
2%
2%
2%
Fig. 30: Global illicit supply of cocaine 1993 - 2003
74
World Drug Report 2005 Volume I. Analysis
COCAINE INTERCEPTED - ASIA 
1993-2003
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
m
et
ric
 t
on
s
COCAINE INTERCEPTED - WORLD 
1993-2003
0
50
100
150
200
250
300
350
400
450
500
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
m
et
ric
 t
on
s
COCAINE INTERCEPTED AMERICAS 
1993-2003
0
50
100
150
200
250
300
350
400
450
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
m
et
ric
 t
on
s
COCAINE INTERCEPTED - EUROPE 
1993-2003
0
10
20
30
40
50
60
70
80
90
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
m
et
ric
 t
on
s
COCAINE INTERCEPTED - AFRICA 
1993-2003
0
1
2
3
4
5
6
7
8
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
m
et
ric
 t
on
s
COCAINE INTERCEPTED - OCEANIA 
1993-2003
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
m
et
ric
 t
on
s
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Cocaine is the primary problem drug of the Americas.
More than 900,000 people were treated in 2003 for
cocaine dependence, with more than 90% coming from
the Americas. In South America, close to 60% of all
treatment demand is for cocaine, and in North America
the figure is close to 40%. About 7% of all cocaine users
are currently in treatment, and five out of every 10,000
people who use cocaine will die as a result each year. In
terms of creating dependence and causing death,
cocaine ranks second only to heroin in the dangers it
poses.
There are an estimated 14 million cocaine users world-
wide, with two-thirds residing in the Americas. The
USA continues to be the world’s largest cocaine market,
although about a quarter of global users are found in
Europe, especially in Spain and the United Kingdom
but also in the Netherlands, Belgium, Ireland, Italy and
Switzerland. Of the global population between the ages
of 15 and 64, only 0.3% use cocaine, but the figure is
higher in North America (2.3%), West and Central
Europe (1%), Oceania (0.9%) and South America
(0.8%).
Globally, cocaine use seems to have stabilised, after years
of strong increases. Expert opinion from member states
suggest use has levelled out in the important market of
North America, as well as in Oceania, most of Asia, and
most of Eastern Europe. But perceived increases were
reported in South America, West and Central Europe,
South-East Europe, and a number of countries in
South-East Asia. 
Key to global cocaine use trends is the situation in the
United States, where use among the general population
is some 50% lower, and use among high-school students
is now about 60% lower, than in the mid-1990s. In
2003, cocaine consumption remained stable in the
USA.  In contrast, surveys in Europe, for both the gen-
eral population and for students, have shown an upward
trend in cocaine use over the last few years. The upward
trend – as shown in student surveys - was, however, lim-
ited to Western Europe in recent years; in Central and
Eastern Europe cocaine use remained stable.  There has
been a creeping upward trend in the spread of crack-
cocaine in recent years, notably in the Americas, Europe
and in Africa, but this appears to have lost momentum
in 2003.  
1.3.3 Abuse
Table 7.  Annual prevalence of cocaine use, 2003/04 or latest year available
Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
Number of  users in % of  population
15-64 years
EUROPE 3,421,000 0.6
West and Central Europe 3,224,000 1.0
South-East Europe 70,000 0.1
 Eastern Europe 127,000 0.1
AMERICAS 8,930,000 1.6
North America 6,548,000 2.3
South America 2,382,000 0.8
ASIA 246,000 0.01
OCEANIA 183,000 0.9
AFRICA 946,000 0.2
GLOBAL 13,726,000 0.3
            Cocaine abuse above global average
            Cocaine abuse around global average
            Cocaine abuse below global average      
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Fig. 32: Global Drug Use Trend Index - Cocaine -
based on expert opinions (country
results weighted by estimated number
of cocaine users), 1993-2003
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* Given changes in the methodology used, general house-
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and Health and NIDA, Monitoring the Future. 
Fig. 33: Cocaine use in the USA: 1985-2003
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Cannabis is a plant that grows well in virtually every
inhabited region of the world, and can be cultivated
with little maintenance in small plots, or even indoors.
In addition, unlike most other street drugs, it can be
consumed with little processing after harvesting.  As a
result, users can feasibly cultivate their own supply, and
consequently production is highly decentralized.  While
substantial international trafficking of cannabis does
occur, it is unclear what share of the total market this
comprises. Thus, our most reliable sources of informa-
tion on the extent of production (crop surveys, satellite
monitoring, and international seizure data) are of lim-
ited use in estimating the size of the cannabis market. 
The matter is further complicated by the fact that there
are also two main forms in which cannabis is consumed
as a drug, which constitute fairly distinct market chains:
• “Cannabis herb” is comprised of the flowering
tops and leaves of the plant, which are smoked like
tobacco using a variety of techniques. While this
drug is consumed throughout the world, the
largest market for cannabis herb appears to be
North America, where 60% of global seizures
occurred in 2003.
• “Cannabis resin” is popularly referred to as
“hashish”, and consists of the secretions of the
plant emitted in the flowering phase of its devel-
opment.  This resin can be gathered by hand
(“hand rubbing”, the traditional practice in
India), or by sieving the herbal material using
some form of screen (the traditional practice in
Afghanistan and Morocco).  It is also possible to
produce “hashish oil”, although this form of the
drug is not widespread. Western Europe is the
largest market for cannabis resin, responsible for
nearly 70% of global seizures in 2003, and 80%
of this hashish was produced in Morocco.19
1.4.1.1  Cannabis herb
Production is globally dispersed.
The unique properties of the cannabis plant have led to
its widespread and diffuse cultivation. Over the 1993-
2003 period, 86 countries provided UNODC with
cannabis production estimates. For comparison, only 40
countries provided estimates for opium-poppy cultiva-
tion, and only six provided estimates for coca-leaf pro-
duction. But the fact that a country did not provide an
estimate does mean that no cultivation exists, as some
countries simply lack the capacity to come up with
accurate estimates. Luckily, there are other ways of iden-
tifying cannabis producing countries. 
Member states were also asked to identify the national
source of the cannabis consumed in their countries. On
this basis, 114 producer countries can be identified.  A
third list of producer countries can be generated by sin-
gling out those that report the seizure of whole cannabis
plants. It is extremely inefficient to transport whole
plants internationally, as only certain parts are useable as
a drug. Thus, when a whole plant is seized, it is very
likely that it was locally produced. Seizures of whole
1.4 Cannabis market
1.4.1 Production
19 France reported that 82% of the cannabis resin found on its market in 2002 originated in Morocco. Similar estimates have been made for Belgium
(80%), Sweden (85%), and the Czech Republic (70%).  Spain, Italy, Denmark, Finland and Ireland reported that almost all of the cannabis resin
originated in Morocco. 
cannabis plants were reported in 144 countries during
the 1993-2003 period. Combining these three lists
results in the identification of some 163 countries and
territories where cannabis is produced, out of 197 coun-
tries reporting (83%).
Most of these countries produce solely to satisfy local
demand, but there are a number of countries that pro-
duce for export. For example, Paraguay produces much
of the cannabis consumed in its neighbouring countries,
and European production hubs include Albania and the
Netherlands. Other significant exporters include:
• In Africa: Nigeria, South Africa, Malawi, Lesotho,
and Swaziland
• In the Americas: Mexico, Canada, Jamaica and
Columbia 
• In Central Asia: Kazakhstan and Kyrgyzstan 
• In the Middle East: Egypt and Lebanon
• In South Asia: India
• In Southeast Asia: Cambodia, Thailand, and the
Philippines
A number of indicators suggest that North America pro-
duces more cannabis than any other region, and this
market is largely self contained: most of production is
consumed domestically. US authorities have reported
that about two thirds of the cannabis consumed in the
country is domestically produced, while over half (56%)
of the cannabis imported to the US comes from Mexico
and another 20% comes from Canada. 
In terms of gross volumes, estimates made available to
UNODC suggest that North America accounts for
about one third of global production, or 14,000 metric
tons. The second largest producer is Africa: 12,000
metric tons of cannabis herb, or about 28% of global
production. Other important cannabis producing areas
are South Asia (9%) and Central Asia (5%). 
Production has been rising and may have exceeded
40,000 mt in 2003.
Estimating the volume of global cannabis production is
extremely difficult. The last World Drug Report provided
an estimate of about 32,000 mt of cannabis herb pro-
duction at the global level, but new calculations suggest
that the true figure may be even larger, perhaps as much
as 42,000 mt Since the methods used in arriving at these
two calculations are different, this should not be inter-
preted as a trend. There are other indications, however,
that global cannabis production has been increasing.
Both estimates of the number of cannabis consumers
globally and the quantities of cannabis seized by law
enforcement have increased in the past decade.  Out of
the 42,000 mt produced, UNODC estimates that only
about 30,000 mt actually reach the end consumers. The
rest is either seized or otherwise lost in transit. 
It would also appear that cannabis is becoming more
potent in a number of markets. In the USA, for
instance, the average THC content (potency) rose from
less than 2% in the 1970s to 6.3% in 2003.20 Increases
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Fig. 35: Distribution of cannabis herb production in
2003/2004 (42,100 mt)
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Fig. 36: Global cannabis herb seizure
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Source: UNODC, Annual Reports Questionnaire Data.
in the THC content were also reported from Canada
and from the Netherlands.21
1.4.1.2  Cannabis resin
Morocco is the world’s most significant resin exporter,
feeding the Western European market. The UNODC
and the Government of Morocco conducted compre-
hensive cannabis resin surveys of the country in 2003
and 2004. The 2003 survey placed total resin produc-
tion at about 3,070 mt, cultivated on 134,000 hectares
of land in the Rif region by some 96,600 families. The
2004 survey showed a 10% decline in the land dedi-
cated to cannabis cultivation (120,500 ha), with an esti-
mated production of 2,760 mt22.
Despite this recent local decline, both resin seizures and
consumption estimates suggest that the long-term trend
is towards a growth in global production since the early
1990s.  Last year’s World Drug Report placed global pro-
duction between 5,100 and 7,400 mt Production in
2003 was likely on the high end of this range. It would
appear that more than 40% of the global cannabis resin
supply is being produced in Northern Africa and more
than a quarter in the Near East and Middle East. These
two regions account for more than two thirds of global
cannabis resin production. Other cannabis resin pro-
ducing regions of importance are Central Asia, South
Asia and, to a lesser extent, South-East Europe and the
Caribbean. 
Cannabis resin production is concentrated in Morocco
as well as in Pakistan and Afghanistan.
When Member States were asked about the source of
cannabis resin in their countries, Pakistan and
Afghanistan were the most often cited as source coun-
tries after Morocco over the period 1999–2003.  Other
important source countries identified are India,
Lebanon, Albania, the Central Asian countries (notably
Kazakhstan and Kyrgyzstan), Nepal, South-East Asia
and a number of African countries. The only country in
the Americas cited as an important country of origin for
cannabis resin was Jamaica.
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20 University of Mississippi, Cannabis Potency Monitoring Project Report #85, May 2004. 
21 Second Technical Conference on Drug Control Research, Vienna, July 19-21, 2004.  A review of the potency evidence undertaken by EMCDDA
in 2004 was, however, less conclusive.
22 Some of the decline appears to have been a consequence of an earthquake, resulting in increased attention being given by the national authorities
and the international community to the region concerned.
Fig. 37: Distribution of global cannabis resin 
production (N = 7,400 mt in 2003/04)
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Fig. 38: Main source countries of cannabis resin, 
1999-2003 
(based on information from 90 countries)
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The increase in cannabis trafficking continues
Cannabis herb and cannabis resin remain the two most
extensively trafficked drugs worldwide. Cannabis herb
seizures amounted to 5,845 mt, cannabis resin to 1,361
mt and cannabis oil to14 mt in 2003. Seizures of the
three cannabis products taken together increased by
24% in 2003 to 7,220 mt, the highest level since 1984
(21,000 mt), more than twice the seizures reported in
the early 1990s and an increase of 46% since 1999.  In
addition, 55 million cannabis plants and 7,600 mt of
cannabis plant material were seized worldwide in 2003,
which corresponds23 to an increase of about 24% in
2003 and more than 50% over the 1999-2003 period. 
1.4.2.1  Cannabis herb
Cannabis herb is the most widely trafficked drug - and
seizures rose again in 2003…
In terms of both volume and geographic spread,
cannabis herb is the most interdicted drug in the world.
Out of 181 countries and territories reporting seizures
to UNODC over the 2001-2003 period, 166 reported
seizures of cannabis herb, more than for heroin (148),
cocaine (140), cannabis resin (118),  amphetamines
(96) or  ecstasy (88).  Cannabis herb seizures rose 25%
in 2003 and were 112% higher than in 1990.  
…with trafficking increasingly concentrated in the
Americas and in Africa. 
58% of global cannabis herb seizures occurred in North
America in 2003. The remainder took place in Africa
(26%), South America (10%) (non-NAFTA),  Asia
(3%) and Europe (3%). The world’s largest cannabis
herb seizures were made – once again – by the law
enforcement agencies of Mexico (2,160 mt or 37% of
the total), followed by those of the United States (1,224
mt or 21% of the total).  The proportion of seizures
made in North America rose from 32% in 1990 to 58%
in 2003, while the proportion of seizures made in South
America (‘non-NAFTA’) declined over the same period
from 46% to 10%. In 2003,  cannabis herb seizures
increased in both Central America (33%) and in South
America (18%) but declined in the Caribbean (-25%).
The proportion of seizures made in Africa increased
from 16% of global cannabis herb seizures in 1990 to
20% in 2002 and 26% in 2003. The increase in
cannabis herb seizures in Africa in 2003 (+65%)  was
mainly due to rising seizures in East Africa. In contrast,
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1.4.2 Trafficking
23 Expressed in kg equivalents.                                                                                                                                                                         
Fig. 39: Cannabis seizures, 1985-2003
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cannabis herb seizures declined in both Asia (-40%) and
in Europe (-32%). Declines in Asia were highest in East
and South-East Asia. Shifts in law enforcement priori-
ties seem to have been largely responsible for the decline
in Western and Central Europe (-40%). Cannabis herb
seizures in Eastern Europe, in contrast, increased by
40%.  
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Fig. 40: Seizures of cannabis herb - regional breakdown, 1985-2003
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Year 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Metric tons 3,360   2,358  3,209    3,077    3,059    2,998    4,042    4,656    4,849    4,745   5,845   
* data refer to 2002
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Fig. 41: Global seizures of cannabis herb, 1993 -2003
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Fig. 42: Global seizures of cannabis herb, 1993 -2003
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1.4.2.2  Trafficking in cannabis resin 
Cannabis resin seizures also increased to a new all time
high in 2003. 
Global cannabis resin seizures increased by 25% in 2003
to 1,361 mt, reaching a new all time high. Resin seizures
increased most significantly in North Africa (63%), in
the Near and Middle East/South-West Asia  (21%) (fol-
lowing an increase by 74% a year earlier) and in Europe
(26%). 
Cannabis resin seizures are concentrated in West and
Central Europe...
Out of global cannabis resin seizures of 1,361 mt,
Europe accounted for 950 mt, of which 947 mt or 70%
of the total, was seized in West and Central Europe,
21% in the Near and Middle East /South-West Asia and
8% in North Africa.  The largest seizures worldwide
were reported by Spain (727 mt or 53% of the total),
followed by Pakistan (99 mt or 7%), Morocco (96 mt
or 7%) and Afghanistan (81 mt or 6%). Authorities in
Iran seized 77 mt (6% of total).  
…and Europe continues to be the main destination of
cannabis resin.
The main destination of cannabis resin is West and
Central Europe. About 80% of the cannabis resin des-
tined for the West and Central European market is esti-
mated to originate in Morocco including large shares of
the markets of Spain (100%) and Portugal, France
(82%),  Belgium (80%),  Sweden (85%), the Czech
Republic (70%). Much of the cannabis resin transits
Spain and the Netherlands before being shipped to
other countries.  The remainder of the resin supply orig-
inates from Afghanistan/Pakistan (e.g. 10% in Belgium,
30% in the Czech Republic), from Central Asia (mostly
in the Russian Federation, other CIS states and some of
the Baltic countries) or from within Europe (mainly
Albania, supplying the markets of various Balkan coun-
tries and Greece).  
The second largest destination of cannabis resin is the
Near and Middle East / South-West Asia region. This
region is mainly supplied by cannabis resin produced in
Afghanistan and Pakistan and, to a lesser degree, by
cannabis resin originating in Lebanon. Some of the
cannabis resin from Afghanistan/Pakistan is also being
shipped to Canada and to countries in Eastern Africa. 
North Africa makes up the third largest market and is
predominantly supplied by cannabis resin produced in
Morocco. The importance of other markets is limited.
Nepal is a source country for cannabis resin exports to
India and to some other countries and Jamaica is a
source country for cannabis resin exports to some other
countries in the Americas.
Fig. 43: Cannabis resin seizures, 1985-2003
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Year 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Metric tons 846      901      1,030   877      818      896      898      1,052   934      1,091   1,361   
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Cannabis is far and away the most commonly consumed
street drug in the world. An estimated 161 million
people used cannabis in 2003, equivalent to 4% of the
global population between the ages 15 and 64. In some
parts of the world, herbal cannabis is most popular,
while others prefer cannabis resin, but most member
states say it is the most widely used illicit substance in
their countries. Cannabis use is most prevalent in the
Oceania region, followed by North America and Africa.
It is less common in Asia, but due to the size of the pop-
ulation, Asia still contains about a third of global
cannabis users.
It also appears that cannabis use is increasing. Accord-
ing to expert opinions solicited from member states, far
more countries felt that cannabis use was increasing
(46% of 101 countries responding) than declining
(16%) in 2003. In the last decade, the consensus is that
cannabis use has been growing faster than use of cocaine
or opiates. 
This year’s estimate of 161 million users worldwide is
about 10% higher than that published in the last World
Drug Report. This is attributable to increases in preva-
lence estimates in South-America (including the
Caribbean and Central America), in Africa, in Europe
and in several countries in Asia. North American esti-
mates have remained largely stable, while declines were
reported for the Oceania region and some countries in
South-East Asia.
In Europe, for example, school surveys among 15-16
year olds found that the share of students reporting
having ever tried cannabis rose by an average of almost
1.4.3 Abuse
in % of 
population age 15-64
EUROPE 30,400,000 5.6
West & Central Europe 22,900,000 7.3
South-East Europe 2,100,000 2.5
East Europe 5,500,000 3.8
AMERICAS 36,900,000 6.6
North America 28,700,000 10.2
South America 8,200,000 2.9
ASIA 53,300,000 2.2
OCEANIA 3,300,000 15.8
AFRICA 37,000,000 8
GLOBAL 160,900,000 4
               Above global average
               Around global average 
               Below global average
Cannabis use
No. of users
Sources: UNODC, Annual Reports Questionnaire Data, Govt. reports, reports of regional bodies, UNODC estimates.
Table 8: Annual prevalence of cannabis use, 2003/04 or latest year available
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25% between 1999 and 2003, or more than 80%
between 1995 and 2003. The increase seems most pro-
nounced in Central and Eastern Europe, where usage
among young people has become almost as common as
in Western Europe in recent years.
On the other hand, countries where cannabis con-
sumption is most common, namely the USA and Aus-
tralia, have not shown increases. The share of 15-16
year-old students in the USA reporting having tried
cannabis fell by 14% between 1999 and 2003. Annual
prevalence of cannabis use among the general popula-
tion and among high-school students in the USA is
about a third less than in the late 1970s.24 Cannabis use
among the general population in Australia has declined
by almost 37% since its peak in 1998.25
Despite its widespread use, cannabis does not generate
demand for treatment at the rate of other street drugs,
but more than 60% of treatment admissions in Africa
are cannabis-related, compared to 45% in North Amer-
ica and 30% in the Oceania region.
24 SAMHSA, National Household Survey on Drug Abuse, 2000 and previous years;  SAMHSA, National Survey on Drug Use and Health, 2002-2003,
NIDA, Monitoring the Future.
25 Australian Institute of Health and Welfare, The 2004 National Drug Strategy Household Survey.
Sources: Sources: UNODC, Annual Reports Questionnaire Data,
Govt. reports, reports of regional bodies, UNODC estimates.
Fig. 46:   Global Drug Use Trend Index - cannabis  -
based on expert opinions     (country results
weighted by estimated number of cannabis
users), 1993-2003
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Sources: Sources: UNODC, Annual Reports Questionnaire Data,
Govt. reports, reports of regional bodies, UNODC estimates.
Fig. 47:   Reported trends of cannabis use at the
global level in 2003 (based on expert
opinion from 101 countries)  
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* unweighted average of ESPAD countries (35 in 2003); weighted
by population age 15-19 and comparing only results from same
countries:   12% in 1995 to 17.6% in 1999 and 17.5% in 1999
to 20.4% in 2003 for all students in Europe.
Sources: Council of Europe, The ESPAD Report 2003 - Alcohol and
Other Drug Use Among Students in 35 European Countries,
previous ESPAD reports (1999 and 1995) and national Govt.
reports.
Fig. 48:   Life-time prevalence among 15-16 year olds
in the USA and in Europe, 1995-2003
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Fig. 49: USA: Cannabis use - annual prevalence among the general population (age 12 years and above)
and among high-school students (12th graders),  1979-2004
Source: Australian Institute of Health and Welfare, The 2004
National Drug Strategy Household Survey.
Fig. 50:   Annual prevalence of cannabis use among
the general population in Australia, 
1993-2004 
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Global ATS production was above 400 mt
Based on ATS consumption estimates,  ATS seizure data
and ATS precursor seizures,  UNODC estimates a total
ATS production26 of 422 mt for the year 2003  (range:
323-542 mt). The total is composed of around 332 mt
of ‘amphetamines’ (mainly methamphetamine and, to a
lesser extent, amphetamine and related synthetic stimu-
lants) and 90 mt of ‘ecstasy’ (mainly MDMA).  While
estimates for 2003 show a similar order of magnitude,
they are slightly lower than the estimates for the years
2000/01 (523 mt; range: 390-631 mt). 
Production of amphetamines  is concentrated in East
and South-East Asia, North America and, to a lesser
extent in Europe, while ecstasy production is concen-
trated in Europe and, to a lesser extent, in North Amer-
ica.
UNODC estimates that about half of global production
of amphetamines takes place in East and South-East
Asia, a third in North America and about 15% in
Europe, mostly in West and Central Europe.  About
78% of global ecstasy is produced in Europe (mostly in
Western and Central Europe), 14% in North America
and 5% in East and South-East Asia.  
Globally the number of dismantled ATS laboratories
increased from 547 in 1990 to 7,028 in 2000 and
11,253 in 2003. While much of the increase in the
1990s was a reflection of  the growth in ATS produc-
tion, there are indications that the ongoing dismantling
of laboratories over the last few years actually helped to
reduce production. Most dismantled ATS laboratories
were producing methamphetamine.
The number of ATS laboratories dismantled increased,
while the amount of ATS seizures, precursor seizures,
and consumption estimates declined.
Lower levels of precursor seizures, lower levels of end-
product seizures and lower levels of ATS consumption
suggest that overall ATS production – following a
decade of massive increases - may have declined over the
last few years, though still operating at far higher levels
than in the 1990s. ATS production will likely recover,
1.5 Amphetamine-type stimulants
1.5.1 Production
Table 9. Production estimates of amphetamine-type stimulants, 2003
Based on:
Amphetamine and 
methamphetamine Ecstasy Total
Consumption 300.9 101.6 402.5
Drug seizures 378 - 397 45.3 - 64.7 323 - 461
Precursor seizures 281 - 401 98.4 - 141 379 - 542
Overall range of estimates 278 - 401 45.3 - 141 323 - 542
Average of all estimates 332 90.2 422
Source: UNODC, UNODC estimates based on Annual Reports Questionnaire Data/DELTA.
26 Only indirect methods are available to estimate the size of ATS production.                                                                                                      
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however, unless pressure to fight ATS production, traf-
ficking and abuse is continued.      
The main methamphetamine production sites in Asia
are in China, Myanmar and the Philippines.
Overall, 23 source countries for the production of
methamphetamine have been identified over the
2002/03 period.  The main origin of methamphetamine
production in Asia is in China, Myanmar and the
Philippines. China, followed by the Philippines and
Myanmar, dismantled the most methamphetamine lab-
oratories in Asia; in terms of output, production levels
seem to be of similar magnitudes in China and in
Myanmar, though methamphetamine production in the
Philippines appears to have increased.  Most of the
methamphetamine production in China is located in
south-eastern China, in Guangdong Province (which
surrounds Hong Kong) and, to a lesser extent, in neigh-
bouring Fujian province, located off the coast of
Taiwan. In addition, important levels of methampheta-
mine production are found in Taiwan, province of
China. China, together with India, is one of the main
sources of ephedrine and pseudo-ephedrine, the main
precursor chemicals used to manufacture methamphet-
amine. Improved control mechanisms in both China
and India  have, however, assisted in curbing clandestine
ephedrine and pseudo-ephedrine exports in recent years.
Methamphetamine production in Myanmar is mainly
encountered in the Shan state (notably in the Wa
region), bordering China. 
Methamphetamine production in Thailand - according
to information provided by the Thai authorities - has
largely ceased to exist.  The main origin of North Amer-
ican methamphetamine imports from Asia are the
Fig. 51: Number of ATS laboratories dismantled
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ATS 
precursor 
seizures
ATS users
ATS 
seizures
Ecstasy P2P 3-4-MDP-2-P Safrole
(in million) (in tons) (in tons)
(in '000 
litres)
(in '000 litres)
(in '000 
litres)
2000 29.6 43.6 5.1 18.3 45.4 7.1 14.4 39.7 3.1
2003 26.2 27.7 4.2 10.3 17.3 6.1 5.5 2.5 0
Change -11% -36% -18% -44% -62% -14% -62% -94% -100%
ATS seizures
Methamphetamine 
precursor seizures
Ecstasy precursor seizures
Ephedrine 
(in tons)
Pseudo-
ephedrine 
(in tons)
Piperonal 
(in tons)
Consumption
Sources: UNODC, Annual Reports Questionnaire Data/DELTA; INCB, 2004, Precursors and chemicals frequently used in the illicit
manufacture of narcotic drugs and psychotropic substances, New York 2005.
Table 10: Changes in ATS indicators: 2000-2003
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Philippines, followed by China. European imports
likely transit Thailand, most probably originating in
Myanmar. Philippines is a lesser supplier. Overseas
exports of South-East Asian methamphetamine are,
however, still very limited. 
The main methamphetamine production sites in the
Americas are the United States, Mexico and Canada. 
The main origin of methamphetamine production in
the Americas are the United States, producing exclu-
sively for the domestic market, followed by Mexico and,
to a lesser extent, by Canada. Criminal groups of Mex-
ican origin are heavily involved in methamphetamine
production in the USA and in Mexico. The US author-
ities continue to dismantle the largest numbers of
methamphetamine laboratories worldwide. Metham-
phetamine production in the USA has been tradition-
ally concentrated in California and several neighbouring
states, though it is spreading to the rest of the country.
Most of the ‘super-labs’, however, continue to be located
in California. Methamphetamine imports from Asia are
of only limited importance. There is no information on
exports of methamphetamine produced in North Amer-
ica to other regions.  
Methamphetamine production in Oceania appears to
have increased in recent years.
Methamphetamine production in the Oceania region is
concentrated in Australia and, at lower levels, in New
Zealand. Methamphetamine production in Australia
takes place in practically all states, though it is particu-
larly concentrated in Queensland.  In addition to locally
produced methamphetamine, there are also imports of
methamphetamine produced in South-East Asia.
Rapidly rising laboratory seizures have had no signifi-
cant impact on prices and purities – suggesting that
overall production increased in recent years.  There is no
indication, thus far, that this translated into more
people consuming methamphetamine. The number of
methamphetamine/amphetamine users even declined
slightly in Australia between 2001 and 2004.
Methamphetamine production in Europe continues to
be very limited… 
Thus far, large-scale methamphetamine production and
consumption in Europe has not occurred. Metham-
phetamine continues to be largely limited to the Czech
Republic and some of the Baltic states. In addition,
some limited  imports of methamphetamine from
South-East Asia (Thailand and the Philippines) have
taken place in recent years. 
… while amphetamine production is largely concen-
trated in Europe.
The main source countries for amphetamine – the
Netherlands, Poland and Belgium – are all located in
Western and Central Europe27. In addition, the Baltic
states (Lithuania and Estonia) and Bulgaria play an
important role in the production of amphetamine.
Amphetamine production outside Europe takes place
primarily in North America and in the Oceania region.
There are also reports of amphetamine production in
East and South-East Asia; however, it is not always clear
whether the substances produced are in fact ampheta-
mine, or methamphetamine.  The key  precursor chem-
ical for the manufacture of amphetamine,  P-2-P (also
Fig. 52: Origin* of methamphetamine as reported by
Asian countries,  2002/03 
* Number of times a country was identified by other countries as
a source country for methamphetamine,  expressed as a pro-
portion of countries providing such information in 2002/03
(N =14). In general, it must be stressed that the reporting of a
country as a  'source country'  or  as a  'country of origin' does
not mean that drugs are actually produced in such a country.
' Origin' usually refers to the countries to which drug shipments
could  be traced back. In a majority of cases this coincides, how-
ever, with the locations where the drugs are actually produced.
Source: UNODC, Annual Reports Questionnaire Data.
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27 Overall 36 countries have been identified by member states as source countries for amphetamine production in 2003.                                           
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known as BMK) continues to originate in China. How-
ever, there have been cases of clandestine manufacture
of P-2-P out of phenylactic acid (a ‘pre-precursor’)
reported in the Russian Federation and the Ukraine and
some indications for such production in Lithuania and
Poland.
Markets in Africa and South-America supplied by
diverted licit ATS.
Overall production of ATS continues to be limited in
South America and in Africa, although in South Africa
clandestine ATS production28 has increased in recent
years. At the same time, surveys suggest that ATS con-
sumption in both Africa and South-America are far
from negligible. There appears to be an ongoing supply
of these markets with diverted licit ATS. 
The Netherlands and Belgium remain the most impor-
tant ecstasy source countries.
As in previous years, the Netherlands (quoted by 75%
of all countries to be among the three main source coun-
tries), followed, by Belgium (23%) produced the most
ecstasy in the world.   Over the 2002-2003 period a
total of 29 ecstasy producing countries were identified
by UNODC member states. Most of the precursors for
the manufacture of MDMA, notably 3,4-MDP-2-P
(also known as PMK), originate in China. However,
there have also been reports of the illicit manufacture of
PMK in the Russian Federation, produced out of sas-
safras oil (a pre-precursor) smuggled into the Russian
Federation from Viet Nam. 
Fig. 53: Origin* of amphetamine in 2003
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Fig. 54: Origin* of ecstasy in 2003
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28 Methcathinone  and increasingly methamphetamine.                                                                                                                                      
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ATS seizures started increasing again in 2003.
After having declined over the 2000-2002 period by
42%, ATS seizures increased by 13% in 2003 to 32 mt,
five times higher than a decade earlier but still less than
in 1999, 2000 or 2001. The highest ATS seizures in
2003 were reported by Thailand (20% of the total), fol-
lowed by China (18%), the United States (14%), the
Philippines (10%), the UK, the Netherlands and Aus-
tralia (6% each). Trafficking, production and consump-
tion growth were more pronounced for ATS than for
the other two main categories of problem drugs. Over
the 1990-2003 period, ATS seizures rose almost  seven
fold while heroin and morphine seizures tripled and
cocaine seizures almost doubled.   About 68% of global
ATS seizures in 2003 were of methamphetamine, 17%
of amphetamine and 13% of ecstasy.
ATS seizures are concentrated in East and South-East
Asia, followed by Western Europe and North America
Globally, 52% of all ATS seizures in 2003 were made by
countries in East and South-East Asia, 22% by countries
in Western and Central Europe and 16% by countries
in North America.
Seizures of amphetamines rose by 29% in 2003. How-
ever, amphetamines seizures are still 37% less than in
the peak year of 2000.  In contrast to opiate or cocaine
trafficking, most the of trafficking in the ‘ampheta-
mines’ continues to be intra-regional; inter-regional traf-
ficking is still largely limited to the precursor trade.
The two most important ‘amphetamines’ are metham-
phetamine and amphetamine (see below). In addition,
trafficking in methcathinone is of some importance in a
number of CIS countries (locally known as ephedrone),
in some parts of the USA,  and – as a recent phenome-
non – in South Africa. Methcathinone is usually locally
produced and trafficking does not involve the crossing
of any borders. In the Near and Middle East, trafficking
in fenetylline (captagon) continues to play an important
role. This is usually produced in clandestine laboratories
in South-Eastern Europe (mainly Bulgaria) and traf-
ficked via Turkey to Syria, Jordan and Saudi Arabia.  
1.5.2 Trafficking
1.5.2.1 Overview
Fig. 55: Seizures of amphetamine-type stimulants, 1980-2003
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1.5.2.2 Methamphetamine
Methamphetamine seizures continue to be concentrated
in East and South-East Asia…
Methamphetamine seizures increased by 40% in 2003
and are now  3% higher than in 2001, though still 40%
less than the peak year of 2000. The largest seizures of
methamphetamine in 2003 were reported by Thailand
(6.5 mt), China (5.8 mt), the United States (3.9 mt)
and the Philippines (3.1 mt), followed by  Mexico (0.7
ton), Australia and Japan (0.5 ton each) and the Lao
PDR and Myanmar (0.1 ton each).    
Methamphetamine seizures continue to be concentrated
in East and South-East Asia (76% in 2003). Two dis-
tinct methamphetamine products are found in East and
South-East Asia: methamphetamine tablets (often
mixed with other substances, such as ephedrine and caf-
feine) and ‘ice’ (high-quality, smokeable, crystal-
methamphetamine). Trafficking in methamphetamine
tablets is most common in South-East Asia (Myanmar,
Thailand, southern China, Lao PDR, Vietnam, Cam-
bodia, Indonesia, Malaysia) while trafficking in ‘ice’ is
more common in East-Asia (Japan, north-eastern
China, Taiwan Province of China, Korea, as well as the
Philippines). The main source countries in East and
South-East Asia in 2003 were Myanmar/Thailand, fol-
lowed by China and the Philippines. Seizures in Thai-
land (the world’s largest ATS market until 2002) fell by
25% as compared to a year earlier, reflecting a major
crack-down on methamphetamine imports from neigh-
bouring Myanmar in early 2003.  As a consequence, the
overall size of the Thai methamphetamine market
declined substantially in 2003. Methamphetamine
seizures in China, in contrast, increased, as some of the
methamphetamine produced in Myanmar was appar-
ently re-directed to markets in that country. There was
also a significant increase of methamphetamine seizures
in the Philippines, reflecting increasing levels of
methamphetamine production following the crackdown
on production facilities in other source countries.
Seizures in Japan,  financially the most lucrative market
for methamphetamine in East Asia, increased slightly in
2003 (+11%), though they were still lower than in 2000
(-52%). This appears to have been the result of a reduc-
tion of trafficking activities. A shortage on the Japanese
market, resulting in rising methamphetamine prices,
points in this direction. Nonetheless, the Japanese
Yakuza (organized crime) continues to play a significant
role in the import and distribution of methampheta-
mine: accounting for 41% of all methamphetamine
related arrests in 2003. Most of the methamphetamine
seized in Japan in 2003 originated in China and Hong
Kong SAR of China, though the Philippines and, to a
lesser extent Malaysia, also emerged as important source
countries.  A similar perception of market trends was
also expressed by the South Korean authorities,  who
reported that 67% of the methamphetamine originated
in China while the share of Philippines methampheta-
mine increased strongly.  Methamphetamine prices also
increased in the Republic of Korea.
…but rose strongly in North America.
The proportion of global methamphetamine seizures
made in North America rose from 10% in 2002 to 21%
in 2003. A strong (3-fold) increase in methampheta-
mine seizures was reported from the United States,
reflecting increasing levels of domestic methampheta-
mine production and increasing imports from neigh-
bouring Mexico. Increased enforcement and prevention
efforts, however, appear to have prevented increased use.
Methamphetamine seizures in Mexico rose by almost
60% in 2003. The main form of methamphetamine
available in North America is powder methampheta-
mine; smaller quantities of ‘ice’ are also available.    
1.5.2.3 Amphetamine
Amphetamine seizures continue to be concentrated in
Europe - and are rising… 
Global amphetamine seizures (5.4 mt) are back to the
levels reported in 1997/98, having increased by 22% in
2003. Amphetamine seizures  continue to be concen-
trated in Europe (>90%), notably in Western and Cen-
tral Europe (79%). However, the share of West and
Central Europe in global amphetamine seizures has
been declining (87% in 2002 and 90% in 2001). 
The largest amphetamine seizures in 2003 took place in
theUK, followed by the Netherlands, Bulgaria, Ger-
many and Sweden.  The main source countries were the
Netherlands, followed by Poland and Belgium. Interna-
tional organized crime groups appear to be less involved
in amphetamine trafficking than in methamphetamine
trafficking. The retail market for amphetamine usually
consists of large numbers of small trafficking groups
who purchase the drugs in the main source countries
and then sell them locally. Recently,  some of the estab-
lished drug trafficking groups have started to smuggle
amphetamine along with drugs they normally move.
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Fig. 56: Breakdown of ATS seizures in 2003 by sub-regions (N = 32 metric tons) 
East and South-
East Asia
52%
West & Central 
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22%
North America
16%
Oceania
6%
Other
4%
Source: UNODC, Annual Report Questionnaire Data / DELTA.
Fig. 57: Breakdown of methamphetamine seizures
in 2003 (N = 21.6 metric tons) 
Oceania
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Source: UNODC, Annual Report Questionnaire Data / DELTA.
Fig. 58: Breakdown of amphetamine seizures by sub-
region in 2003 (N = 5.6 metric tons)
Source: UNODC, Annual Report Questionnaire Data / DELTA.
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Fig. 59: Global seizures of amphetamines*, 1993 - 2003
Year 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Metric tons 5          6          7          10        15        14        33        44        26        21        27         
* data refer to 2002
** total seizures reported by national as well as State & Territory law enforcement agencies which may result in double counting.
 * metric ton equivalents. 1 unit assumed to be equivalent to 30mg. 
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Fig. 60: Global seizures of amphetamines, 1993 - 2003
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1.5.2.4 Ecstasy 
Trafficking in ecstasy remains largely intra-regional
within Europe and inter-regional outside Europe.
Ecstasy seizures in kilogram equivalents amounted to
4.3 mt, 37% less than in the peak year of 2002 possibly
reflecting a decline of ecstasy production in Europe.
Declines in ecstasy seizures were reported from West
and Central Europe, as well as from North America, the
Caribbean, the Near and Middle East and Southern
Africa; in contrast, ecstasy seizures rose strongly in the
Oceania region and in East and South-East Asia.
Trafficking in ecstasy remains largely intra-regional
within Europe and inter-regional outside Europe, as
European countries continue to be the main production
locations for MDMA. The main source countries are
the Netherlands and Belgium. Source countries outside
Europe are, inter alia, the United States, Canada, China,
Indonesia and South-Africa.  The intra-regional distri-
bution of ecstasy within Europe – like trafficking in
amphetamine – is undertaken  by a large number of
rather small drug trafficking groups of various national
backgrounds. In contrast, trafficking of ecstasy from
Europe to North America and some other regions
appears to be mainly controlled by criminal groups of
Israeli origin, sometimes with links to Russia, other
European countries and the USA. These trafficking
groups operate mainly outside Israel, though, in some
instances, they have been also involved in trafficking
ecstasy from the Netherlands and Belgium to Israel. In
addition,  criminal groups from the Dominican Repub-
lic have also become involved in shipping ecstasy from
Europe via the Caribbean to the USA. If seizures over
the 2001-2003 period are analysed,  the Netherlands
accounted for 22% of global seizures, followed by Aus-
tralia (13%), the United States (12%),  the UK (12%),
and Belgium (11%).29
Fig. 61: Breakdown of ecstasy seizures* by sub-
region in 2003 (N = 4.2 mt)
West & Central 
Europe
54%
Oceania
26%
North America
11%
East and South-
East Asia
5%
Others
4%
* in kilogram equivalents, using a conversion ratio of 100 mg for
an ecstasy pill.
Source: UNODC, Annual Report Questionnaire Data / DELTA.
29 In 2003, the national and the State and Territory law enforcement agencies of Australia seized more than 1 ton of ecstasy (26% of global ecstasy
seizures),  slightly more than the Netherlands (close to 1 ton or 23% of global seizures).
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 * total seizures reported by national as well as State & Territory law enforcement agencies which may result in double counting.
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Fig. 62: Global seizures of ecstasy*, 1993 - 2003
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Consumption of amphetamine-type stimulants
Amphetamine-type stimulants (ATS), as defined by the
UNODC, consist of amphetamines (amphetamine,
methamphetamine), ecstasy (MDMA and related sub-
stances), and other synthetic stimulants (methcathi-
none, phentermine, fenetylline, etc.). 
After the opiates, ATS are the main problem drugs in
Asia, and in some countries they have overtaken heroin
in terms of their contribution to treatment demand.
While overall use levels are less than 1% in most regions,
ATS are responsible for a substantial share of treatment
admissions in Asia (16%), Oceania (13%), North
America (12%), and Europe (9%). Most admissions are
for methamphetamine and amphetamine dependence,
and relatively few are related to ecstasy. 
An estimated 26 million people, or 0.6% of the popu-
lation aged between 15 and 64, used methampheta-
mine, amphetamine, or related substances in 2003,
while about 7.9 million people used ecstasy.
Almost two thirds of the world’s amphetamine and
methamphetamine users reside in Asia, most of whom
are methamphetamine users in East and South-East
Asia. But the prevalence of use is highest in the Oceania
region (3% of the population age 15-64), followed by
East and South-East Asia (1.2%) and North America
(1.1%). In all of these markets, methamphetamine
dominates as the main ATS. In Europe, in contrast,
amphetamine use is more common than methampheta-
mine use.  
Use of ecstasy continues to be concentrated in Europe
and North America. West and Central Europe account
for a third of global ecstasy use, followed by North
America, accounting for almost 30%. More people
report having used ecstasy in the last year in the Ocea-
nia region (3.1%) than any other region, followed by
West and Central Europe (0.9%) and North America
(0.8%). 
Global ATS use seems to have declined in 2003, largely
due to decreasing methamphetamine use in Thailand
1.5.3 Abuse
in % of population in % of population 
15-64 years 15-64 years
EUROPE 2,670,000 0.5 3,030,000 0.6
West & Central Europe 2,160,000 0.7 2,670,000 0.9
South-East Europe 180,000 0.2 194,000 0.2
Eastern Europe 330,000 0.2 166,000 0.1
AMERICAS 4,340,000 0.8 2,834,000 0.5
North America 2,980,000 1.1 2,328,000 0.8
South America 1,360,000 0.5 506,000 0.2
ASIA 16,710,000 0.7 1,260,000 0.05
OCEANIA 630,000 3 634,000 3.1
AFRICA 1,810,000 0.4 136,000 0.03
GLOBAL 26,160,000 0.6 7,894,000 0.2
        Above global average                Around global average                         Below global average
Use of amphetamines Use of ecstasy
No. or users No. of users
Table 11: Annual prevalence estimates of ATS use: 2003-2004
Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
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(formerly the country with the highest prevalence rate)
and lower levels of ecstasy use in the USA. Metham-
phetamine abuse in Japan, one of the world’s most
lucrative ATS markets, was reported to have remained
stable in 2003.  
When weighted by the number of ATS users in their
respective countries, total expert opinions reported to
UNODC suggest that  the use of ATS stabilised in
2003, following years of sharp increases in the late
1990s. There are, however, early reports that metham-
phetamine may again be on the rise in East and South-
East Asia in 2004. 
European student surveys show that ecstasy use
increased over the 1999-2003 period while use of
amphetamines declined. Growth in European ATS use
was stronger among females than males, leading to less
significant gender differences and, in some countries, to
higher levels of ATS experimentation by female students
(age 15-16) than by their male counterparts.     
Following strong increases in the 1990s, use of amphet-
amines and ecstasy remained basically stable in Central
and Eastern Europe over the 1999-2003 period. In
Western Europe, amphetamine use declined while
ecstasy use continued to increase - though in some
countries the opposite trends were observed. 
Based on the calculation of unweighted averages, Cen-
tral and Eastern Europe is already (marginally) ahead of
ATS consumption levels in Western Europe, for both
amphetamines and for ecstasy.  Weighted by popula-
tion,  the average ATS life-time prevalence rates for stu-
dents, age 15-16,  in Western Europe are still slightly
higher than the corresponding rates in Central and East-
ern Europe.
Fig. 63: Drug Use Trend Index - ATS - based on
expert opinions (weighted by the estimated
number of ATS users), 1993-2003
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Source: UNODC, Annual Reports Questionnaire Data.
Fig. 64: Reported violations against the Stimulants Law in Japan, 1950-2003
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* Data for 2003 are still preliminary.
Sources: Ministry of Health and Social Welfare, National Police Agency of Japan, UNODC, Annual Reports Questionnaire data.  
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Fig. 65: Changes in the annual prevalence of methamphetamine use in Thailand*,  1993-2003  
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* All estimates suggest a strong increase of methamphetamine abuse in Thailand in the 1990s. Following the crack-down on the ATS
market in Thailand in 2003, household survey data showed a more than 90% decline in methamphetamine use. Some of this
reported decline, however, seems to have been a reflection of an increasing reluctance of methamphetamine users to publicly admit
their habit. This can be also deduced  from a drastically falling  life-time prevalence rate over a 2-year period (2001-2003). A parallel
rapid assessment study conducted among methamphetamine users in Thailand suggested that the decline was not 90% but around
46% in 2003 - which is still a massive reduction.    
Sources: Thailand Development Research Institute, 1995, ONCB, Thailand Narcotics Annual Report 2002 and 2003, National Household
Survey 2003 quoted in  UNODC (Regional Centre for East Asia and the Pacific), Regional ATS Update and training meeting -
Final Report,  2004. 
Fig. 66: Changes in the annual prevalence of ATS use in the USA, 2002-2003 (age 12+)
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Source: SAMHSA, National Survey on Drug Use and Health, 2002 and 2003. 
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Fig. 67: Annual prevalence of ATS use among students in the United States, 1991-2004
Source: NIDA, Monitoring the Future 
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Fig. 68: Life-time prevalence of ATS use among 15-16 year old students in the USA and in Europe, 1995-2003
Source: NIDA, Monitoring the Future and Council of Europe , The ESPAD Report 2003 - Alcohol and Other Drug Use Among Students in
35 European Countries, previous ESPAD reports (1999 and 1995) and national Govt. reports
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2. ESTIMATING THE VALUE OF 
ILLICIT DRUG MARKETS
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The illicit drug industry operates outside the law. Its
‘companies’ are not listed on any stock exchange, they
are not valued by any private accounting firm, and the
dynamics of the drug industry are not regularly pored
over by analysts, economists and forecasters. Yet the
overall size of the illicit drug industry is known to be
large and, therefore, a potential threat to a number of
economies in terms of the financial power generated.
The funds generated can be used to intimidate (includ-
ing by means of violence) or corrupt government offi-
cials or, in some cases, political systems as a whole, as
well as to crowd out licit economic activities, thus jeop-
ardizing a country’s future. If the illicit drug industry is
to be successfully controlled, there is a need to come to
an understanding of the likely amount of money
involved and where these funds are being generated. 
The utility of undertaking such an exercise is clear from
both a policy and a trend analysis perspective. Knowl-
edge of the market’s value is indisputably useful for
policy formulation. An informed estimate of the size of
the drug markets also will enable analysts to look at the
relative importance of the size of the markets vis a vis
local economies and it will facilitate the comparison of
the importance of different drugs in economic terms. In
addition, knowledge of the size of these markets will
give us an element for comparison with other illicit mar-
kets – an important issue when it comes to allocating
scarce economic resources to fight various illegal activi-
ties.  
The obscurity of the global illicit drug market makes the
exercise of estimating its size difficult. This is not
because the drug market does not behave like most
others in terms of supply and demand - there is a grow-
ing acceptance that it does. It is rather because the most
basic inputs that are needed for such an estimation –
data on production, prices, quantities exported,
imported and consumed – are themselves often esti-
mates and are frequently based on deficient data. 
A number of attempts to measure the size of the illicit
drug industry have been made in the past, including by
the Financial Action Task Force and the United
Nations. The Financial Action Task Force (FATF) esti-
mated that in the late 1980s, sales of cocaine, heroin
and cannabis amounted to approximately US$124 bil-
lion per year in the United States and Europe1, of this
total some US$85 billion or 70% was considered to
have been available for money laundering and invest-
ment.2 Taking inflation into account, the FATF estimate
of the size of the illicit drug industry for the late 1980s
would be equivalent today to some US$200 billion
(expressed in 2005 US dollars).3
Other United Nations estimates, based on cash flows
from international banking and capital account statis-
tics, suggested that up to US$300 billion per year could
have been available for money laundering in the late
1980s.4
2. Estimating the value of illicit drug markets
2.1 Background
1 The FATF estimated the retail drug sales turnover during the 1980s at $108 billion in the United States and $16.3 billion in Europe, i.e. a total of
$124.3 billion. The largest amount was estimated for cannabis ($74.7 billion), followed by cocaine ($28.8 billion), and heroin ($12 billion).
Organisation for Economic Co-operation and Development, FATF Working Group on Statistical and Methods, Narcotics Money Laundering -
Assessment of Scale of the Problem, 1989, Financial Action Task Force on Money Laundering, report, February 7, 1990.
2 Organisation for Economic Co-operation and Development, Financial Action Task Force on Money Laundering, Paris 1990, p. 6, quoted in
UNDCP, Economic and Social Consequences of Drug Abuse and Illicit Trafficking, Vienna 1997, p. 27. 
3 The $124 billion referred to estimates for 1988; based on the US Consumer Price Index, this amount would be equivalent to $201 billion in 2005
(http://data.bls.gov/cgi-bin/cpicalc.pl). 
4 This figure was, however, qualified as "suspect" (probably too high) by the Intergovernmental Expert Group to Study the Economic and Social
consequences of Illicit Traffic in Drugs (see E/CN.7/1991/25, p. 25). 
Based on 1995 drug production estimates, UNDCP
arrived at a global estimate of $360 billion, with a range
from $85 billion to $1,000 billion.5 Given this broad
range and the high degree of uncertainty about the
validity of some of the assumptions made, UNDCP’s
1997 World Drug Report estimated a likely turnover of
the illicit drug industry at around $400 billion.6 This
figure was questioned by some experts in the field as
possibly too high. However, no alternative calculations
on the likely size of the global drug industry were pro-
vided. 
Another attempt as part of a broader exercise to estimate
the total value of money laundered annually (from crim-
inal activities) was started by the Financial Action Task
Force in the late 1990s. It was decided to begin this
exercise by looking into the illicit drug market, given
the fact that it was better studied than most other ille-
gal markets. A number of expert meetings were con-
vened, bringing together expertise from various
international, regional and national organisations.
Given the extreme data limitations, existing weaknesses
and contradictions of some of the data, the experts
could not agree on the most appropriate methodologi-
cal approach. The basic question was whether a top-
down approach (starting from global production
estimates) or a bottom-up approach (starting from
country estimates based on prevalence rate and esti-
mates of expenditure per drug user which would then
have to be aggregated) offered a better chance to arrive
at a realistic estimate of the total value of the drug
market. Recommendations were made to encourage
countries to improve their drug data collection systems
and to encourage them to undertake drug market esti-
mates at the national level.7 Thus far only a limited
number of country estimates on the value of the illicit
drug market are currently available. These alone would
be insufficient for generating global estimates.    
Using the valuable lessons learned from these past exer-
cises UNODC has continued work in this area. The
organisation’s objective is to have a reliable idea of the
size of the value of the market, and to stimulate further
research. 
Three principles guided the production of these esti-
mates: first only readily available data were used; second,
the methodology and the model were kept straightfor-
ward and the assumptions transparent; and third, it was
ensured that by distilling the market down to its most
basic economic rules, the model  would be easily
updateable. In addition, the methodology chosen tries
to combine, as far as possible, the top-down with the
bottom-up approach. While UNODC is fully aware
that the results will never have the same level of accu-
racy as could be expected from a comparable analysis of
a licit market, and must be thus treated with caution,
the new valuation methodology provides the best possi-
ble results, based on existing knowledge and data pro-
vided by Member States to UNODC. The methodology
used and the results will be discussed in this Chapter.
2.1.1. The model
A global input-output model was developed building on
existing UNODC data collection systems, thus making
it replicable as well as allowing for expert opinion to be
taken into account. The model used data published in
last year’s World Drug Report (2002/2003 data), sup-
plemented –where data was missing - with data
obtained from Member States over the last year. The
model was used for the analysis of the main drug mar-
kets: opiates, cocaine, cannabis herb, cannabis resin,
amphetamines and ecstasy. 
Models work on assumptions, but these are made
explicit so that they can be improved over time. The
main assumption of this model is that what is being pro-
duced, less seizures and less losses, is available for con-
sumption and is consumed. The amounts available for
consumption in each sub-region are multiplied with the
average purity adjusted prices of the respective sub-
regions to arrive at the sub-regional market values.
These values are then added up to arrive at the total
market value. The model looks at the market sub-
regionally. Data inconsistencies are detected in large
part because the model looks at the market both from
the supply side and the demand side. 
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5 This estimate amounted to US$117 billion for cocaine, US$107 billion for opiates, US$62 billion for cannabis herb, US$13 billion for cannabis
resin and US$60 billion for synthetic drugs. UNDCP, Economic and Social Consequences of Drug Abuse and Illicit Trafficking, UNDCP Technical
Series, p. 51. 
6 United Nations International Drug Control Programme, World Drug Report, (Oxford University Press 1997), p.124.
7 Financial Action Task Force, Report of the FATF Ad Hoc Group on Estimating the Magnitude of Money Laundering on Assessing Alternative Methodologies
for Estimating Revenues from Illicit Drugs, FATF-XI/PLEN/45 (2000).
The model starts with global drug production per sub-
region and allocates it, less local consumption and
purity adjusted seizures made in the source countries,
either according to seizures made in the different sub-
regions (for potential ‘supply constrained regions’)8 or
according to the ‘number of drug users multiplied by
per capita drug consumption ratios’ (for potential
‘demand constrained regions’).9 The model thus allows
for different per capita consumption rates for different
sub-regions.10 From the allocated amounts per sub-
region, the model deducts purity adjusted seizures and
losses (set at 10%) and then multiplies the remaining
amounts that are available for consumption in each sub-
region with the purity adjusted prices. It uses the purity
adjusted wholesale prices to estimate the wholesale value
and the purity adjusted retail prices to calculate the final
retail value. Adding up these sub-regional values gives
the estimates at the global level. 
The drug prices and drug purities of each country are
weighted by the number of drug users in that country
in order to calculate the regional average. The ‘typical’
drug prices and drug purities, provided by Member
States were used. If no such typical prices or purity data
were provided, the mid-point estimates of minimum
and maximum values were used instead. If for any indi-
vidual country no price or purity data is available, the
model uses the unweighted sub-regional averages as a
proxy.    
The model allows for a number of calibrations, based on
expert knowledge, to adjust, as far as possible, the
model’s  assumptions to reality. Thus, it is possible to
adjust for the likely effectiveness of law enforcement
bodies in different regions. This affects the calculated
interception rates and thus the allocation of the drugs to
the various regions. For instance, enforcement effective-
ness can be assumed to be higher in North America than
in Africa, thus lower drug seizures in Africa can still go
hand in hand with substantial levels of drug consump-
tion. The model also has a built-in distribution mecha-
nism that assumes that drugs produced in a region are,
first of all, used to supply local demand before being
exported. The subsequent distribution of drugs to the
destination markets is then a function of geographical
proximity (i.e. the closer any specific drug producing
region is to another region, the higher the likely pro-
portion of total exports going to such a region). Again,
these model assumptions can be altered based on expert
knowledge. For instance, special ethnic links and estab-
lished drug trafficking routes are known to play, in some
cases, a far more important role than mere geographic
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8 The main hypothesis for this approach has been that seizures are positively correlated with the size of a drug market. In addition, seizures are, of
course, also a function of the effectiveness of law enforcement bodies. This is taken into account by 'rating' the effectiveness of law enforcement of
some regions versus others. In regions with a weak enforcement infrastructure even small seizures may indicate a sizeable drug market while the
opposite can be true in regions with highly effective law enforcement bodies.  
9 As a default value, the model assumes that all regions are 'supply constrained', i.e. people would use as much of a drug as they could secure. For
drug producing and main transit countries, such an assumption is however, not very realistic. Such regions are subsequently set to become 'demand
constrained'. This requires an assumption of the likely per drug capita consumption. If no additional information was available, it was usually
assumed that average consumption of such regions would be close to the global average, estimated as amounts of drugs available (derived from
production estimates less seizures and less losses), divided by the total number of drug users. In order to make the results of the two approaches
('supply constrained' and 'demand constrained') comparable, purity adjusted seizures are then added to arrive at the allocated amounts. 
10 This is important because, information on per capita consumption rates is still very limited. It is hoped that this will improve over the next few
years, which should strengthen the 'bottom-up' approach in the model.  
Table 1. Drug related data routinely collected by UNODC
Production Trafficking Consumption
Cultivation Drug seizures Annual prevalence
Yields Origin of drugs Trends in drug consumption 
Manufacture Transit of drugs
Laboratory seizures Destination of drugs
Prices Prices
Purities Purities
Largely missing: Information on quantities
of drugs consumed 
proximity. For some specific cases, theoretical trafficking
links could be completely ruled out (such as exports of
North American cannabis herb to Africa or South Asia;
differences in price levels would mean that traffickers
involved in such operations would simply lose money).  
One advantage of such a systematic approach with
built-in cross-checks is to make explicit to the analyst all
potential data inconsistencies. This systematic analysis
of existing data is particularly important given well-
known data weaknesses. It enables the identification of
data that needs to be re-checked and/or indicates new
areas of research. Moreover, the model helps to incor-
porate new estimates, research findings and intelligence
whenever they should become available.  
Key to the outcome of the model are, of course, the
inputs used. The main inputs into the model are drug
production estimates, seizures, drug price data (farm-
gate, wholesale and retail prices), drug purity data
(wholesale and retail level), estimated number of drug
users and estimates of per capita drug consumption.
Most of these data are routinely collected by UNODC. 
Seizure, price and purity data are collected annually
from countries through UNODC’s Annual Reports
Questionnaires and are supplemented by information
collected from other international or regional bodies
(such as INCB, Interpol, WCO, Europol, OAS etc.).
Seizure data is thus the most complete data set. In addi-
tion, countries report typical drug trafficking patterns to
UNODC, including the most typical trafficking routes.
This information entered the model in the form of ex-
post calibrations.  
Prevalence data is basically collected through UNODC’s
Annual Reports Questionnaires. However, this data set
is not as complete as seizure data as many governments
still do not have appropriate monitoring systems in
place. Thus, UNODC developed over the years a spe-
cial methodology to estimate annual prevalence data
from partially available data sets (e.g. extrapolating
annual prevalence data from life-time prevalence data,
from student surveys or from treatment data using
annual prevalence data from other countries in the
region as benchmark figures). 
Largely missing – and not part of any routine data col-
lection – is information on the per capita consumption
of drugs by drug users. The lack of this information has
been one of the biggest constraints to market analysis on
the demand side and thus a main stumbling block to
almost every attempt to gain greater insight into the
market from the consumption side. There is almost no
systematic and comparable data on the quantities of
individual substances consumed per users in different
regions. The information which does exist is limited and
often contradictory. More research efforts in this area
are clearly needed.
UNODC’s strongest data sets are is for the cultivation
of coca and opium poppy. Through its International
Crop Monitoring Programme, UNODC, in coopera-
tion with the respective national governments, uses
ground and satellite based survey methods to measure
the extent of cultivation (for coca, opium poppy and
cannabis resin11). In combination with yield surveys,
drug production estimates can thus confidently be
established. 
Production estimates on cannabis herb have been taken
from replies to UNODC’s Annual Reports Question-
naire as well as from other Government reports. The
problem here is that most of these estimates are not
based on rigorous scientific studies. In addition, for
many countries the information is missing altogether. A
number of countries in Africa, Asia and Europe, for
instance, have been frequently identified by other coun-
tries as important source countries, but they did not
provide any cannabis production estimates to
UNODC. In such cases, it was assumed that the coun-
tries cover their local demand and use a certain per-
centage for export purposes. The total cannabis herb
production estimate thus increased from otherwise
35,000 mt to 42,000 mt for the year 2003. However, a
similar amount (5,000 mt) was subsequently deducted
again as ‘extraordinary losses’ from one sub-region
(North America) as available production estimates in
this sub-region, reported to UNODC by various
national authorities, seemed to exceed realistic con-
sumption estimates.12
In the case of ATS indirect estimation methods were
used, as described in other parts of this report, based on
ATS consumption, ATS seizures and ATS precursor
seizures.   
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11 For Morocco.                                                                                                                                                                                              
12 This had to be done as a possible alternative explanation - exports - does not apply in this case; no information is available to UNODC that cannabis
herb produced in North America is being exported to any other region in significant quantities. 
2.2  Results
Based on the inputs and the calculations explained
above, the value of the global illicit drug market for the
year 2003 was estimated at US$13 bn at the production
level, at $94 bn at the wholesale level (taking seizures
into account), and at US$322bn based on retail prices
and taking seizures and other losses into account. This
indicates that despite seizures and losses, the value of the
drugs increase substantially as they move from producer
to consumer.  
The largest market, according to these estimates, is
cannabis herb (with a retail market size of $113 bn), fol-
lowed by cocaine (US$71 bn), the opiates (US$65bn)
and cannabis resin (US$29 bn). The ATS markets
together (methamphetamine, amphetamine and
ecstasy) amount to US$44 bn. The valuation does not
take into account the value of other drugs. 
While UNODC is reasonably confident with its esti-
mations on opiates, cocaine and the ATS, the degree of
certainty is far lower for cannabis, notably for cannabis
herb, as information for production and consumption
of this substance is highly contradictory. If better infor-
mation becomes available, a major revision cannot be
ruled out.  
If compared to global licit exports (US$7,503 bn in
2003)13 or compared to global GDP (US$35,765 bn in
2003)14 the estimated size the global illicit drug market
may not appear to be particularly high (0.9% of global
GDP at retail level or 1.3% of global exports measures
at wholesale level).15
Nonetheless, the size of the global illicit drug market is
substantial. The value, measured at retail prices, is
higher than the GDP of 88% of the countries in the
world (163 out of 184 for which the World Bank has
GDP data) and equivalent to about three quarters of
Sub-Saharan Africa’s combined GDP (US$439 bn in
2003). The sale of drugs, measured at wholesale prices,
was equivalent to 12% of global export of chemicals
(US$794 bn), 14% of global agricultural exports
(US$674 bn) and exceeded global exports of ores and
other minerals (US$79 bn) in 2003. Such sales of drugs
were also higher than the combined total licit agricul-
tural exports from Latin America (US$75 bn) and the
Middle East (US$10 bn) in 2003.16
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Fig. 1: Size of the global illicit drug market in 2003
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Fig. 2: Size of the global illicit drug market in 2003
by substances
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Source: Illicit Drug Market Estimation Model, based on UNODC,
Annual Reports Questionnaire Data, Govt. reports and UNODC
production and consumption estimates. 
Source: Illicit Drug Market Estimation Model, based on UNODC,
Annual Reports Questionnaire Data, Govt. reports and UNODC
production and consumption estimates. 
13 World Trade Organisation, International Trade Statistics 2004, p. 19.                                                                                                                 
14 World Bank, World Development Indicators 2005 Report, http://www.worldbank.org/data/wdi2005/. 
15 The comparison with wholesale prices is more appropriate as export prices are usually closer to wholesale than to retail prices. 
16 World Bank, World Development Indicators database, April 2005. 
The relative importance of the size of illicit drugs
market becomes more pronounced if compared to the
exports of individual products. Exports of wine
(US$17.4 bn) and beer (US$6.7 bn) are equivalent to
just a quarter of the wholesale value of illicit drugs.17
Coffee, one of the world’s most ubiquitous beverages,
used to generate some US$15bn in export revenue in
the 1990s,18 falling to less than US$6 bn in 2003.19
Global exports of tobacco products (including ciga-
rettes) are equivalent to about a fifth of the global
wholesale value of illicit drugs. Wheat, a staple of a large
portion of the global population, generated US$16bn in
export revenue in 2003. All cereal exports together
resulted in export revenue of $41 bn,20 less than half the
wholesale value of the global illicit drugs market.  
In terms of the regional distribution, the world’s largest
drug market – in economic terms – was identified to be
North America,21 accounting for 44% of the world’s
total drug sales at the retail level, followed by Europe
(33%). Within Europe, West and Central Europe22 is
the dominant drug market (27% of total). The next
largest retail drug markets are Asia (11%) followed by
Oceania (5%) and Africa (4%). 
128
World Drug Report 2005 Volume I. Analysis
17 Food and Agriculture Organization of the United Nations, FAOSTAT,  http://faostat.fao.org/faostat/collections?version=ext&hasbulk=0.                
18 Aksoy, M.A. and Beghin, J.C. eds., Global Agriculture and Trade in Developing Countries, World Bank, Washington DC, 2005, p 297 (evaluated
at 1997-98 average prices and volumes.)
19 International Coffee Organization, Annual Review 2003/04, p. 6.
20 Food and Agriculture Organization of the United Nations, FAOSTAT,  http://faostat.fao.org/faostat/collections?version=ext&hasbulk=0
21 North America is defined to include: Canada, Mexico and the United States of America. 
22 West & Central Europe includes the 25 EU countries, the EFTA countries and small countries such as Monaco, Andorra and San Marino. 
Fig. 3. Value of illicit drugs at wholesale level (in billion US$) compared to the export values of selected
agricultural commodities in 2003
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Fig. 4: Regional breakdown of the global illicit drug
market in billion US $ (N = $322 bn)
* Including Caribbean and Central America.
Sources: UNODC, Illicit Drug Market Estimation Model.
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On a per capita basis, the results of the model suggest
that the highest expenditures on drugs per year
(expressed in current US-dollars) are found in the Ocea-
nia region, followed by North America and West and
Central Europe. Below average expenditures on drugs
are seen in Asia, Africa and South America. This is
mainly the result of far lower drug prices in these coun-
tries. Global expenditures on drugs amount to about
US$50 per person per year. 
Expressed as a percentage of GDP, drug sales (at the
retail level) seem to be most important in the Oceania
region, followed by East and South-East Europe23 and
Africa. The lowest importance of retail sales of drugs as
compared to the size of the overall economy is in Asia.  
Though only about a third of the world’s drug users are
located in OECD countries, about three quarters of the
world’s retail drug market – in economic terms - is
found in the industrialized world (some US$245 bil-
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Fig. 5: Per capita expenditure on drugs (in current US$)
* Including Caribbean and Central America.
Sources: UNODC, Illicit Drug Market Estimation Model, United Nations, Population Division, Department of Economic and Social Affairs,
World Population Prospects: The 2002 Revision (POP/DB/WPP/Rev.2002/4/F1).
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Fig. 6: Expenditure on drugs in % of GDP (2003)
* Including Caribbean and Central America.
Sources: UNODC, Illicit Drug Market Estimation Model, World Bank,World Development Indicators 2005.
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is defined to include Turkey and the (non EU-25) Balkan countries.                                                                                                                 
lion). 
The calculations also show that, in absolute terms, the
highest profits are made between the wholesale and the
retail level. Given the concentration of the retail markets
in the industrialized countries, the results suggest that
most of the ‘value-added’ (gross profits) of the illicit
drug industry actually takes place in the industrialized
world. Of the total ‘value-added’ of the illicit drug
industry, 76% is generated in the industrialized coun-
tries, 19% in developing countries and the rest in tran-
sition countries. Total producer income is, on average,
4% of the final retail value. For heroin and cocaine, it is
close to 1% of the final retail value.
2.3 Results of the individual
markets
2.3.1 The cocaine trade - valued at over
US$70 bn per year (retail level)
Table 2 presents an analysis of levels of production in
source countries and distribution to consumer coun-
tries. For a variety of reasons, it was necessary to base the
cocaine production estimates on a three-year average
(2001-2003), resulting in a figure of 761 mt This
amount, however, does not reach the consumers. After
deducting seizures in the source countries (Colombia,
Peru, Bolivia), the amount available for shipment to
consumers was 653 mt Based on these data and average
cocaine base prices of US$808 per kilogram, the local
income from cocaine base production in South America
was estimated at US$527 million. 
In order to determine the destination of this produc-
tion, the number of consumers in each region was first
considered. In addition, the cycle of the epidemic plays
an important role. Countries or regions in an early stage
of a drug epidemic can be expected to have many recre-
ational users but only a limited number of hard-core
addicts, while the opposite is true in more advanced sit-
uations. Based on a limited number of studies on the
per capita consumption patterns of drug users, it was
estimated that the average cocaine user in North Amer-
ica consumes 44 grams of pure cocaine per year while
the average cocaine user in Western and Central Europe
and in South America consumes some 35 grams per
year. 
Taking the information on the estimated number of
cocaine users and the estimated number of per capita
consumption rates into account, the model calculates
the amount of drugs consumed in these sub-regions.
Factoring in the purity adjusted seizures made in these
sub-regions, the model arrives at the likely amounts of
cocaine being imported. Based on these calculations, it
would appear that the bulk of the cocaine produced in
the Andean region goes to North America (352 mt),
with lesser amounts being received in West and Central
Europe (134 mt), the Caribbean (17 mt) and Central
America (16 mt). About 101 mtare retained in South
America for domestic consumption. Between them,
these regions account for the bulk of the cocaine traf-
ficked (96%). Deducting purity adjusted seizures and
losses (set at 10%), the model calculates the amounts
actually available for consumption24 in North America
(280 mt of pure cocaine), West and Central Europe
(107 mt), and South America (69 mt).  For other
regions, see Table 2.
Multiplying these amounts with the purity adjusted
average cocaine prices (i.e. prices calculated for 100%
pure cocaine) gives a wholesale value for the region.
Adding up the wholesale-values from all regions gives a
total market value of US$18.8 bn, including the large
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Fig. 7: Distribution of the ' value added' of the illicit
drug industry (N = $322 bn)
Sources: UNODC, Illicit Drug Market Estimation Model, World
Bank.
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24 The model does not differentiate between seizures made at the wholesale level and those made at the retail level. The implicit assumption here is
that most of the seizures and losses take place in the shipment of cocaine from the Andean region to the destination countries; seizures at a later
stage, i.e. at the retail distribution level, are considered to be rather small. Such seizures are already included in the overall seizures figures at the
wholesale level.                                                                                                                                                                                           
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markets of North America (US$ 9.1 bn),  West and
Central Europe (US$6.8 bn), and South America
(US$0.3 bn). The South American figure reflects, how-
ever, only the gross income of wholesalers supplying the
domestic market. The total wholesale income in South
America, where much of the cocaine is not destined for
local consumption but for exports, is much larger. The
total gross income of wholesalers in South America
would be equivalent to about US$2.6 bn. 
Retail values were calculated by multiplying the
amounts available for consumption by the purity
adjusted retail prices, resulting in remarkably high fig-
ures in North America (US$44 bn), West and Central
Europe (US$17 bn), and South America (US$3 bn).
The global retail market for cocaine adds up to US$70.5
bn. The results of the model suggest that North Amer-
ica (62%), followed by Europe (26%) are, in economic
terms, the largest cocaine markets. 
2.3.2 The opiates trade - valued at
US$65 bn per year(retail level)
Global production of opiates is estimated at 476.5 mt
(in heroin equivalents) in 2003, most of which is pro-
duced in the Near and Middle East/South-West Asia
sub-region (365 mt), which includes Afghanistan. In
contrast to cocaine, however, opiate production takes
place in more than one region. The second most impor-
tant production region is East and South-East Asia (94
mt), mainly Myanmar and Laos. Other production
areas of importance are in North America (reflecting
production in Mexico) and in South America (mainly
reflecting production in Colombia). 
For each of these production areas, distinct distribution
patterns can be identified. Most of the opiates produced
in the Near and Middle East/South-West Asia sub-
region are either consumed locally (more than a fifth) or
exported to Europe (about half ). The rest goes to other
regions. In the case of East and South-East Asia, two
thirds are for consumption within the region. All of the
opiates produced in North America remain within this
region (mainly destined for the US market) and opiates
produced in South America are for the local market and
for the market in North America. 
According to the results of the model, close to 100 mt
of heroin are destined for the markets of West and Cen-
tral Europe, about 90 mt for East Europe and 10 mt for
South-East Europe. Deducting seizures and losses
(assumed to amount to 10%), 84 mt are actually avail-
able for consumption in West and Central Europe,
equivalent to 58 grams per heroin user per year. This is
higher than the average at the global level (28 grams).
However, one internal study, commissioned by
UNODC, found that average heroin consumption
among heroin users in the three months prior to under-
going drug treatment was close to 68 grams of pure
heroin per year.25 According to reports from the Swiss
heroin maintenance program, which covers a group of
hard-core heroin addicts, 135 grams per addict are con-
sumed annually.26 Against this background, a per capita
consumption of 58 grams of heroin per year in West
and Central Europe appears to be feasible. 
132
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Fig. 8: Regional distribution of cocaine retail sales in
2003 in billion US$ (N = US$70.5 bn) 
* including Caribbean and Central America
Sources: UNODC, Illicit Drug Market Estimation Model.
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25 These results were based on the results of a UK study on people entering treatment in 1997 (Gossop et al., "National Treatment Outcome Research
Study in the United Kingdom", Psychol. Addictive Behaviours, 1997). The study showed an average consumption of 0.6 grams per day, and a
consumption of, on average, 22 days per month. Average consumption per month was thus 14.9 grams of heroin (at street purity), which amounts
to 179 grams per year. Applying the average purity of around 38 % reported by forensic laboratories in the UK in 1997 (The Forensic Science
Service, "Drug Abuse Trends", various issues), average annual consumption would be 68 grams of pure heroin per problem drug user.     
26 Institut für Suchtforschung, Universität Zürich, Institut für Sozial und Präventivmedizin, Versuche für eine ärztliche Verschreibung von
Betäubungsmitteln, Synthesebericht, (Ambros Uchtenhagen), June 1997.                                                                                                             
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Multiplied with purity adjusted retail prices, weighted
by the number of consumers in each country, the value
of the opiate market in West and Central Europe is
estimated at US$25 bn. This is in line with previous
UNODC estimates on the size of West Europe’s heroin
market. The total retail market value of Europe’s opiate
market (including those of East and South-East Europe)
is estimated at US$37 bn. Europe accounts thus for
56% of the global opiates retail market, valued at
around US$65 bn. The next largest retail market – in
economic terms – is Asia, accounting for 22% of the
total. The third largest market is North America, which
consumes US$9 bn worth of the drug or 14% of the
total.27
2.3.3. The cannabis trade, valued at over
US$140 bn per year (retail level)
There are two distinctly different cannabis markets:
herbal cannabis, valued at US$113 bn and cannabis
resin, valued at US$28 bn. 
A great deal of effort has gone into modelling the
cannabis markets. Nonetheless, a word of caution is
needed. The potential error between the estimations
shown below and the ‘true value’ of the cannabis market
could be significant, much higher than the potential
errors that could be expected from the calculation of the
heroin or the cocaine market. This is due to apparent
data inconsistencies that make it difficult to reconcile
supply-based estimates with demand-based estimates.
Nonetheless, as far as possible, such an attempt was
made, based on the assumption that the ‘truth’ is some-
where in the middle. The resulting estimates are the best
that could be made, given the current level of informa-
tion.  This does not rule out the possibility that sub-
stantial changes could occur (notably for cannabis
herb), once better, scientifically generated information
becomes available.  
Valuation of cannabis herb
Production estimates were taken from Member States’
replies to UNODC’s Annual Reports Questionnaires
and official Government reports. Very strong year-to-
year changes, particularly with regard to yields, suggest
that these estimates were based on limited information
and are not always reliable. One example of the data
weakness in this area is the lack of credible production
estimates for Africa. A number of African countries are
frequently reported as important source countries for
cannabis herb imported into Europe, but these coun-
tries do not provide production estimates to UNODC.
Based strictly on available data, the model would predict
that North America should be exporting cannabis to
Africa, a trafficking route that does not, in fact, exist.
The same applied to a significant number of countries
from other regions as well. 
Against this background, a systematic review was under-
taken of all the countries that, over the last decade, had
been reported by other countries as a source of cannabis
or themselves reported the seizure of whole cannabis
plants. The seizure of whole plants is indicative of
domestic cultivation, because only a portion of the plant
is used as a drug, and so whole plants are rarely traf-
ficked across borders. For these countries, production
was estimated to cover domestic demand, multiplying
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27 Estimates for North America, however, highlighted a problem that still needs to be resolved in future. There are some apparent contradictions as to
the origin of heroin and its reported availability. According to US Government reports, heroin produced in Colombia and Mexico account for the
bulk of illegal heroin imports in the USA. However, current production estimates available for these countries are not sufficient to cover the bulk
of the North American demand for heroin.   
Fig. 9: Regional distribution of opiate retail sales in
2003 in billion US$ (N = US$64.8 bn)
* including Caribbean and Central America
Sources: UNODC, Illicit Drug Market Estimation Model.
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the number of estimated cannabis users by the average
global cannabis herb consumption rate, derived from
the initial calculations. For countries that were identi-
fied as cannabis producing countries but were not iden-
tified as major cannabis exporting countries, a certain
percentage of domestic demand was used to estimate
local production. The percentages chosen depended on
quantitative and qualitative information available for
different regions. For instance, based on estimates pro-
vided by the authorities of some European countries,
local cannabis herb production from European coun-
tries, which (i) apparently had domestic production but
(ii) had not provided a production estimate to
UNODC, was set at 25% of calculated domestic
demand. Clearly, this is not an ideal estimation tech-
nique but, in a number of cases, subsequent indications
of likely orders of magnitude of cannabis production,
referred in scientific literature, came rather close to these
results. 
Proceeding along these lines on a country-by-country
basis, global cannabis production estimates increased
from 35,000 mt to 42,000 mt Looking at the seizure
figures, this would suggest an interdiction rate of
around 14%, which is not unrealistic. After the model
was run with these ‘adjusted’ production figures, the dis-
tribution pattern with regard to importing and export-
ing regions fell into line with what is known about
actual trafficking patterns. The basic pattern reflected in
this model is that, for most countries, local production
is destined for domestic demand and only relatively
small amounts are destined for export. The most impor-
tant importer is West and Central Europe, while the
largest market is North America. 
One problem remained with regard to reconciling these
production estimates with consumption figures: North
America. Cannabis production estimates in North
America exceed estimated consumption levels. This
problem has been highlighted by US authorities else-
where28, but no solution has been found to overcome
this data discrepancy. One potential explanation – that
cannabis herb is being exported from North America –
can be also ruled out, as cannabis prices are high in
North America and exports to most markets would
result in losses for the traffickers. 
Both demand side estimates and supply side estimates
seem to be based on scientific research, and this makes
it difficult to simply ignore one or the other. Assuming
that the truth is probably somewhere in the middle,
UNODC tried to find a compromise solution. The
approach was to choose the lowest available production
estimates (14,370 mt for Mexico, the USA and
Canada,29 instead of production estimates of around
25,000 mt for the region30) and to subsequently deduct
another 5,000 mt (about a third of the lower production
estimates) as ‘extraordinary losses’. After deducting
seizures made in the region, this resulted in an estimate
of 5.9 mt of cannabis herb available for consumption in
North America, equivalent to a per capita consumption
135
2. Estimating the value of illicit drug markets
28 Drug Availability Steering Committee, Drug Availability Estimates in the United States, December 2002,
http://www.whitehousedrugpolicy.gov/publications/pdf/drugavailability.pdf; see also UNODC, World Drug Report 2004. 
29 Estimate for cannabis herb production in North America: Mexico: 7,900 tons in 2002 (US. Dept. of State, International Narcotics Control Strategy
Report, 2004), USA: 5,670 tons in 2003 (UNODC, ARQ), Canada: 800 tons in 2003 (UNODC, ARQ).  
30 According to the National Drug Intelligence Center, National Drug Threat Assessment 2005, cannabis herb production increased in 2003 in Mexico
to 13,500 tons; US cannabis production, according to ONDCP, may have amounted to more than 10,000 tons (ONDCP, National Drug Control
Strategy 2003) and the upper estimate of production in Canada was reported at 2000 tons. (National Drug Intelligence Center, National Drug
Threat Assessment 2005).
Fig. 10: Regional distribution of cannabis herb retail
sales in 2003 in billion US$ (N = US$113.1 bn)
* including Caribbean and Central America
Sources: UNODC, Illicit Drug Market Estimation Model.
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rate of 165 grams. This is about twice the rate indicated
by some previous US studies,31 but it is in line with the
orders of magnitude shown in studies or reports from a
few other countries. It also seems to be a feasible order
of magnitude, taking the distribution pattern between
infrequent and intensive cannabis users as well as infor-
mation about the amounts of cannabis herb taken by
such groups32 in North America into account. 
Multiplying these consumption estimates by reported
prices (US$10.6 per gram at the retail level), the North
American cannabis herb market was calculated to
amount to some US$63 bn. This is far more than pre-
vious estimates, starting from the demand side, had sug-
gested, but it is the lowest estimate UNODC could
come up with without completely disregarding North
American cannabis production estimates. The next
largest market, using similar per capita consumption
rates of around 200 grams per year, are Europe (US$24
bn), followed by Asia (US$9bn) and Africa (US$8 bn). 
In short, there are existing data weaknesses on both the
supply and the demand side with regard to cannabis
herb. An attempt was made, based on the triangulation
of existing data and information, to reconcile, as far as
possible, the data discrepancies. This resulted in an over-
all estimate of the amounts available for consumption of
30,000 mt of cannabis herb, giving a global farmgate
value of cannabis production of U$9 bn, a wholesale
value of U$30 bn and a retail value of US$113 bn. 
Valuation of cannabis resin 
An evaluation of global cannabis resin production was
done by UNODC, for the first time, for last year’s
World Drug Report. In co-operation with the Govern-
ment of Morocco using modern remote sensing tech-
nology, ground verification and a yield survey,
UNODC estimated resin production in that country at
3,070 mt in 2003. This led to a minimum global
cannabis resin production estimate of 5,100 mt Based
on a slightly different approach, analysing cannabis herb
and cannabis resin seizures, a final global production
estimate of 7,400 mt was established.33
Making use of existing cannabis resin estimates from the
previous year and information from the main source
countries, the remaining 4,330 mt were allocated to the
different regions.34 This resulted in an estimate of close
to 2,000 mt for the Near and Middle East/South-West
Asia region, mainly reflecting production in
Afghanistan, Pakistan and Lebanon, and an estimate of
around 600 mt for the Central Asia and Caucasus sub-
region, reflecting, in particular, important levels of pro-
duction in Kazakhstan and Kyrzystan. 
The model assumes that the main destination for the
cannabis resin produced in North Africa is Europe,
notably West and Central Europe, while the bulk of
cannabis resin produced in Near and Middle
East/South-West Asia region is for local consumption
and only smaller amounts are destined for markets in
Western Europe. The bulk of cannabis resin consumed
in East Europe is assumed to originate in Central Asia.
Cannabis resin produced in the Caribbean (mainly
137
2. Estimating the value of illicit drug markets
Fig. 11: Regional distribution of cannabis resin retail
sales in 2003 in billion US$ (N = US$28.8 bn)
* including Caribbean and Central America
Sources: UNODC, Illicit Drug Market Estimation Model.
$22.3
Europe
78%
$0.0
South-
America*
0%
$1.5
North 
America
5%
$0.1
Oceania
0%
$2.4
Asia
8%
$2.6
Africa
9%
31 Abt Associates, What America's Users Spend on Illegal Drugs, 1988-1998, December 2000.                                                                                   
32 The 1998 US household survey distinguished between three groups of cannabis users: those consuming it on 51 days or more (36% of all cannabis
users), those consuming it on 12 to 51 days (20%) and those consuming it on less than 12 days (44%). Assuming that a group of 'hard-core' cannabis
users smokes up to 4 grams (8 joints) for, on average, 107 days a year (equivalent to 1.2 grams of cannabis herb or 2.4 joints per day, every day),
that the second group uses a daily cannabis dose of 1.5 grams for 31.5 days a year, and the third group uses a dose of 0.5 grams for 6 days a year,
and applying the cannabis prevalence data from the 2003 Survey on Drug Use and Health to this distribution pattern, the average cannabis
consumption per user (annual prevalence) would be equivalent to 165 grams.  
33 UNODC, 2004 World Drug Report, Volume 1: Analysis, p. 129.
34 The allocation is of cannabis production according to regions is intended to show the production pattern, but is not critical for the final outcome
of the wholesale or retail values of the cannabis resin market.
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Jamaica) is destined for North America. Cannabis resin
produced in South Asia (mainly Nepal) is destined for
consumption within the region and for export to West
and Central Europe. 
After seizures and losses, the model assumes that about
6,000 mt of cannabis resin are available for consump-
tion. The number of cannabis resin users was deduced
from the total number of cannabis users, based on the
split between cannabis resin and total cannabis seizures
over a ten-year period, and taking the possibility of
some overlap between cannabis herb and resin con-
sumption into account. This estimate resulted in a per
capita estimate of 150 grams of cannabis resin per user.
This is in line with some estimates on per capita con-
sumption of cannabis resin obtained from countries in
Europe. It is also in line with reports that the average
potency of cannabis resin is still higher than the average
potency of cannabis herb (even though there are impor-
tant exceptions when it comes to hydroponically pro-
duced cannabis), which means that per capita
consumption of cannabis resin is usually lower than per
capita consumption of cannabis herb. 
Based on prevalence data and per capita consumption
figures, the largest cannabis market resin market is that
of West and Central Europe (2,900 mt), which, when
multiplied with average retail prices, gives a market
value of US$21 bn. Europe thus accounts for 78% of
the global cannabis resin market, followed by Africa
(9%) and Asia (8%). The main cannabis resin market in
Asia is the Near and Middle East; the main market in
Africa is North Africa.     
2.3.4 Amphetamine-type stimulants
trade - valued at US$44 bn per
year (retail level) 
The ATS market consists of three main products:
methamphetamine, amphetamine and ecstasy. Metham-
phetamine, amphetamine and related stimulants are
combined under the category of ‘amphetamines’ . The
global amphetamines retail market was valued at US$
28 bn. The global ecstasy retail market, including
MDMA and related substances, was valued at US$16
bn. Taken together, the ATS retail markets add up to
US$44 bn. The largest ATS retail markets in economic
terms are North America (57%), followed by Asia
(20%), Europe (11%) and Oceania (9%). 
Valuation of the amphetamines market
The valuation of the amphetamines market started from
a global production estimate of 332 mt (range: 278 –
401 mt), derived from production estimates based on
extrapolation from seizures of amphetamines, seizures of
precursors and consumption estimates.  This produc-
tion was ‘allocated’ to countries based on identifications
as a source country by other countries; the number of
dismantled laboratories; and seizures made in countries
with dismantled laboratories that were identified by
other countries as significant source countries. In addi-
tion, information from production estimates from
North America was used to adjust the weights given to
the different indicators. According to ONDCP,
methamphetamine production in North America is esti-
mated to range between 106 and 144 metric mt35
The results of these calculations suggests that the largest
share of the world’s production of amphetamines is in
East and South-East Asia (162 tons), followed by North
America (114 mt) and West and Central Europe (39
mt). While most of the production in East and South-
East Asia and in North America concerns methamphet-
amine, European production is mainly focused on
amphetamine. 
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2. Estimating the value of illicit drug markets
Fig. 12: Regional distribution of ATS retail sales in
2003 in billion US$ (N = US$44.3 bn)
* including Caribbean and Central America
Sources: UNODC, Illicit Drug Market Estimation Model.
$8.7
Asia
20%
$4.8
Europe
11%
$1.4
South-
America*
3%
$3.8
Oceania
9%
$0.2
Africa
0%
$25.4
North 
America
57%
35 The White House, The National Drug Control Strategy, February 2003.                                                                                                             
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The model also reflects the general perception that
amphetamines are mainly traded intra-regionally. Thus,
most of the production of East and South-East Asia is
for consumption within the region, and the same
applies to North America and to West and Central
Europe. Out of the total of 332 mt, 295 mt are esti-
mated to be available for consumption after seizures and
losses are deducted. The model assumes that 129 mt are
available for consumption in East and South-East Asia,
111 mt in North America, and 25 mt in West and Cen-
tral Europe. The implied per capita consumption is high
for North America (32 grams per user per year)36 and
much lower in West and Central Europe (12 grams) and
in East and South-East Asia (7 grams). This is a conse-
quence of the rather high production levels estimated by
the authorities in North America, and the fact that there
is no information of methamphetamine or ampheta-
mine produced in North America being shipped to
other regions. Thus, all of the amphetamines produced
in North America, less seizures and losses, are presum-
ably consumed there. Using these consumption levels,
the amphetamines market in North America was esti-
mated at US$17 bn, in East and South-East Asia at
US$7 bn and in Oceania and in Europe at US$2 bn
each. The total market was valued at US$28 bn. 
The model shows some trafficking of amphetamines to
countries in Africa and South America. This, however,
is only partially correct. Both Africa and South America
have, in terms of ATS users, quite substantial ATS mar-
kets, but much of these markets are sourced from legally
produced ATS which are subsequently diverted, rather
than from illicitly produced ATS. This is a problem for
the current model, as such diverted drugs were not con-
sidered in the initial phase when the model was
designed. This means that the overall markets for
amphetamines (licit and illicit) in Africa and South
America are larger than what is reflected in this model.  
Valuation of the ecstasy market
Global production of ecstasy – extrapolated from
seizures of ecstasy, from seizures of ecstasy precursors
and from consumption estimates was estimated at 90
mt (range: 45 – 141 mt). The allocation of production
to countries/regions was based on dismantled laborato-
ries, citations as countries of origin by other countries,
and seizures (for countries that had laboratories and
which were cited as countries of origin). 
Using this approach, data suggest that the bulk of
ecstasy production (69 mt out of 90 mt or 77%) con-
tinues to take place in West and Central Europe. The
141
2. Estimating the value of illicit drug markets
36 Per capita consumption of amphetamines, according to these estimates, is still lower in North America than the corresponding estimates for cocaine,
another stimulant.                                                                                                                                                                                       
Fig. 13: Regional distribution of amphetamines retail
sales in 2003 in billion US$ (N = US$28.3 bn)
* including Caribbean and Central America
Sources: UNODC, Illicit Drug Market Estimation Model.
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Fig. 14: Regional distribution of ecstasy retail sales in
2003 in billion US$ (N = US$16.1 bn)
* including Caribbean and Central America
Sources: UNODC, Illicit Drug Market Estimation Model.
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next largest ecstasy producing region is North America
(12 mt), followed by East and South-East Asia (4 mt).
The model results also suggest that Europe is the only
region with important ecstasy exports. More than half of
the ecstasy produced in West and Central Europe is des-
tined for export to other regions. With ecstasy prices
almost three times the level seen in West and Central
Europe, North America seems to be a particularly lucra-
tive market, but European ecstasy exports go to most
other regions as well. 
Deducting seizures and losses, about 80 mt remain
available for consumption. Using existing prevalence
estimates and applying an average rate of 10 grams per
person per year (equivalent to some 100 pills a year, or
two pills per weekend), the largest ecstasy market
appears to be North America (33 mt), followed by West
and Central Europe (27 mt). Multiplying these
amounts with reported prices, the North American
ecstasy market appears to be substantially larger
(US$8.5 bn) than the European market (less than US$3
bn). However, this may change, as there are strong indi-
cations that the North American ecstasy market is
shrinking. As outlined in the beginning of this chapter,
data used for the market calculations were those pub-
lished in last year’s World Drug Report (2.7 million
ecstasy users for North America). The numbers pub-
lished in this year’s World Drug Report are already 15%
less (2.3 million ecstasy users in North America), and –
using school surveys as an early indicator for subsequent
trends in the general population - one can still expect
further declines to take place. While the bulk of the
ecstasy market is in North America and Europe, 30% of
the global ecstasy market is in other parts of the world,
notably in Asia (12%), Oceania (10%) and South
America (7%).
2.4 Conclusions
This review of UNODC’s global drug market valuation
has highlighted some of the complexities involved in
making such estimations. The technical details of the
model have not been discussed in this review. Clearly
there are still areas where estimates can be improved.As
new information emerges, it will be incorporated into
the model. The overall figure of US$322 bn should be
seen as representing reasonable order of magnitude.  As
stated previously, some market estimates can be made
with more precision than others. The estimates for the
opiates market (US$65 bn) and the cocaine market
(US$70 bn), for example,  are quite strong – because
there is rigorous data at least on the production side.
The estimates for the ATS (US$44 bn) and the cannabis
resin (US$28bn) markets are also reasonably well
grounded; but the cannabis herb market estimate
(US$113 bn), remains rather weak due to the paucity of
underlying data. 
Ideally, results from the top-down and the bottom-up
approaches should match, simply because there is no
drug consumption without production and there will
be, most probably, no drug production without a
demand for drugs. This does not preclude the possibil-
ity that stocks can be built-up or depleted, thus distort-
ing this relationship in the short-term. 
One key parameter for analysing the market from both
sides is still largely missing: the average consumption
per user. Only some vague and often contradictory
information is currently available, often from case stud-
ies which may or may not be representative of a locality,
a country or a region. This put a severe constraint on
this exercise. More systematic research on quantities
consumed could greatly improve the rigour of the
results. 
In presenting this work in progress, UNODC shares its
understanding of the illicit drug markets, as well as lack
of it in some areas, in order to improve the common
level of understanding, stimulate discussion and prompt
new research to overcome existing gaps in information. 
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Globally, sexual transmission of HIV continues to be
the most common way the virus is spread, but drug use
is contributing to the pandemic in at least four ways.
First, the most common and best-researched method of
transmission is via the use of contaminated injection
equipment among people who inject drugs. Second,
there is sexual transmission of the virus between those
who inject drugs and their sexual partners. The dual
transmission risk in the case of sex workers who also
inject drugs leads to epidemics that expand quickly and
act as a bridge to the rest of the population. Third, non-
injecting use of drugs such as cocaine and ampheta-
mine-type stimulants leads to high-risk sexual
behaviour. And finally, HIV can be transmitted from an
infected mother - a commercial sex worker, an injecting
drug user and/or a sexual partner of a drug user - to her
child. While very little systematic information is avail-
able on this particular mode of transmission related to
drug use, anecdotal examples suggest that this could be
a potential entry point for HIV to get into the general
population. For example, during 1996–2001, most of
the HIV-infected infants in the Russian Federation were
born to mothers who were either injecting drug users or
sexual partners of injecting drug users.
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Fig. 1: HIV transmission routes related to drug abuse
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3.1 Epidemiology of HIV/AIDS
and drug use
Worldwide, more than 55 million people use opiates,
cocaine and amphetamine-type stimulants, and an esti-
mated 13.2 million people inject these drugs. Most
(78%) injecting drug users live in developing and tran-
sitional countries.1
While the relationship between injecting drug use and
HIV/AIDS is relatively well researched, little systematic
epidemiological information is available on the extent
and patterns of HIV transmission caused by non-inject-
ing drug use. This is unfortunate because there is emerg-
ing evidence that the use of cocaine, crack and
amphetamine-type stimulants increases sexual risk
taking behaviour related to HIV transmission. Some of
this information has been reviewed later in this chapter.
However, to date, an epidemiological review of
HIV/AIDS related to drug use still has to rely mostly on
information related to injecting drug use, which
undoubtedly underestimates the real impact of drug use
on the HIV/AIDS epidemics. Consequently, prevention
of HIV transmission related to drug use continues to
focus mostly on injecting drug use, missing out the
potential opportunities of primary and secondary drug
use prevention for stopping the spread of the virus.
3.1.1 Injecting drug use
In the early stages of the pandemic, HIV/AIDS among
injecting drug users was largely viewed as self-limiting,
affecting injectors and their immediate sexual partners
but not leading to a more generalised spread of the
virus. Recent work on the Asian and Eastern European
HIV/AIDS epidemics has proven this perspective to be
incorrect.2 Globally, it is estimated that 5% -10% of all
HIV infections are attributable to injecting drug use,
mostly via the use of contaminated injection equip-
ment.3 In many countries of Europe, Asia, the Middle
East and the Southern Cone of South America, the use
of non-sterile injection equipment has remained the
most important mode of HIV transmission, accounting
for 30%-80% of all reported infections. 
The risk of HIV transmission in an injecting commu-
nity is dependent, among other things, on the sub-
stances involved. Injection frequency is highly
correlated with HIV transmission,4 and there are differ-
ences in the rate of injection between drugs. Among
heroin dependent individuals, it is common to inject 1
- 3 times a day. Cocaine, on the other hand, is com-
monly injected more than 10 times a day. This increases
significantly the likelihood of HIV transmission as it
reduces the chances of sterile injecting equipment being
used each time.5 
The context in which drugs are injected can also impact
on the risk of transmission. “Shooting galleries” are
communal drug use venues that are associated with a
high risk of needle and syringe sharing. A needle or
syringe in a shooting gallery may be used by hundreds
of injection drug users. Frequenting shooting galleries to
inject has been associated with a markedly higher risk of
acquiring HIV.6 “Syringe mediated drug sharing” is the
use of a metered syringe to divide a drug among several
users,7 and occurs in many countries, being particularly
prevalent in countries of the former Soviet Union.8 In
1 Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injection drug use and HIV infection among injection drug users. London:
Centre for Research on Drugs and Health Behaviour on behalf of the United Nations Reference Group on HIV/AIDS Prevention and Care among
IDU in Developing and Transitional Countries, 2004.
2 WHO/ UNAIDS/ UNODC. Advocacy Guide:HIV/AIDS Prevention Among Injecting Drug Users. WHO, 2004.
3 UNAIDS, Institute OS, Agency CID. The Warsaw declaration: A framework for effective action on HIV/AIDS and injection drug use. 2nd
International Policy Dialogue. Warsaw; WHO/ UNAIDS/ UNODC. Advocacy Guide: op.cit.
4 Bruneau J, Lamothe F, Soto J, Lachance N, Vincelette J, Vassal A, Franco EL. Sex-specific determinants of HIV infection among injection drug
users in Montreal. Cmaj 2001;164:767-73.
5 Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco.
Jama 1989;261:561-5; Strathdee SA, Galai N, Safaiean M, Celentano DD, Vlahov D, Johnson L, Nelson KE. Sex differences in risk factors for HIV
seroconversion among injection drug users: a 10-year perspective. Arch Intern Med 2001;161:1281-8.
6 Schoenbaum EE, Hartel D, Selwyn PA, Klein RS, Davenny K, Rogers M, Feiner C, Friedland G. Risk factors for human immunodeficiency virus
infection in intravenous drug users. N Engl J Med 1989;321:874-9; Celentano DD, Vlahov D, Cohn S, Anthony JC, Solomon L, Nelson KE. Risk
factors for shooting gallery use and cessation among intravenous drug users. Am J Public Health 1991;81:1291-5.
7 Grund JP, Friedman SR, Stern LS, Jose B, Neaigus A, Curtis R, Des Jarlais DC. Syringe-mediated drug sharing among injection drug users: patterns,
social context and implications for transmission of blood-borne pathogens. Soc Sci Med 1996;42:691-703.
8 Green ST, Taylor A, Frischer M, Goldberg DJ. ‘Frontloading’ (‘halfing’) among Glasgow drug injectors as a continuing risk behaviour for HIV
transmission. Addiction 1993;88:1581-2; Van Ameijden EJ, Langendam MW, Notenboom J, Coutinho RA. Continuing injecting risk behaviour:
results from the Amsterdam Cohort Study of drug users. Addiction 1999;94:1051-61; Hunter GM, Donoghoe MC, Stimson GV, Rhodes T,
Chalmers CP. Changes in the injecting risk behaviour of injection drug users in London, 1990-1993. Aids 1995;9:493-501; Rodes A, Vall M,
Casabona J, Nuez M, Rabella N, Mitrani L. [Prevalence of human immunodeficiency virus infection and behaviors associated with its transmission
among parenteral drug users selected on the street]. Med Clin (Barc) 1998;111:372-7.
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Asia, where needle and syringe sharing is common,9
injection by “professional injectors” is widespread.10
Professional injectors sell the drug and the injection (so
that the drug user does not have to self-inject). Profes-
sional injectors tend to use the same needle and syringe
repeatedly, multiplying the chance of HIV transmission
dramatically.11
Epidemics driven by injecting drug use have different
characteristics than epidemics where sexual transmission
is the main mode of infection.12 Most importantly, the
efficiency of HIV transmission per injection is almost
six times higher than for heterosexual acts. Most studies
have also found that heroin injectors inject about 1-3
times per day, and cocaine users even more frequently,
so the number of possible exposures is also greater. Due
to the greater efficiency and higher frequency of risk-
exposure associated with injecting drug use, these epi-
demics tend to spread more rapidly than those driven by
sexual transmission. Soon after HIV is introduced into
a community of injecting drug users, infection levels in
these populations can rise from zero to 50–60% within
1–2 years.13
Most injectors are males, but the proportion of female
injectors has risen rapidly, particularly in Asia and East-
ern Europe. Female addicts may pay for their drugs
through sex work, and this may lead to transmission of
the virus to clients outside the injecting community.14
The epidemiology of HIV/AIDS in injecting drug user
populations varies from country to country. Injecting
drug use is well established in Western Europe and
North America, where HIV/AIDS prevalence in inject-
ing drug user populations is generally low, apart from
Southern Europe, Western Canada and the eastern
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Fig. 2: HIV/AIDS prevalence (%) among injecting drug users (1998- 2003)
9 Reid G, Costigan G. Revisiting ‘The Hidden Epidemic’: A situational assessment of drug use in Asia in the context of HIV/AIDS. Melbourne:
Centre for Harm Reduction, 2002; Bezziccheri S, Bazant W. Drugs and HIV in South East Asia. Bangkok: UNODC Regional Centre for East Asia
and the Pacific, 2004.
10 Reid G, Costigan G. Revisiting ‘The Hidden Epidemic’: A situational assessment of drug use in Asia in the context of HIV/AIDS. Melbourne:
Centre for Harm Reduction, 2002.
11 Kral AH, Bluthenthal RN, Erringer EA, Lorvick J, Edlin BR. Risk factors among IDUs who give injections to or receive injections from other drug
users. Addiction 1999;94:675-83.
12 Pisani E, Garnett GP, Grassly NC, Brown T, Stover J, Hankins C, Walker N, Ghys PD. Back to basics in HIV prevention: focus on exposure. BMJ
2003;326:1384-7.
13 WHO Training Guide for HIV Prevention Outreach to Injection drug users. Geneva. 2003.
14 WHO. Where sex work, drug injecting and HIV overlap (In Preparation).
Source:UN Reference Group on HIV/AIDS prevention and care among IDUs, 2003
seaboard of the United States. It is widespread through-
out most countries of Asia, and Central and Eastern
Europe. Injecting is an increasing form of illicit drug
administration in Latin America and the Middle East.
Africa and Central America face early stages of injecting
drug use, though there are worrying trends of increases
in many cities in these regions.15
Asia
Injecting drug use is the most prevalent method of HIV
transmission in Indonesia, Viet Nam, Malaysia, Myan-
mar, Nepal, China and parts of India:16
• Indonesia: In 2000, only 1% of known HIV
infections were attributed to injecting drug use. In
2004, the figure was nearly 20%. In Jakarta and
Bali, 35%- 56% of injecting drug users are HIV
infected.17
• Viet Nam:  The overall HIV/AIDS prevalence
among injecting drug users is 32%,18 but preva-
lence is much higher in Hai Phong (over 70%),
Ho Chi Minh City (over 80%) and Binh Dinh
(nearly 90%).19 
• Thailand: The HIV/AIDS prevalence among
injecting drug users is estimated at 54%, with an
estimated annual incidence of 5 – 10% for the
past 10 years. 20 
• Myanmar: HIV/AIDS prevalence among injecting
drug users is estimated at 65%.21
• Nepal: HIV/AIDS prevalence among injecting
drug users is estimated at 45%. 22
• China: The use of contaminated injection equip-
ment is the most common mode of HIV trans-
mission in China. In 2002, there were 410,000
registered injectors in China, though the real size
of the injecting drug use community is estimated
to be several times larger.23 Overall, it is estimated
that 43% of injecting drug users are HIV posi-
tive,24 although individual provinces show much
higher rates, such as Xinjiang (84%), and Yunnan
provinces (58%-80%).25
• India: HIV/AIDS prevalence among injecting
drug users has been determined in several cities
and regions, including Manipur (58%),26 Delhi
(14%), Karnataka (3%), Mumbai (25%), West
Bengal (3%) and Chennai (64%).27
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15 Archibald C, Bastos F, Beyrer C, Crofts N, Des Jarlais D Grund J-P, Hacker M, Heimer R, Rhodes T and Saidel T. The nature and extent of
HIV/AIDS among injecting drug users. Evidence  For Action: Establishing the Evidence-Base for Effective HIV Prevention among Injecting Drug
Users. WHO. Geneva (In preparation)
16 Costigan, G., Crofts, N., and Reid G. Manual for Reducing Drug-Related Harm in Asia. 2003, Centre for Harm Reduction and Asian Harm
Reduction Network. Melbourne; Detels, R. HIV/AIDS in Asia: an introduction AIDS Education and Prevention 2004 Vol 16, Supp. A, June: p. 1-
6; UNAIDS. Rhodes, T., Platt, L., Filatova, K., Sarang, A., Davis, M., and Renton, A. Behavioural Risk Factors in HIV Transmission in Eastern Europe
and Central Asia Geneva: in press.
17 Costigan, G., Crofts, N., and Reid G. 2003 op. cit.
18 Hien, N.T., Long, N.T. and Huan, T.Q. HIV/AIDS epidemics in Vietnam: evolution and responses. AIDS Education and Prevention 2004 Vol 16,
Supp. A, June: p.137-154.
19 Hien, N. “HIV prevalence trends and risk behaviours among injection drug users in  Vietnam”. in Global Research Network Meeting on HIV
Prevention in Drug-Using Populations, 3rd Annual Meeting. 2000. Durban, South Africa
20 Costigan, G., Crofts, N., and Reid G. 2003 op. cit.
21 Dehne, K., Adelekan, M., Chatterjee, A. and Weiler, G. The need for a global understanding of epidemiological data to inform human
immunodeficiency virus (HIV) prevention among injection drug users. Bulletin on Narcotics, vol. LIV, Nos 1 and 2, 2002
22 Aceijas C et al 2004. op cit.; Burrows, D. Policy and Environment Assessment: Illicit Drug Use, the Burden of Drug-related Harm, and HIV Vulnerability
in Cambodia The Policy Project, Phnom Penh. 2003
23 Reid and Costigan 2002. op.cit.
24 Wu, Z., Rou, K. and Cui, H. The HIV/AIDS epidemic in China: history, current strategies and future challenges AIDS Education and Prevention 2004
Vol 16, Supp. A, June: p. 7-17
25 UNAIDS. HIV/AIDS: China’s Titanic Peril, 2001 Update of the AIDS situation and Needs Assessment report., UN theme Group on HIV/AIDS in
China. China, 2001.
26 Dorabjee, J. and L. Samson, A multi-centre rapid assessment of injection drug use in India. 2000. Int J Drug Policy 11(1-2): p. 99-112; Dorabjee,
J., Building the capacity of NGOs and other institutions to work with injecting drugs users in India. 2002, Family Health International: New Delhi,
India.
27 NACO (2004b). NACO, HIV Prevalence levels State wise: 1998 – 2003, accessed at http://www.nacoonline.org/factsnfigures/Statewisehiv.pdf.
Central Asia and Eastern Europe 
Injecting drug use transmission accounts for the bulk of
infections in the Russian Federation, Ukraine, Moldova,
Belarus, Kazakhstan, Uzbekistan, Estonia, Latvia,
Lithuania, Armenia, Azerbaijan, Georgia and Poland.31
HIV prevalence above 50% among injecting drug users
has been found in Svetlogorsk (Belarus) and Togliatti,
Irkutsk, Tver and Kaliningrad (Russian Federation)
Karaganda, Pavlodar (Kazakhstan); over 30% in Poltava
(Ukraine), Rostov, Samara and Saint Petersburg (Russ-
ian Federation); and over 15% in Kharkiv (Ukraine),
Ekaterinburg (Russian Federation), Minsk (Belarus),
and Moldova.32
Fig. 3: Newly registered HIV infections among 
injecting drug users, selected CIS countries 
(1994 – 2003)
Source: EuroHIV, End-year report 2003
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Box 1: HIV/AIDS in China and India
The HIV/AIDS epidemics in China and India are
predicted to become two of the largest ever. In
2003, the Chinese Centre for Disease Control and
Prevention, the National Centre for AIDS/STD
Control and Prevention, WHO, UNAIDS and the
US Centres for Disease Control and Prevention
estimated  that there are 840,000 people living with
HIV/AIDS in China, a national prevalence rate of
less than 0.1%. Between 1995 and 2000, HIV
prevalence increased by about 30% each year. The
rate of increase has been much greater in the first
few years of the 21st century, reaching 122% in
2003. Most HIV infections are among injecting
drug users. Heroin is the most commonly used
drug, accounting for almost all drug treatment
admissions, and use rates have been on the increase.
The use of amphetamine-type stimulants is also
expanding in China. A survey conducted in
Guizhou province in 1999 found that heroin was
the most commonly tried drug among school stu-
dents in this region (3%), followed by ATS (0.7%)
and then cannabis (0.3%). There are also reports
that methamphetamine is injected.28 
In India, an estimated 5.1 million people are HIV
infected, a national prevalence rate of 0.9% among
the general adult population in 2004.29 UNODC
has found that the use of a range of drugs, includ-
ing ATS and cocaine, is increasing in parts of India,
and that opiate users are switching from snorting or
smoking heroin to injection of heroin and phar-
maceutical drugs such as buprenorphine and dex-
tropropoxyphene.30
28 Wu Z, Rou K and Cui H. The HIV/AIDS Epidemic in China: current strategies and future challenges AIDS Education and Prevention 16 Suppl A:
7-17. 2004.
29 MAP 2004. op.cit.
30 India Country Profile. UN Office on Drugs and Crime. New Delhi 2003.
31 UN Development Program (UNDP). HIV/AIDS in Eastern Europe and the Commonwealth of Independent States - Reversing the epidemic: Facts and
policy options 2004: Bratislava.
32 UNAIDS Rhodes T et al. In Press. op. cit.; Dehne et al 2002. op. cit.
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Fig. 4: Newly registered HIV infection among 
injecting drug users, Russian Federation and
Ukraine (1994 – 2003)
Source: EuroHIV, End-year report 2003
Western Europe 
The prevalence of HIV among injecting drug users in
Finland, Germany, Greece, Iceland, Luxemburg, Slove-
nia, Switzerland, Austria and the United Kingdom is less
than or near 5%, but is much higher in countries such
as France (up to 19%), Italy (up to 65%), and Spain (up
to 66%).33
Middle East and North Africa
Injecting drug use is the most prevalent mode of HIV
transmission in Iran, Bahrain and Libyan Arab
Jamahiriya, and it is suspected of being prominent in
several other countries such as Algeria, Egypt, Morocco,
Tunisia and Sudan.34 
• Iran: It is estimated that there are 1.2 million
opioid-dependent people and approximately
15,000 people living with HIV/AIDS; 60%-75%
of these infections are attributable to the sharing
of contaminated injection equipment.35
• Egypt: In Cairo, about 30% of heroin users inject,
though the proportion is lower (16%) in other
regions, and 59% of injecting drug users report
sharing injection equipment. High-risk sexual
behaviour is prevalent among drug users in Cairo,
with 51% of heroin users reporting sex with a sex
worker, 10% engaging in male-to-male sex, and
59% reporting that they never use condoms.36
• Libyan Arab Jamahiriya: Approximately 50% of
heroin users seeking treatment are HIV infected.37 
Latin America
HIV infections among injecting drug users have been
found in Uruguay (24%); Asunción, Paraguay (15%),
Bogotá, Colombia (16%);38 and Puerto Rico (30%-
45%).39 The dominance of crack cocaine as a drug of
choice in some countries in the region and the emer-
gence of an increasing supply of heroin have implica-
tions for injecting drug use and risk behaviour in the
Southern Cone.
• Brazil: Injecting drug use, mainly of cocaine,
played a major role in the first wave of HIV infec-
tion in the 1980s and early 1990s, as it is in new
epidemics in the south and southwest of the coun-
try. High HIV infection prevalence among inject-
ing drug users have been determined in Rio de
Janeiro (25%) and in Sao Paolo (almost 75%) in
2000,40 though the prevalence has fallen in these
cities in recent years.41 
• Argentina: In 2002, it was estimated that 12,000
and 34,000 injecting drug users were infected
with HIV, and HIV prevalence among injecting
drug users in treatment in 2003 was 39%.42 
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33 Archibald et al. In Preparation. Op. cit.                                                                                                                                                         
34 Alaei, K., Alaei, A., Saeydi, M., Mansoori, D. and Vaziri, S. The adherence to antiretroviral therapy in HIV IDUs compared to non IDU HIV infected
and non HIV infected cases. in XV International AIDS Conference. 2004. Bangkok
35 Archibald et al. In Preparation. Op. cit.
36 El Shimi, T. UNODC Global Assessment Programme in Egypt, Cairo, 2003
37 Abdool, R. Mission report on Libya – drug abuse and HIV/AIDS, Nairobi, 2004
38 Aceijas C et al 2004. op cit.
39 Monitoring the AIDS Pandemic (MAP) 2000. op. cit.
40 Monitoring the AIDS Pandemic (MAP). HIV and AIDS in the Americas: an epidemic with many faces. 2000. Monitoring the AIDS Pandemic
Network.
41 Bastos, F.I., de Pina, Md.F. and Szwarcwald C.L.  The social geography of HIV/AIDS among injection drug users in Brazil International Journal of
Drug Policy 2002 13: 137-144.
42 Sosa-Estani, S., Rossi, D. and Weissenbacher, M. Epidemiology of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome in
injection drug users in Argentina: high seroprevalence of HIV infection. Clin Infect Dis, 2003. 37 Suppl 5: p. S338-42.
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North America
HIV spread rapidly among injecting drug users in the
northeast United States in the 1980s, reaching levels of
50% or more in New York City and Newark, New
Jersey, and urban areas directly connected with these
centres such as San Juan, Puerto Rico. By contrast, HIV
prevalence outside the region has remained lower, with
the lowest prevalence found west of the Mississippi
River in cities such as Houston, Denver, Los Angeles,
and Seattle. In each of these cities, HIV prevalence
among injectors has remained below 10%.43 Various
studies have concluded that between 14% and 47% of
injecting drug users are HIV positive in Canada.44
Africa
The epidemics of sub-Saharan Africa have been domi-
nated by sexual transmission of the virus, but injecting
drug use is becoming more common in a number of
countries in the region: 
• Nigeria: HIV prevalence among the general pop-
ulation was found to be much lower in Kano state
(3.8%) and River State (7.7%) than among inject-
ing drug users in these same states (14.3%).
Despite 95% of interviewed injecting drug users
being aware of the modes of HIV transmission,
sharing of needles and syringes was common and
only 20% used condoms.45 
• Kenya: The national HIV/AIDS prevalence
among adult population is 6.7%-9%, but it is esti-
mated that in the injecting population prevalence
is 68%-88%. In Mombassa, a sero-prevalence
study among injecting drug users found that
49.5% were HIV positive and 70% had hepatitis
C; six out of every seven female injecting drug
users were HIV infected.46 
Vulnerable Groups
Although all injecting drug users using potentially con-
taminated injecting equipment are at high risk of HIV
infection, specific populations are especially susceptible
to infection. These include young injecting drug users
because of inexperience in obtaining clean injecting
equipment (see Box 3); female injecting drug users
because of sexual risk and injecting practices over which
they may have less control; and the increasing number
of drug-injecting sex workers, both male and female.
Similarly, prisoners are at an increased risk of HIV infec-
tion because they lack access to preventive and care serv-
ices ).
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47 Martin V, Cayla JA, Moris ML, Alonso LE, Perez R. Predictive factors of HIV-infection in injection drug users upon incarceration. Eur J Epidemiol
1998;14:327-31.
48 Bravo MJ, Barrio G, de la Fuente L, Royuela L, Domingo L, Silva T. Reasons for selecting an initial route of heroin administration and for
subsequent transitions during a severe HIV epidemic. Addiction 2003;98:749-60; Swift W, Maher L, Sunjic S. Transitions between routes of heroin
administration: a study of Caucasian and Indochinese heroin users in south-western Sydney, Australia. Addiction 1999;94:71-82.
49 Archibald et al. In Preparation. op. cit.
50 Dunn J, Laranjeira RR. Transitions in the route of cocaine administration—characteristics, direction and associated variables. Addiction
1999;94:813-24; Crofts N, Louie R, Rosenthal D, Jolley D. The first hit: circumstances surrounding initiation into injecting. Addiction
1996;91:1187-96.
51 Crofts N, Louie R, Rosenthal D, Jolley D. The first hit: circumstances surrounding initiation into injecting. Addiction 1996;91:1187-96; Des Jarlais
DC, Casriel C, Friedman SR, Rosenblum A. AIDS and the transition to illicit drug injection—results of a randomized trial prevention program. Br
J Addict 1992;87:493-8.
52 O’Connell JM, Spittal P, Li K, Tyndall MW, Hogg RS, Schechter MT, Wood E. Requiring help injecting independantly predicts incident HIV
infection in a prospective cohort study of injection drug users. Proceedings of the XVth International AIDS Conference. Bangkok, 2004.
53 UNICEF. Walking on two legs 2001. op. cit.
Box 3: The decreasing age of initiation into drug abuse and drug injecting
The age at which people begin to use drugs varies considerably and depends on factors such as social cohesion,
norms and drug availability. In the Commonwealth of Independent States, for example, injecting is especially
common among young people, with initiation starting as early as 12 years of age. Transition to injecting drug
use is an important step in increasing HIV risk to an individual. The most common reasons for making the
transition are perceived superior effectiveness and superior efficiency of drug administration.48 Among women,
having a partner who injects is associated with initiation,49 whereas in men it is the peer group that is the major
social influence. Low socioeconomic status, homelessness, low educational attainment, a younger age of sub-
stance use initiation and polysubstance use are all associated with transition to injecting.50 Heroin is the most
common drug first injected.51
The initiation phase into drug injecting is associated with higher levels of risk behaviour because the technique
has to be learnt, generally in a communal injecting environment. For example, in northern Viet Nam, once indi-
viduals were comfortable with administering the injection themselves, injectors reported engaging in fewer cir-
cumstances conducive to sharing. However, even after the initiation phase, requiring help to inject is a risk factor
for HIV transmission.52 A review of HIV transmission related to injecting drug use in the countries of Central
and Eastern Europe, the Baltic States and Commonwealth of Independent States found that young people in
this region engage in two of the highest risk behaviours for acquiring HIV – sharing injecting equipment among
injecting drug users and having unprotected sex with sex workers and other sexual partners – at a higher rate
than in many other parts of the world.53
Box 2: Drug abuse and HIV/AIDS in prison settings
Prisons are a high-risk environment for HIV transmission. Drug use in general, and injection drug use in par-
ticular, as well as violence and sex between men are widespread in prisons. Drug users are often over-represented
in prison populations and may continue using drugs while incarcerated. A significant proportion of drug users
have a history of incarceration, often for drug-related crimes.
Frequent sharing of contaminated drug injection equipment is the predominant mode of HIV transmission
among prisoners.47 HIV is also transmitted in prisons through unsafe sexual behaviour, sometimes associated
with sexual violence. Prison overcrowding, gang violence, lack of protection for the youngest inmates, corrup-
tion and poor prison management increase significantly the vulnerability to HIV transmission among inmates.
High turnover rates (worldwide at any given time, there are 10 million) prison inmates, with an annual turnover
of 30 million also fuel the spread of HIV and other blood-borne infections.  After release, prisoners return to
social networks in the general community, thereby facilitating the spread of HIV infections to the non-incar-
cerated community.
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3.2 Drug use, sexual behaviour
and HIV/AIDS
The relationship between drug abuse and sexual behav-
iour is complex, and it is more difficult to quantify HIV
transmission related to this drug abuse-sexual behaviour
interaction than it is for equipment sharing among drug
injectors. Different drugs affect sexual behaviours dif-
ferently, and the context of use is clearly important.
HIV is transmitted sexually through a range of prac-
tices, some more effective in transmission than others.
High-risk sexual behaviour includes engaging in unpro-
tected sex (penetrative sex without the use of a
condom),54 exchanging sex for drugs or money,55 and
having multiple sex partners.56
While most HIV transmission among injectors world-
wide is related to the sharing of injection equipment, in
some areas, sexual behaviour is primarily responsible for
HIV transmission among injecting drug users. Inter-
ventions aimed at reducing risky injection practice may
not be as effective at reducing risky sexual behaviour.57
There is also increasing evidence of the link between
HIV epidemics among injecting drug users and other
drug users and of the spread of HIV epidemics in the
general population through sexual networks.58
The learned behaviour of associating drugs with sex
makes it difficult to reduce high-risk sexual behaviour.59
Frequency of drug abuse correlates with increased sexual
activity, as does the frequency of high-risk sex.60 Rates
of condom use among drug users vary widely. In a study
of 26,982 injecting drug users and crack users from 22
cities in the United States, over 80% reported having
unprotected sex within the last 30 days.61 A study of
injecting drug users in Brazil found that only 12.5%
always used a condom, whereas 77.7% reported they
always used a clean needle and syringe.62 However, in
France in 2003, 64% of injecting drug users used con-
doms as their primary form of contraception compared
to 10% of the general population, indicating that inject-
ing drug users are more aware of the risk of HIV trans-
mission in that country.63
There are also strong links between drug use, particu-
larly crack use,64 injecting drug use and risky sexual
behaviour.65 HIV transmission increases in populations
with high-risk behaviours related to both drug injecting
and sex. This appears to be true of all drugs, but is espe-
cially so for cocaine injectors. There also appears to be a
link among these high-risk behaviours. Injecting drug
users who inject with a needle and syringe known to
have been previously used by another injector (without
any attempt to disinfect it) are more likely to report
non-use of condoms than injecting drug users who
attempt to protect themselves from injection-related
HIV infection.66 HIV infection among injecting drug
users in one study was associated with injection of
cocaine, more frequent injection, needle sharing, and
injection in a shooting gallery. Sexual behaviour vari-
ables associated with HIV incidence include a sexually
transmitted infection, male homosexual behaviour, and
sex with another injecting drug user.67
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3.2.1 Cocaine and crack, and sexual HIV
transmission
There is a clear association between the use of cocaine
and/or crack and HIV infection.68 Cocaine and crack
are drugs highly associated with an increase in sexual
activity69. This is linked to perceived increases in libido,
the trade of drugs for sex, and the binge pattern of con-
sumption associated with these drugs. 
A United States study of 6,291 injecting and non-inject-
ing drug users found that, compared to heroin injectors,
cocaine injectors reported a higher rate of risky sexual
behaviour such as sex with multiple partners.70 A study
of Spanish and Brazilian injecting drug users found
sexual abstinence and consistent condom use among
heroin injectors, but these behaviours were less common
among cocaine injectors, who also had a higher number
of casual partners and partners who inject themselves.
Cocaine injectors also reported sharing injection equip-
ment more frequently.71 
Crack users are more likely to engage in higher levels of
risky sexual activity than other drug users,72 and the use
of crack is linked with sex work.73 A United States study
found that, after controlling for a range of variables, cur-
rent crack users were over five times more likely than
non-crack using drug users to exchange sex for drugs or
money.74 Female crack users in another United States
study who traded sex for drugs reported 13 times more
partners a month than those that did not trade sex for
drugs. They were also substantially more likely to report
a history of sexually transmitted infections.75 A study of
African American residents of two communities in
Houston revealed that a history of crack use signifi-
cantly predicted the trading of sex for money and drugs,
and sellers of sex were more likely to have engaged in
recent high-risk sexual behaviour than those who had
never sold sex.76 An analysis of in-depth interviews of
crack users in Portland (United States) found that sexual
activity involving multiple anonymous partners often
takes place within the context of crack use.77 An analy-
sis of in-depth interviews with crack users in Trinidad
and Tobago also found high rates of trading sex for
drugs.78 People who both use crack and inject drugs
were found to be more likely to engage in sex with mul-
tiple partners, trade sex for drugs, have unprotected sex,
and have sex with other injection drug users. 79
3.2.2 Amphetamine use and sexual
transmission of HIV
There is a significant body of literature associating the
use of amphetamines with sexual activity and risky
sexual behaviour. Amphetamines are used during the
sexual act to prolong stamina and increase pleasure.80 In
the United States, HIV infected amphetamine users
were found to have an average of more than nine sexual
partners in two months. The average number of unpro-
tected vaginal, anal, and oral sex acts over the two
month period were 21, 6 and 42, respectively.81 Only
50% used a condom during these acts. In Ethiopia, a
study of 561 young people aged 15-24 years found the
use of khat (a local amphetamine-type stimulant) pre-
dicted the likelihood of having ever engaged in sexual
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activity.82 In a study of men in Northern Thailand
found that those reporting a history of sexually trans-
mitted infections were more likely to have used amphet-
amines.83
In a study of HIV infected men who have sex with
men,84 it was found that methamphetamine use was
associated with high rates of anal sex, low rates of
condom use, multiple sex partners, and anonymous sex.
Users reported using the drug to promote sexual please
and to reduce negative feelings associated with being
HIV infected. This was also demonstrated in a study of
male homosexual and heterosexual non-injecting
amphetamine users attending HIV clinics in Califor-
nia.85 In contrast, being HIV infected has been shown
to be associated with condom use among amphetamine
injectors in Sweden.86
There is evidence of a link between amphetamine use
and risky sexual behaviour in East and Southeast Asia,
and thus the recent increase in the availability of these
drugs in the region has implications for HIV control.87
In an HIV vaccine trial among injecting drug users in
Bangkok, amphetamines use was associated with unpro-
tected vaginal intercourse.88
Ecstasy use has mainly been studied in industrialised
countries. Compared to those who use amphetamines
but not ecstasy, ecstasy users tend to be of a higher
socioeconomic status and have more same sex part-
ners.89 There is evidence that ecstasy use is associated
with unsafe sexual activity. For example, in a study of
young homosexual and bisexual men in New York City,
ecstasy use was associated with having more male part-
ners, more visits to bars, clubs, sex clubs or bathhouses,
and greater likelihood of having unprotected anal sex.90
3.2.3 Opioid use and sexual HIV
transmission
Heroin is believed to reduce sexual activity and impair
sexual arousal.92 However, there is significant evidence
that heroin dependent individuals engage in sexual
activity. In a study of predominantly heroin injecting
drug users in London, 80% had been sexually active
within the preceding six months, with an average of 2.1
non-commercial opposite sex partners. Two-thirds
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Box 4: Increasing abuse of amphetamine type
substances in South-East Asia
The increase in the use of amphetamine-type sub-
stances (ATS), mainly methamphetamine, in the
East Asia Pacific region began in the mid-1990s
and has spread even to those countries where
opioid use has traditionally been widespread.
Methamphetamine pills are the main form of ATS
found in Thailand, Myanmar, Cambodia, Viet
Nam and the Lao People’s Democratic Republic,
while crystalline methamphetamine predominates
in Japan, Philippines, Singapore, Brunei Darus-
salam and Malaysia. Methamphetamine use con-
tinued to increase during 2003-2004 in many
countries in the region, although it stabilized in
Brunei Darussalam, Japan, the Philippines and
declined in Thailand. Methamphetamine was the
primary drug for which people sought drug treat-
ment in the Philippines in 2002, accounting for
3,466 (58%) of the 5,965 admissions to drug treat-
ment that year.91
(66%) had vaginal intercourse at least once a week.
There was a high level of risky sexual behaviour, with
68% never using condoms with primary partners and
34% never using condoms with casual partners. Those
having sexual intercourse most often were least likely to
use condoms. About 10% of the study group were HIV
infected.93
Across most studies, there is a clear link between the reg-
ularity of sexual intercourse with the primary sexual
partner and the frequency of condom use. Condom use
is low with regular partners of heroin users, especially
within marriage,94 and higher with casual partners.95
The severity of opioid dependence usually increases the
likelihood of risky sexual behaviour.96 Severe depend-
ence can also lead to an increase in commercial sex
work, and, consequently, reduced use of condoms.97
3.2.4 Female sex workers
Sex workers who inject drugs are more likely than non-
injecting sex workers to:
• Work in ways that offer least possibility to protect
themselves from HIV infection (for example,
street or highway sex work);
• Have unprotected sex for additional payment;
• Have more clients per week;
• Have sex partners who are also injecting drug
users; 
• Share injection equipment with injecting partners
or clients in sex-for-drug transactions.98
Sex work and injecting drug use are highly associated in
some areas. In Moscow, 31% of sex workers are also
injecting drug users.99 In Togliatti in the Russian Feder-
ation, 50% of female injecting drug users reported
having exchanged sex for goods or money in the past
and of these, 86% were currently active sex workers.100
Estimates of the proportion of female sex workers who
inject drugs in the Russian Federation as a whole vary
between 25% and 90%,101 and it is estimated that
approximately 30% of female sex workers across the
Newly Independent States (NIS) of the former Soviet
Union are injecting drug users.102 While data are lim-
ited, studies of female injecting drug users in Eastern
Europe estimate that between 20% and 50% are
involved in sex work, and in Central Asia, the propor-
tion is between 10% and 25%.103
One study in Viet Nam found that in Ho Chi Minh
City, over 15% of street-based female sex workers
reported injecting drugs within the last six months. In
Hanoi, high rates of injecting were found among street-
based sex workers and sharing injecting equipment was
common, especially with the primary sexual partner. In
this group, drug use began after becoming a sex worker.
Some subjects of the study reported drug use as a ‘trend’
among sex workers. ‘Partnering’ with a male injecting
drug user was common, with the female earning to sup-
port the couple’s drug habit. In return, the male pro-
vided protection, transport and accommodation.104
In many countries, a higher proportion of sex-working
injecting drug users are found at the street level than in
brothels, bars, hotels and other settings.105 In some set-
tings, drug injecting is stigmatised in brothels; in others,
pimps or others associated with the sex industry may be
drug users or dealers.
Sex workers who use drugs show higher HIV/AIDS
prevalence in some studies. A study of 400 street-based
sex workers in Ho Chi Minh City, Viet Nam, found
that infection was associated with injecting by the sex
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worker, injecting by the regular sex partners of the sex
worker or by their partners, and with younger (under
26) sex workers.106 In Nepal in 1999, HIV prevalence
was approximately 20% among sex workers, 50%
among injecting drug users and 75% among sex work-
ers who inject drugs.107 In Manipur (India), the preva-
lence of HIV among the sex workers who inject drugs
was 57%, compared with 20% of those who did not
inject.108
Evidence suggests that sex workers who inject drugs face
increased risk of sexual HIV transmission because they
often have a higher number of clients, are more willing
to engage in unprotected sex, and have sexual partners
who also inject drugs. Sex workers who inject may also
be more likely to pass on HIV if infected. Lower levels
of condom use have been shown among those injecting
drugs and selling or buying sex.  For example, only 10%
of injecting drug users from three cities in Indonesia,
many of who had multiple commercial sex and other
partners, reported condom use.109 Among injecting
drug users in Vancouver, Canada, and in several cities of
the United States, condom use with all types of sexual
partners (paying, casual, and primary partners) is rare or
low among those exchanging sex for drugs or money.110
Female drug users are more likely than male drug users
to trade sex for drugs. In an analysis of 1,055 drug users
in the United States, female users were more than three
times more likely to engage in trading sex for drugs than
male users. Between 6% and 11% of male users traded
sex for drugs. Homelessness, unemployment and the use
of crack (in order of decreasing correlation) were all
associated with trading sex for drugs.111The exchange of
sex for drugs is a risk factor for HIV infection.112
3.2.5 Male sex workers
Risk behaviours among male sex workers are relatively
under-researched. A 1994 study found important dif-
ferences between male street sex workers and those
working at home. Street-workers were more likely to
inject drugs, to have a heterosexual preference, to have
no other occupation, to have more clients, and to have
a more negative working attitude. The study also found
that male sex workers were more likely to engage in anal
intercourse with steady clients, with clients whom they
trusted regarding condom use, with clients they felt sex-
ually attracted to, or when in dire need of drugs. Of
those who had anal intercourse in the previous year, a
majority had consistently used condoms. The same fac-
tors that encourage anal intercourse also appear con-
ducive to unprotected intercourse.113
3.2.6 Sexual partners of drug users
Sexual partners of injecting drug users are at risk for
acquiring HIV infection, and it is this link that is said
to be responsible for the generalised epidemics in Asia
and Eastern Europe. Partners of injecting drug users are
not necessarily injectors themselves, and therefore the
risk is predominantly sexual. For example, a study of
516 injecting drug users and their partners in London
found that 62% of respondents’ primary and casual
partners did not inject drugs. In a study of 650 male
injecting drug users in three cities in Indonesia, 68%
had been sexually active within the last year. Of the total
study group, 24% had engaged in sexual activity with a
regular partner, 40% with a sex worker, 29% with a
casual female partner, 48% with multiple partners, and
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Box 5: Female injecting drug users
In the World Health Organization Multi-City Study on Drug Injecting and Risk of HIV Infection during 1989-1992,
analysis was conducted on the basis of gender. The share of injecting drug users who were female ranged from 5% in
Bangkok to 44% in Berlin, with a mean of 25%.114 It is estimated that women account for approximately 17% of the
estimated 1 million injection drug users reported in China, and in some provinces, this can reach up to 40%.115 The
average age of female drug users (between 22 and 27) in China is considerably lower than male drug users and approx-
imately half of female drug users have engaged in sex work. Syphilis rates among female drug users vary between 1% and
29%.116
Women injecting drug users are at greater risk of acquiring HIV than male injecting drug users, partly due to the large
proportion of women injectors who are also sex workers, and partly due to their combination of injection-related and
sexual risks:117
• Female injecting drug users are more likely than men to report being injected by another 
person and to have assistance injecting.118 Being injected by another person or being helped 
to inject is a predictor of HIV infection.119 Also, many female injecting drug users are 
dependent on their sexual partners to obtain drugs, which compromises their ability 
to negotiate safer sex or safer injecting practices.120
• Men will usually inject first if a male-female couple is sharing injecting equipment, again lead
ing to greater likelihood of women acquiring HIV from contaminated injecting equip
ment.121 
• Women’s access to services of all kinds is lower than that of male injectors. This has been found 
among HIV prevention programmes in Central and Eastern Europe and South-East Asia, and 
among drug dependence treatment programmes in South Asia. 
Various social and cultural norms force women more than men to hide their drug use. More so than for men, drug use,
sex work, and HIV infection carry great social stigmas for women. The very invisibility of women injecting drug users
increases their risk of acquiring HIV. It is difficult for interventions to target this group and, therefore, they may not
receive education, information, and prevention materials as readily or as often as male injecting drug users.122
The interaction between injecting drug use and participation in the sex industry is complex. Drug use may lead to sex
work due to financial needs.123 Sex work can lead to injecting drug use124 because drug use is often used as a means to
cope with the emotional demands of sex work.125
In at least some countries, female injecting drug users are more likely to be in a sexual relationship with another inject-
ing drug user than are male injecting drug users. A woman in partnership with a male injecting drug user tends to default
to sex work in order to support both her and her partner’s drug dependence.126
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1.5% with a male partner. Thirty-five percent had had
unprotected commercial sex.127
A study in Sao Paulo, Brazil, found that 40% of HIV
infected females were infected through unsafe sexual
activity with injecting drug users.128 A study of the
wives of HIV positive male injecting drug users in
Manipur, India, revealed that 45% were HIV infected,
although none reported ever injecting, and 97%
reported having sexual relations only with their hus-
bands. Only 15% reported using condoms at least half
the time within the last year. An association was also
established between the husband reporting a sexually
transmitted infection and HIV prevalence in wives, sug-
gesting either that sexually transmitted infections are a
marker of unsafe sexual activity or that they facilitate
the transmission of HIV.129 Studies have found that 8%
of sexual partners of HIV infected injecting drug users
in the Russian Federation have been infected, compared
to 6% in Ukraine and a similar percentage in Belarus.
In Argentina, it is estimated that 12% of all HIV infec-
tions in women result from unsafe sexual activity with a
male injecting drug user.130
A consistent characteristic across studies is that injecting
drug users are less likely to use condoms with primary
sexual partners. In situations where the partner also
injects, injecting drug users are also more likely to share
injecting equipment with their primary partner. This is
illustrated by a study of injecting drug users at needle-
syringe programmes in the north-eastern United States,
where 54% said they never used a condom with their
primary sexual partner compared with 33%, who never
used one with non-primary partners. Twice as many
injecting drug users reported that they shared injecting
equipment with their primary sexual partner as com-
pared with a non-primary partner.131
3.2.7 Men and women who have same
sex partners
Having sex with another man creates additional risk of
HIV transmission for male injecting drug users. A
survey of this population in Denver in the United States
demonstrated high-risk sexual behaviours with multiple
partners of both genders. Over 80% had more than one
male partner, 20% had non-primary female partners,
and 15% exchanged sex for money or drugs. Condom
use was inconsistent and infrequent for all types of sex
(vaginal, anal and oral) and with all types of partners;
90% injected cocaine and 59% used methamphetamine
- drugs associated with risky injecting and sexual prac-
tices; 45% of this sample was HIV infected. Signifi-
cantly, in this study, men who had sex with men and
who injected did not identify strongly with either men
who have sex with men or injecting drug users.132 Other
studies have shown that men who have sex with men
and inject identify most strongly with their drug use
rather than their sexual practice.133
In a 10-year analysis of the “AIDS Linked to the Intra-
venous Experiences” (ALIVE) project in Baltimore, the
United States, having sex with another man nearly dou-
bled the risk of HIV sero-conversion among injecting
drug users.134 In a study of Latino injecting drug users
in New York, compared with heterosexual men, gay
men were significantly more likely to have received
money or drugs for sex (64% versus 33%), and women
who have sex with women were significantly more likely
to have had unprotected sex with an injecting drug
user.135
In Canada, men who have sex with men and who inject
were found to be younger than other men who have sex
with men and are more likely to be HIV infected,
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indigenous, economically disadvantaged, engaged in the
trade of sex for money or drugs, and to report having
female sexual partners. Marginalisation of this group is
compounded by HIV prevention and treatment serv-
ices, which have a propensity to target either men who
have sex with men or injecting drug users but not the
intersection between these two groups.136 In a study of
injecting drug users in Montreal, men who had sex with
other men were 2.5 times more likely than injectors who
did not, to have HIV at study entry.137
3.3 Conclusions
Despite insufficiencies of data, particularly on non-
injecting drug use, there is no doubt that the use of
drugs, whether injected or taken otherwise, increases the
risk of becoming infected with HIV. If injected, the use
of contaminated injection equipment can lead to the
rapid spread of the virus in the injecting community
and beyond. Certain drugs that are not injected can also
increase HIV transmission due to their impact on sexual
risk-taking behaviour. The sexual partners of drug users,
whether drugs users themselves or not, can spread the
virus to the larger community, particularly if they are
commercial sex workers. 
Consequently, many researchers and analysts believe
that the role of primary drug abuse prevention is widely
underestimated and neglected for HIV/AIDS preven-
tion. Also important are interventions to prevent non-
injecting drug users from becoming injectors, and to
encourage those who inject to consider non-injecting
alternatives such as substitution treatment. 
For example, in Eastern Europe and Central Asia, drug
use starts at a very early age and traditional HIV pre-
vention strategies addressing injecting drug use may not
be appropriate. In countries of Latin America, where
crack use is widespread, interventions addressing inject-
ing drug use may miss the role this drug plays in the
sexual transmission of HIV. In South and South-East
Asia, we are currently witnessing a large epidemic of
ATS use, but we know very little about how this will
impact the HIV situation in the region. The number of
injection drug users in China and India is on the
increase, as are the HIV/AIDS rates among these drug
users, which indicates that not enough is being done in
primary and secondary drug use prevention. And even
in the advanced HIV epidemics of Africa, increased
drug use and injection drug use could diminish the
impact of prevention campaigns aimed at sexual behav-
iour.
Worldwide, we are witnessing a feminization of the
HIV/AIDS epidemics, meaning that the share of people
living with HIV/AIDS who are women is steadily
increasing. Unfortunately, there appears to be a parallel
process among drug users. The number of female drug
users, particularly of injecting drug users, is increasing
in many parts of the world. Some of them are partners
of male drug users, some are sex workers using drugs to
cope with the strains of their profession. Interventions
for female drug users face a number of dilemmas,
because they are particularly hard-to-reach, highly stig-
matized and extremely vulnerable to HIV infection.
Interventions have been developed mainly for male
injecting drug users, and these interventions do not take
into account the particular needs and characteristics of
female drug users. While there is increasing knowledge
on what needs to be done, good intervention modalities
have still not been developed and implemented on a suf-
ficient scale. The information from this chapter, how-
ever, indicates that there is an urgent need to develop
these interventions.
The message of this chapter is clear. Both injection and
non-injection drug use need to be targeted in efforts to
reduce the spread of HIV. To be able to do so effectively,
more information on non-injection drug use and its
implication for HIV transmission is needed urgently.
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International drug control is about a century old. The
notion of a ‘drug problem’, as well as the will to tackle
it, have thus gained a strong foothold in public opinion,
government policy and multilateral cooperation.  Yet,
traditionally presented as a supply-demand issue, split
between the three sectors of production, trafficking and
consumption, and further broken down into various
drug categories, the “drug problem” has so far not found
a representation that goes beyond the existing mosaic of
perceptions and statistics, and encompasses them into a
single standard measure. 
The resulting heterogeneity has made it difficult to
establish benchmarks and to make straightforward com-
parisons of the drug problem across regions/countries
and over time.  One of several consequences has been,
for instance, a difficulty in bridging the divide, estab-
lished in public discourse, between producing and con-
suming countries.  Another effect has been to limit
possibilities of exploring correlations with other socio-
economic indicators and indices.  Of even more direct
relevance to drug control, this absence of a suitable
yardstick has perpetuated the difficulties of assessing the
impact and effectiveness of drug control policies.  For
how should one decide if the drug problem is getting
better or worse when, say, the number of abusers
changes and abuse shifts from one substance to another?
Or when production declines but consumption
increases in a given region?
Indicators and indices are necessarily reductionist and
cannot represent the whole truth.   The loss in com-
plexity they entail is commensurate with the degree of
aggregation they require. The risk of distorting reality
through oversimplification is further compounded by
weaknesses in the underlying data on illicit drugs.  Pro-
vided their drawbacks are clearly kept in mind, indica-
tors and indices can nevertheless be useful, as reflected
in their increasing presence in social sciences and policy.
They contribute, in particular, to introducing more
objective approaches in policy debate, in programme
monitoring and in impact evaluation.  They also help
countries to assess their relative positions on a global
scale and to better gauge the significance of the problem
they face, or the overall progress they have made in any
particular area.
Entrusted by Member States with the responsibility to
promote and support a coordinated and multilateral
response to the world’s drug problem, UNODC has
been striving to improve the analytical tools at the dis-
posal of governments and the international community
to develop increasingly effective control measures.  In
this context, it has been working with governments and
a variety of organizations to establish norms and stan-
dard indicators; to improve data collection and report-
ing systems; and to facilitate the dissemination of data
and information on the nature, extent and evolution of
the drug problem and its various dimensions.  As part
of the ongoing effort to expand the knowledge base that
informs policy making, UNODC is now working
towards developing a global Illicit Drug Index (IDI)
with a view to fill the gap identified above.  To initiate
the multifaceted discussions and efforts that such an
undertaking will necessarily require, preliminary work
was undertaken by a working group established in the
Policy Analysis and Research Branch of UNODC.1 The
initial results of this work are presented in the following
pages.  They should be seen as work in progress and it
4. Towards the creation of an Illicit Drug Index  
4.1 Introduction
1 Members of the working group included the following individuals : Anna Alvazzi Del Fratte, Sandeep Chawla, Thibault le Pichon, Thomas
Pietschmann, Barbara Remberg, Wolfgang Rhomberg, Howard Stead, Javier Teran and Melissa Tullis. 
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is hoped that they will generate the interest and the con-
tributions that the further development of such a tool
requires.  The Index is intended primarily to establish
values and enable comparisons at country level.  At this
early stage, however, results are only presented at the
regional level and for the year 2002, as a way to illus-
trate the basic concept and methodology.  
The purpose of an Illicit Drug Index
The objective is to create a single standard measure of
the drug problem that would enable direct comparisons
across regions/countries and over time.
The Illicit Drug Index would provide a single, standard
and comparable measure of a country's overall drug
problem, weighted by the size of its population.
4.1.2 Assumptions, choices and
limitations 
In the preparatory work undertaken thus far, a number
of assumptions and choices were made and several lim-
itations were identified.  They apply to the preliminary
version of the index presented here (referred to as ‘the
index’ hereafter).
• The index is based solely on component drug
indicators, and unlike many indices in other
domains, does not rely on other socio-economic
correlates.  At this stage, this is seen rather as an
advantage, since it enables a more direct measure
of the drug problem.  Moreover, too little research
has been done so far to explore possible correla-
tions between the drug problem and other socioe-
conomic dimensions.  In the longer-term however,
the inclusion of component indicators drawn
from other domains could enrich the index and
help to compensate for some of the many weak-
nesses of the illicit drug data set.
• The Index is a function of illicit drug production,
trafficking and abuse and is therefore based on the
combined extent of those three traditional sectors
of the drug problem. It does not include other
variables such as money laundering, corruption or
drug related acquisitive crime. Apart from the
issue of data availability, it was assumed that such
problems tend to be closely related to the extent of
drug production, trafficking and abuse in a given
country.  While this may be true in most cases,
there are likely to be some exceptions, such as the
laundering of drug money in an offshore centre,
which may otherwise not be particularly affected
by drug production, trafficking or abuse.
• Although illicit drugs can create a variety of
related harms (violence, corruption, etc.), the
potential harm to individual health was selected as
central to drug control policies as a whole and
thus established as a common denominator for the
components of the IDI.  This choice is necessarily
limiting but finds clear support in the underlying
philosophy of the drug control system: protecting
public health by limiting potentially harmful psy-
choactive substances to medical and scientific use.
The most fundamental reproach that a drug con-
trol agency will make to an illicit opium farmer is
that he produces dangerous drugs that will endan-
ger the health of other people.  The fact that, in
doing so, he also contributes to perpetuating an
illicit market is considered, under the drug control
system for which this index is established, as an
important but secondary harm.  The same reason-
ing applies to a drug trafficker with respect to, say,
violence or corruption. 
• Due to the many gaps and weaknesses in the data
set used to calculate the index, additional caveats,
over and above the ones usually associated with
indicators and indices, must be made.  While the
results obtained thus far were considered encour-
aging and meaningful enough to be presented for
further discussion, they should still be seen as very
tentative and subject to revision. 
Technical challenges
Any attempt to develop a global illicit drug index will
necessarily face formidable technical challenges. If not,
such an index would have been established a long time
ago.  Two main obstacles, in particular, need to be
cleared at the outset.  
• The substance boundary, created by the existence
of various drug categories and related effects. How
does one compare cocaine, cannabis or heroin?  
• The sectorial boundary, resulting in the differing
mix of production, trafficking and consumption
found in any given region or country.  How does
one compare the production of a kilogram of
opium by a farmer with its subsequent consump-
tion (in the form of opium and/or heroin) by
hundreds of consumers?
Technical solutions 
• To remove the first stumbling block, the various
drug categories were converted into a single hypo-
thetical reference drug. As explained further
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below, this was achieved by establishing the poten-
tial harm to health of each drug category2 and by
merging their measurement into a common scale. 
The Illicit Drug Index combines all the main categories of
illicit drugs by converting them into a hypothetical reference
drug.
• The second obstacle, created by the difficulty of
comparing production, trafficking and consump-
tion, was removed by identifying the common ele-
ment in the three main sectors and using it to
establish a single measure for all three of them.
One can indeed view production, trafficking and
abuse as sequential steps in a market continuum
along which illicit drugs are processed and moved.
Using the reference drug and the harm factor
mentioned above, activities in all three sectors can
then be defined as the act of processing/moving a
certain amount of potential harm associated with
a given quantity of the reference drug along the
market chain. In other words, what the opium
farmer, the drug trafficker and the drug addict
have in common is that they are all handling a cer-
tain amount of potential harm to the health of
individuals and contributing to actualising that
potential.  That harm is associated with the quan-
tity of drugs (converted into the reference drug)
they are moving along the supply-demand chain.
As noted above, while there are several other forms
of harm associated with illicit drugs (violence, cor-
ruption, etc.), at this stage, potential harm to
health was chosen as the central unifying factor. 
The Illicit Drug Index combines the extent of illicit drug
production, trafficking and abuse into a single measure of
potential harm that moves along the market chain.
The Illicit Drug Index thus attempts to capture all the
main dimensions of the drug problem into a single
measure.  This measure, in turn, can be disaggregated
into its various component indicators, thus allowing for
a more specific representation of, say, a country’s drug
problem in terms of production, trafficking or abuse for
all substances combined, or in terms of a particular sub-
stance for all three sectors combined.
The size of a country’s population is taken into account
in the calculation of the IDI, which is therefore based
on a value per capita.  The preliminary version of this
index is based on more than 4800 data records for the
year 2002, provided by Member States to UNODC and
covering 177 countries and territories. An average of 27
data records per country have thus been used to gener-
ate this version of the index.   As noted earlier, results
presented below are aggregated at the regional level.
The Illicit Drug Index reflects the extent of the drug
problem affecting a particular country in comparison with
others, weighted by the size of its population.
4.2  Methodology 
The IDI is a composite of three sub-indices which
reflect the situation of a country in terms of drug pro-
duction, drug trafficking and drug abuse.  
4.2.1 Main components of the index
Illicit drug production sub-index
Production is calculated in terms of the quantity of
illicit drugs produced in a country. For the main plant
based drugs, the estimates are generally based on surveys
of the area under cultivation, yields and the typical
transformation rates for the conversion of the psy-
choactive plant products (opium, coca leaf ) into the
respective end products (heroin or cocaine). 
In the case of cannabis, Member States’ estimates of
areas under cannabis cultivation and yields were used.
Given the lack of scientific surveys for most countries,
the overall reliability of these estimates is much lower
than in the case of heroin or cocaine.  
Establishing estimates for synthetic drugs, such as
amphetamines (methamphetamine and amphetamine)
or ecstasy, is a far more challenging task. For such drugs,
UNODC has developed a triangulation approach,
which involves the following elements:  
a) estimates based on the number of consumers and
the typical amounts consumed per user;
b) estimates based on seizures of end products; and 
c) estimates based on seizures of precursors. 
The average of the three estimates was used as
UNODC’s global production estimate for ampheta-
mines and ecstasy. In the next step, the global produc-
tion estimate was allocated to countries, based on
Member States’ information on source countries identi-
fied, laboratory seizures, and drug seizures. The result-
ing estimates are necessarily only indicative of likely
levels of production.   
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2 Namely: opiates, cocaine, cannabis (herb and resin), amphetamines and ecstasy. These drugs account for the bulk of the drug problem worldwide.
Production, trafficking and abuse of other drugs were disregarded as they would hardly change the overall index.
The results in weight equivalents were then transformed
into typical consumption units (‘doses’), reflecting the
fact that a typical ‘dose’ of cannabis herb (around 0.5
grams), for instance, is larger than a typical dose of
cocaine (around 0.1 grams), ecstasy (0.1 grams), heroin
(around 0.03 grams) or amphetamines (0.03 grams)3.  
Even transformed into typical drug doses, the results
could still be misleading, as some drugs are known to
have a higher abuse risk and associated harm than
others.  Compared with other illicit drugs, opiates, for
instance, have a consistently worse record in terms of
treatment demand, spread of blood-born diseases such
as HIV-AIDS and drug related deaths. Thus, the total
number of doses produced in a country were weighted
by a ‘harm/risk factor’ (see below for details on the
harm/risk factor), which gives, for instance, a higher
weight to opiates than to cannabis.   
Illicit drug trafficking sub-index
Measuring illicit drug trafficking is notoriously difficult
and can only be done through indirect indicators.  For
the purposes of this model, the establishment of the
illicit drug trafficking sub-index relied on the combina-
tion of two indicators:    
a) Reported illicit drug seizures (‘seizure indicator’)
b) Reported illicit drug seizures routes (‘route indi
cator’) 
a) Seizure indicator
The first component of the illicit drug trafficking sub-
index is the quantities of drugs seized by law enforce-
ment services in a country, transformed into typical
doses and then weighted by the harm factor (see below). 
Seizure records offer one of the most developed global
datasets on illicit drugs and therefore present consider-
able value for monitoring the evolution of the traffick-
ing problem over time. If law enforcement capabilities
were identical across the world, seizures could be a good
proxy for assessing the extent of drug trafficking activi-
ties. This, however, is clearly not the case. The level of
resources allocated and the priority given to controlling
drug trafficking varies significantly from country to
country. Seizures may therefore reflect as much the
importance of the problem as the extent of the effort to
tackle it, with no straightforward way of assessing the
potential bias thus introduced in the measure of the
actual volume of trafficking. The seizure indicator there-
fore needs to be complemented with another source of
information. 
b) Route indicator
The second component of the trafficking sub-index is
itself composed of three elements, or sub-indicators:  
(i) countries identified by reporting countries
as main origins of drug shipments, 
(ii)  countries identified as main transit 
countries and 
(iii)  countries identified as main destination  
countries. 
As part of UNODC’s Annual Reports Questionnaire,
Member States report the place of origin, transit and
destination of drugs seized on their territory. ‘Origin’ in
this context does not necessarily mean the source coun-
try of the drugs, but the country from which drug traf-
fickers arrested in the reporting country typically
obtained the drugs.  The three sub-elements – origin,
transit and destination countries – were then aggregated
into a ‘route indicator’.  
If several countries identified a specific country as a
country of origin, transit, or destination, it is likely that
such a country is afflicted with significant levels of drug
trafficking activities (even if itself made, or reported, no
drug seizures, or only few of them).  
Such reports do not, however, provide any information
on the actual volume of trafficking from, through, or to,
a given country.  This creates a technical difficulty.
Should the information provided by a country with a
small drug abuse population and located far away from
major drug trafficking routes be given the same weight
as the information provided by a country with a large
drug market? Probably not, as overall trafficking to a
country with a small market is most likely significantly
less than trafficking to a country with a big market.  The
size of the population is not necessarily an appropriate
weighting factor in this case.  For instance, information
on the origin or the transit of cocaine reported by coun-
tries such as India or China – which have very limited
cocaine consumption, but very large populations –
would have more weight than reports from the USA,
the world’s largest cocaine market.
The information on the origin, transit and destination
of drugs was therefore weighted by the quantities of
drugs seized in the reporting country. As a consequence,
information provided by the USA or Colombia (the two
countries reporting the highest cocaine seizures world-
wide) on the origin, transit and destination of cocaine is
given more weight than cocaine related information
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reported into weight equivalents, and vice-versa.
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provided by other countries; similarly, information on
the origin, transit and destination provided by Iran,
Pakistan and China on opiates (which report the largest
opiate seizures worldwide), or by Thailand and China
on amphetamines (reporting the largest methampheta-
mine seizures worldwide) is given more weight than
information provided by other countries. 
The sub-components (origin, transit destination) of the
‘route indicator’ were established as follows: the break-
down of the countries of origin (or transit, or destina-
tion), as reported by Member States, was used to
‘allocate’ the seizures made by the reporting countries to
the countries of origin, transit and destination (e.g.
country A 50%, country B 30%, country C 20%). If
the reporting country did not provide a breakdown (and
no additional information was available), seizures made
in that country were distributed equally among the
origin, transit or destination countries reported. 
The seizures were then transformed into standard drug
doses and multiplied with the harm/risk-factor. The
scores of countries were then aggregated to establish the
second component of the trafficking sub-index.    
This method for ‘re-allocating’ seizures of reporting
countries to ‘countries of origin’, ‘transit countries or
‘destination countries’ thus provided an alternative way
of assessing trafficking flows. With such an indicator,
decreasing seizures in a given country would not neces-
sarily lower that country’s position on the international
trafficking scale. All things being equal, reduced law
enforcement successes against drug trafficking in a given
country may lead to increased trafficking flows (and
seizures) in neighbouring countries.  These countries
would, in turn, be as or even more likely than before to
identify that particular country as origin or transit area. 
One could theoretically consider using the route indi-
cator to replace the seizure indicator altogether. One
limitation, however, is related to the consistency of the
data.  Unfortunately, not all countries provide reports
on the origin, transit and destination of drugs, which
introduces a potential bias.  A second limitation comes
from the varying degree to which countries are affected
by international drug trafficking as opposed to local
drug trafficking.  Some countries which are not, or mar-
ginally, used as origin or transit countries, but which
make significant seizures, will get a low score under the
‘route indicator’. The ‘route indicator’ is thus a power-
ful tool for detecting trafficking hubs, but the seizure
indicator provides an important complement for esti-
mating the level of drug trafficking activities at the
national level. 
Further steps in the development of the illicit drug
index model will include a critical review of the short-
comings of the trafficking index.  It is clear that the cur-
rent version presents a number of weaknesses and can
only provide a rough approximation of trafficking vol-
umes.  One alternative – which would require substan-
tial research efforts – would be to develop global
trafficking flow models for the various drugs, estimating
for each country the amounts of drugs entering and
leaving the country, taking into account trafficking
routes, domestic production, consumption and seizures.
Such models would potentially offer a better reflection
of the actual quantities of drugs trafficked via various
countries.  At the same time, however, such models may
be less effective in identifying trafficking hot-spots,
where drugs change hands among the various criminal
groups involved in drug trafficking (and which are thus
particularly vulnerable to all of the negative side-effects
resulting from drug trafficking).       
Abuse sub-index 
The method chosen to calculate the abuse index is rela-
tively straightforward. Abuse is measured by the number
of people using drugs (based on annual prevalence esti-
mates, established for UNODC’s World Drug report),
multiplied with an average annual dose per drug and the
harm/risk factor.  
In order to arrive at such an average annual dose, global
production for each drug less seizures (adjusted for
purity) was calculated over a 10-year period and divided
by the average number of users over this period. This
approach was used as a way to mitigate the effects of
stocks and time lags along the supply-demand chain,
because of which total production and total consump-
tion are not necessarily identical in any specific year.
Over longer periods of time, one can assume that stock
movements even out and have a neutral effect on the
system. This approach – average annual production less
average annual purity-adjusted seizures – should thus
give a reasonable order of magnitude of average annual
drug availability for consumption. This result was then
divided by the average number of users over the 10 year
period in order to arrive at an average annual amount
per user, which was in turn multiplied by the number of
drug users to arrive at an estimation of the amount of
illicit drugs consumed in a country. The result in kilo-
grams per country was then transformed into typical
doses and multiplied with the harm/risk factor in order
to make the different drugs comparable.   
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4.2.2 Aggregating information
Harm/risk factor
One innovative approach in the model proposed for the
calculation of an Illicit Drug Index was the establish-
ment of a ‘harm/risk factor’ for drugs.  This allows for
aggregating results from different drugs into one single
hypothetical reference drug. 
Drugs inflict a large number of harms to the individual
as well as to society at large. The approach used for the
purposes of this model was to concentrate on the health
consequences of drug abuse. Thus, the harm-factor used
in this model does not include broader societal conse-
quences, such as substance specific differences in the
level of drug related violence, corruption, acquisitive
crime, organized crime, financing of terrorist groups,
etc. Such a broader concept of drug related harm to
society in all its manifestations could be envisaged for
future development phases of this model. For the time
being, most of the data necessary to establish such a
broader concept of drug related harm, on a global scale,
are not available.     
Even focussing on the health consequences of drug
abuse does not yield easy answers, given the complex
nature of drugs and their interactions with the human
body.  The consequences of drug abuse differ substan-
tially depending on the drugs used (lung cancer versus
brain stroke, cardiac versus renal failure, etc.), making
direct comparisons extremely difficult. Thus a common
measure for the medical risks and consequences of drug
abuse had to be identified.   
Following an in-depth review of data currently available
in the scientific literature and at UNODC, the follow-
ing elements were selected to establish the risks and
harm related to substance abuse: 
• treatment demand (per 1000 drug users), 
injecting drug use (per drug category) to reflect
the risk of diseases such as hepatitis B, hepatitis C
or HIV/AIDS, 
• toxicity (typical/recreational versus lethal dose); 
and 
• drug related deaths (per 1000 users).   
The first key indicator on the consequences of drug
abuse is treatment demand. One can assume that that
the more serious the drug problem for an individual, the
more likely drug addicts will seek professional help. In
order to be used as a risk measure, treatment demand
must be put against the number of people consuming
such drugs.   Thus one component for the establishment
of a composite harm/risk factor is ‘treatment demand’
generated by substance abuse, compared to the total
number of people using such drugs.  Based on treatment
demand data provided by 123 countries, and UNODC
estimates of the number of people using illicit drugs, it
was calculated that an average of 78 people per 1000
users of opiates undergo treatment. This is more than
the corresponding rates for cocaine (66 per 1000 users),
amphetamines (16) or cannabis (7).  
Another indicator for the risks of drug abuse is linked
to the route of administration, notably injecting drug
use (IDU). It is commonly acknowledged that IDU is a
highly problematic route of administration, potentially
leading to hepatitis B, hepatitis C or HIV/AIDS infec-
tions when injecting equipment is shared among drug
users. Information provided by 36 Member States to
UNODC shows that opiates have the highest probabil-
ity of being injected, followed by amphetamines
(methamphetamine and then amphetamine), cocaine
and ecstasy. Injecting has not been reported for cannabis
use. In combination with other risk factors, the IDU
indicator thus integrates one key dimension in the
harm/risk factor – the risk of the spread of blood borne
diseases, which is a serious concern in many countries
around the world.  
A further risk factor, the toxicity, was used to measure
the ‘relative safety’ of drugs.  This provides information
on the likelihood of an overdose, as a result of users’
mistakes and/or changes in drug purity levels. This
factor is based on two sub-indices, the dose index and
the toxicology index.  
One way of measuring the relative ‘safety’ of a drug is to
consider the ratio (Dose Index) between a typical  dose
and a lethal dose. Such an index (comparing the effec-
tive dose (ED50) with the lethal dose (LD50)) is used
routinely in clinical pharmacology as a measure of the
safety of a drug. The ED50 is defined as the estimated
dose required to produce a specified effect in half of a
particular population.  For this model, the typical ‘dose’
for each of the drugs (divided by 70 kg for an average
adult) is used as the ED50.  The LD50 is a measure of
the dose which kills half of the experimental animals to
whom a particular drug is administered. A comparison
of the two suggests, for instance, that ecstasy is more
dangerous than cannabis, though less dangerous than
other drugs.  The comparison of doses for animals with
those for human beings, however, has some limitations
and results must be interpreted with caution. 
Another level of analysis was based on concentration
levels of drugs or drug metabolites in the blood of
people who died from overdose. Results were then com-
pared with concentration levels in persons who had
been given drugs for therapeutic use (Toxicology Index).
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This index shows, as one would expect, that the great-
est risk of dying from an overdose is associated with opi-
ates (already at five times the concentration levels
resulting from a therapeutic dose) whereas cannabis has
the lowest risk of acute drug related death. 
Combining the results of the two sub-indices, a new
‘toxicity index’ was established. This index suggests that
the highest risks of accidental death from a drug over-
dose is associated with the abuse of opiates, followed by
cocaine, amphetamines and ecstasy.
Finally, the actual risk of dying from drugs was estab-
lished by analysing data supplied by Member States on
the number of people reported to have died in connec-
tion with the use of specific drugs, as compared to the
total number of people using such drugs (drug death
index). This analysis – based on information from 20
countries – suggests that, on average, out of 100,000
opiate users, 261 users die in a year (0.3%), far more
than the corresponding rates for cocaine (48), amphet-
amines (18), or ecstasy (3).   
The overall ‘risk/harm factor’, used for the calculations
in the Illicit Drug Index model, was established by pool-
ing the results of the four components discussed above.
The risks arising from the use of opiates was set at 100
and the average of the four sub-indices was calculated.
The four components of the harm/risk factor were given
equal weight. The results suggest that the highest risks
from a typical dose are associated with opiates, followed
by cocaine, amphetamine and ecstasy. 
4.2.3 Aggregating the individual
components of the Illicit Drug
Index and preliminary results 
The Illicit Drug Index, as described above, consists of
three components: production, trafficking and abuse. In
order to arrive at the overall Illicit Drug Index, the var-
ious components have to be combined. 
The individual scores of production (production in
kilograms converted into typical consumption units and
multiplied by the harm factor) and consumption
(number of drug users multiplied by an average annual
dose, converted into typical consumption units and
multiplied by the harm factor) can be directly aggre-
gated. The results, in each case, can be interpreted as
total production or total consumption of the hypothet-
ical reference drug expressed in typical drug doses.
The aggregation of the trafficking sub-index with the
other two components was more complicated and an
additional calculation had to be introduced. As drugs
are usually moved from the place of production to the
place of consumption, the overall amounts of drugs traf-
ficked are basically equivalent to global drug produc-
tion, less seizures.4 Thus, for the purposes of this
model, seizures (transformed into doses and multiplied
by the harm factor) were subtracted from global drug
production (transformed into doses and multiplied by
the harm factor) to calculate the global drug trafficking
scores. The distribution pattern resulting from the traf-
ficking sub-index was then used to distribute ‘total drug
trafficking’ (production less seizures) among countries.
As indicated earlier, this current version of the illicit
trafficking sub-index, could be improved in the future
by an index derived from detailed trafficking flow
models (which remain to be developed).  
The preliminary results fo the calculations described
above suggest that the world’s drug problem continues
to be primarily associated with production, trafficking
and abuse of opiates (56%), followed by cocaine (22%),
cannabis (12%) and ATS (10%).
The next two graphs suggest that, on a per capita basis,
the Near & Middle East/South-West Asia is the sub-
region which is most severely affected by the drug prob-
lem. It has the highest drug production problem,  the
largest trafficking problem and suffers from significant
levels of drug abuse. The drug problem of this sub-
region is mainly linked to opiates.  The second region
most affected by the drug problem is South America.
The main problems there are again drug production,
followed by trafficking and, to a lesser extent, drug
abuse, with the problem mainly linked to cocaine.  In
the case of North America, the third most affected
region by drugs, the main problem is drug abuse, fol-
lowed by trafficking and drug production. The prob-
lems in North America are primarily linked to cocaine,
though opiates, ATS and cannabis also play a role. 
The extent of the drug problem in the Oceania region
is above the global average while the drug problem in
4 This, is, of course, a considerable simplification of reality: (i) The relationship assumes a basically stable drug market.  In case of large increases or
decreases in production, or the existence of large movements of stocks, the relationship would not hold; (ii) Tthe assumption that the total drug
flow is equivalent to production less seizures, does not take into account the actual location of seizures. If seizures took place exclusively in consumer
countries, the total trafficking flows would be larger than predicted by the model. In reality, however, significant amounts of drugs are seized in and
around the producer countries so the actual potential error should not be too significant; (iii) Subtracting reported seizures may not be entirely
appropriate as, along the trafficking route, drugs are usually ‘cut’ or diluted. Actual seizures in pure drug equivalents should be thus less. However,
there are also losses along the trafficking routes.  In other words, the two biases may actually offset each other.  In short, while this model, assuming
that  ‘production less seizures’ equals trafficking flows, can, of course, deviate from reality, it seems to be - as long as there is no dramatic change in
the market – an acceptable approximation of reality.  
Europe is close to the global average. The drug problem
in West & Central Europe as well as in East Europe is
mainly linked to abuse, while in South-East Europe
(covering Turkey and the Balkan countries) it is prima-
rily linked to trafficking. While a number of substances
are present in the drug markets of West and Central
Europe, the main problem is related to the abuse of opi-
ates.
The drug problem in Africa and Asia (except the Near
and Middle East/South-West Asia) is relatively low, on
a per capita basis. The main problems of production in
these two regions are encountered in North Africa, in
Central Asia and in  East & South-East Asia. In North
Africa cannabis constitutes the main problem. The main
drug problem for Central Asia and East & South-East
Asia is  linked to opiates.    
The results presented here are shown at the sub-regional
level for illustrative purposes. They could provide a
simple way to identify the extent of a country’s drug
problem as well as its patterns and – once calculated for
a number of years – its evolution. The main idea of the
IDI is to provide Member States with a comparable
measure of the extent and the evolution of the drug
problem, which should also improve the targeting of
assistance by the international community.  This, in
turn will increase the efficacy of technical assistance pro-
gramming and facilitate progress towards the ambitious
goals set out in the 1998 Special Session of the General
Assembly (UNGASS).     
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Sub-region Production Trafficking Abuse IDI
Caribbean 2.46                  7.21                       2.39                         12.06                     
Central America 0.25                  4.04                       3.32                         7.62                       
Central Asia  and Transcaucasian countries 3.53                  6.07                       4.96                         14.56                     
East Africa 0.30                  1.13                       0.80                         2.23                       
East and South-East Asia 2.40                  0.60                       2.09                         5.09                       
East Europe 0.15                  1.26                       10.96                       12.38                     
Near and Middle East /South-West Asia 32.24                14.95                     5.48                         52.67                     
North Africa 4.85                  1.12                       1.54                         7.51                       
North America 4.98                  9.79                       9.63                         24.40                     
Oceania 3.87                  5.56                       9.42                         18.86                     
South America 14.46                9.31                       4.49                         28.26                     
South Asia 0.28                  0.10                       2.68                         3.06                       
Southeast Europe 1.40                  9.19                       2.15                         12.75                     
Southern Africa 1.52                  1.45                       2.35                         5.32                       
West & Central Europe 1.07                  5.80                       6.23                         13.10                     
West and Central Africa 0.82                  0.73                       3.49                         5.03                       
Mean 4.33                  3.26                      3.77                        11.36                    
Per capita values
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Illicit Drug Index, per capita, by Sub-region and Component, 2002
- 11.36 22.72 34.08 45.44 56.80
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Illicit Drugs Index, per capita, by Sub-region and Drug-category, 2002
- 11.36 22.72 34.08 45.44 56.80
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Volume 1
The negative impacts of the illicit drug trade touch every society
in the world. This year's World Drug Report estimates that 200
million people, or 5% of the global population age 15-64, have
consumed illicit drugs at least once in the last 12 months. The
drug trade is pernicious and large. UNODC estimates its retail
value at US$ 321bn. It impacts almost every level of human
security from individual health, to safety and social welfare. Its
consequences are especially devastating for countries with
limited resources available to fight against it.    
The World Drug Report 2005 provides one of the most
comprehensive overviews of illicit drug trends at the
international level. In addition, this year it presents the work of
UNODC in two new areas of research. Both aim to provide tools
to enrich our understanding of an immensely complex situation:
an estimate of the financial value of the world drug market, and
the preliminary steps towards the creation of an illicit drug
index. The analysis of trends, some going back 10 years or more,
is presented in Volume 1. Detailed statistics are presented in
Volume 2. Taken together these volumes provide the most up to
date view of today's illicit drug situation. 
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